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Abstract 
Glioblastoma multiforme (GBM) is the most common form of primary brain cancer and 
the current prognosis for patients is poor. New therapies are required that target the 
invasive cells that are characteristic of GBM. GBM is infiltrated by immune cells but, as 
with other cancers, immune evasion pathways minimise productive anti-tumour 
immunity. Natural killer (NK) cells are able to recognise and kill tumour cells and are 
being developed for the immunotherapy of other cancers. The aim of this work was to 
analyse the interaction between human NK cells and GBM cells in vivo and in vitro, as a 
prerequisite to future NK cell based immunotherapy of GBM. Analysis of the cell 
surface phenotype for GBM infiltrating NK and T cells revealed that the tumour 
microenvironment exerts localised immune evasion mechanisms which downregulate 
activation receptors and upregulate inhibitory receptors. The interaction of NK cells 
with patient-derived GBM stem cells, which are thought to be responsible for 
recurrent disease, was investigated in vitro. A high-throughput, multiplex flow 
cytometry-based screen of tumour cells revealed the expression of a number of cell 
surface molecules that regulate NK cell activation. Furthermore, GBM cells were more 
susceptible to NK cell lysis in vitro compared to a non-cancerous neural progenitor cell 
line, revealing specificity in the NK cell response. Furthermore, this screen identified 
potential mechanisms by which GBM might evade immune surveillance in vivo. 
Targeting these pathways and restoring functional immune surveillance provides a 
potential route for future immunotherapy of this disease. However, GBM patients 
often experience cerebral oedema and are treated with immunosuppressive 
corticosteroids, such as dexamethasone; this induces a similar immunosuppressed 
phenotype to that observed with the GBM infiltrating NK cells, and inhibits their lytic 
function. Gene expression profiling identified the transcription factor c-Myc as a key 
regulator of NK cell activation and as a hub for the immunosuppressive action of 
steroids and the immunosuppressive cytokine TGF-β. The demonstration that 
therapeutic steroids target the same pathway as TGF-β and induce 
immunosuppression has important implications for the use of steroids in patients 
undergoing immunotherapy. 
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Chapter 1 Introduction 
1.1   The immune system and cancer 
Cancer is an umbrella term for a group of diseases that can arise in almost any tissue. 
In 2000, Hanahan and Weinberg summarised that most, if not all cancers, are 
characterised by the following ‘hallmarks’; a limitless replicative potential, sustained 
angiogenesis, evading apoptosis, self-sufficiency in growth signals, insensitivity to anti-
growth signals and the ability to invade tissue and metastasise (Hanahan & Weinberg 
2000). Cancer is one of the leading causes of death in the UK, accounting for more 
than 25% of deaths (Cancer Research UK 2016a) and it is estimated that 50% of people 
in the UK born after 1960 will develop cancer within their lifetime (Ahmad et al. 2015). 
Accordingly, a vast amount of research has been conducted to try to depict the 
aetiology of each cancer and how it progresses. As our understanding grows, so too 
does the advancement of treatments. Although overall cancer survival rates have 
doubled since the 1970s to around 50% (Quaresma et al. 2015), the prognosis for 
some patients, such as those with a brain tumour known as glioblastoma multiforme 
(GBM) has remained poor, with just 12% survival at 3 years post diagnosis (Jovčevska 
et al. 2013). There is a real need to find new therapies to improve the outlook for 
these patients. 
In the last 15 years there has been a shift in the way we think about and study cancer; 
from a cancer cell based focus to one which recognises that cancers are complex 
tissues that act as parasitic organs, recruiting and manipulating healthy cells to 
propagate their growth. In light of this insight, the list of cancer hallmarks has been 
expanded. It is now established that in order for tumours to prevail they must not only 
sustain division but also evade the body’s defence mechanism against external and 
internal threats; namely the immune system (Hanahan & Weinberg 2011). 
1.1.1   Immunosurveillance 
The notion that the immune system could suppress tumour formation is as old as 
immunology itself, being first proposed by Paul Ehrlich in 1909 (Ichim 2005). However, 
it was not until 1957, when tumour specific antigens were discovered, that Burnet and 
Thomas proposed the theory of ‘cancer immunosurveillance’. They suggested that it 
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was evolutionarily necessary to be able to eliminate transformed cells and that the 
mechanism responsible was immunological (Burnet 1970). The discovery of natural 
killer (NK) cells and their ability to spontaneously kill tumour cells supported this 
theory (Herberman & Holden 1978), yet a lack of characterisation and knowledge of 
NK cell regulation, coupled with the use of unsuitable animal models rendered the 
theory controversial until the mid 1990s (Dunn et al. 2002). The tumour suppressive 
nature of the cytokine interferon gamma (IFNγ) (Dighe et al. 1994) and the observation 
that perforin, a key constituent of NK cell cytolytic granules, prevents chemically 
induced tumours in a mouse model (Russell & Ley 2002) helped to silence the critics. 
Furthermore, an increase in the incidence of certain tumours in immunocompromised 
patients strongly supports the cancer immunosurveillance theory (Vajdic & van 
Leeuwen 2009). 
1.1.2   Immune evasion and immunoediting 
If the immune system is capable of eliminating transformed cells then its stands to 
reason that patients’ tumours acquire mechanisms to escape detection or destruction. 
In fact this requirement for a tumour to ‘evade immune destruction’ is listed as one of 
the hallmarks of cancer (Hanahan & Weinberg 2011). As is often seen in nature, when 
a selective pressure is applied to a population, those that have variations allowing 
them to survive will propagate to form similarly adapted offspring. This Darwinian 
mechanism thus not only applies at the level of the organism, but also at the cellular 
level. Transformed cells that are highly immunogenic are destroyed by the immune 
system, allowing only weakly immunogenic cells to remain, expand and colonise until 
the cancer is a clinically detectable entity. This sculpting effect of the immune system 
is known as ‘immunoediting’ and has been demonstrated in experiments involving 
transplanted tumours from both immuno- compromised and competent mice (Kim et 
al. 2007; Teng et al. 2008). 
1.1.3   Pro-tumour immune cells 
Not only is cancer able to evade the immune system but an increasing volume of 
research supports the counterintuitive finding that some immune cells actually 
promote tumour progression. This is achieved in a multitude of ways. For example, by 
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the release of tumour growth factors such as EGF (Qian & Pollard 2010), the secretion 
of the proangiogenic growth factor VEGF, the synthesis of prometastatic matrix-
degrading proteins (Murdoch et al. 2008) and the suppression of cytotoxic immune 
cells (Nguyen & Ohashi 2015). 
1.1.4   Immunotherapy for cancer treatment 
Therapies involving the manipulation of the immune system are known as 
immunotherapies. These are already being used in the clinic to treat cancer and many 
more are currently being developed. For example, antibodies such as trastuzumab and 
rituximab target ERBB2-positive breast cancer and CD20-positive B cell malignancies 
respectively. Tumour regression in patients treated with these antibodies is, in part, 
due to antibody-dependent cell-mediated cytotoxicity (ADCC) (Scott et al. 2012). In 
2011, ipilimumab, an antibody that blocks cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) expressed on T cells, was approved by the FDA to treat patients with 
metastatic melanoma (Fellner 2012). CTLA-4 acts as an ‘immune checkpoint’ by 
preventing the activation of T cells. In doing so it plays an important role in thwarting 
autoimmunity. By inhibiting this immune checkpoint, ipilimumab is believed to 
enhance the antitumor T-cell response (Fellner 2012). Cellular based immunotherapies 
and viral therapies are also being developed with the goal of turning the immune 
evasion pathways operating in patients into productive anti-tumour immunity. 
Immunotherapy offers a new avenue of treatment, especially for cancers such as GBM 
that have a poor prognosis with the current treatment options. To make effective 
immunotherapy a reality for the treatment of GBM it is essential to establish the 
mechanisms of immune evasion in the diseased state. 
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1.2   Glioblastoma Multiforme 
1.2.1   Current treatment and outlook 
GBM is the most common type of primary brain tumour and has a 5 year survival rate 
of just 6% (Cancer Research UK 2016b). The current standard treatment involves 
surgical resection followed by radiation in conjunction with temozolomide 
chemotherapy and a further 6 rounds of temozolomide treatment (Stupp et al. 2005). 
However, tumours inevitably become resistant to treatment and the patients no 
longer respond. Accordingly, the median survival is only 12-15 months (Ahmed et al. 
2014). 
1.2.2   Glial cells 
On a simplified level, the central nervous system (CNS) can be categorized into two cell 
types; neurons and glial cells. The neurons principally act to relay electrical signals, 
whilst the glial (Greek for glue) cells support the neurons. The glial cells can be further 
subdivided into four groups; astrocytes, oligodendrocytes, ependymal cells and 
microglia (Figure 1.1). Astrocytes have a star-like morphology with long protrusions. 
They help to support neurons, maintain chemical concentrations in the extracellular 
space, remove waste, repair tissue damage and form an integral part of the blood 
brain barrier (BBB). Oligodendrocytes have a similar role to Schwann cells found in the 
peripheral nervous system (PNS), insulating axons by synthesizing a myelin sheath (Hall 
2006). Ependymal cells are specialized ciliated cells that line the ventricles of the brain. 
Their cilia help to circulate the cerebrospinal fluid (CSF) which is made within the 
choroid plexus. The CSF acts as a protective cushion for the brain, as well as 
contributing to CNS metabolism and homeostasis. Microglia are brain-resident 
macrophages and provide innate immune defence in the brain (Perry & Teeling 2013). 
They are discussed in more depth in section 1.2.4. 
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Figure 1.1. Central nervous system glial cells. Oligodendrocytes (white), astrocytes (green) and microglia (violet) are located in the brain 
parenchyma. Microglia are brain-resident macrophages. Oligodendrocytes insulate the axons of neurons (blue). Astrocytes support neurons, 
facilitate tissue homeostasis and their foot processes form an integral part of the blood brain barrier (BBB). Ependymal cells (orange) line the 
ventricles and help to circulate CSF. 
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1.2.3   Tumour grading 
Gliomas are currently graded according to their malignancy as described by the WHO 
classification system (Louis et al. 2007). This system is based on seminal research done 
by Bailey and Cushing in 1926 (Bailey & Cushing 1926). Tumours were grouped 
according to patient prognosis and subsequently the histological morphology was used 
to annotate the groups. Tumours dubbed astrocytomas and oligodendrogliomas 
resembled astrocytes and oligodendrocytes respectively. The cells within tumours 
from patients with the worst prognosis mirrored less differentiated precursor cells. 
Therefore, malignant astrocytomas were coined astroblastomas. (Louis et al. 2001). 
Although tumour cells morphologically mimic other cell types, and are named 
accordingly, the tumour initiating cells are still unknown. It is speculated that 
malignant gliomas could arise from a number of cells including neural stem cells, 
neural/glial progenitors, oligodendrocytes or astrocytes (Hadjipanayis & Van Meir 
2009). Currently four groups of astrocytomas are defined; pilocytic, grade I: diffuse, 
grade II: anaplastic, grade III and glioblastoma multiforme (GBM), grade IV. GBM is 
highly invasive into surrounding healthy tissue (Denysenko et al. 2010) and it is 
therefore difficult to excise all of the malignant cells during surgery. In general cancer 
nomenclature, a primary cancer is one that originates within a certain region and a 
secondary cancer is one that metastasizes to the location. However, a primary GBM is 
one that arises de novo and a secondary GBM is one that has progressed from a lower 
grade. Secondary GBMs account for 10% of cases (Van Meir et al. 2010)). An overview 
of the grading system is shown in figure 1.2. 
Over the past 30 years an increasing number of genetic alterations have been 
identified within GBM that correlate, to some extent, with the response to different 
treatments and patient prognosis (Van Meir et al. 2010). Research by The Cancer 
Genome Atlas (TCGA) consortium has confirmed and expanded our knowledge about 
genes and key pathways that are implicated in GBM (Cancer Genome Atlas Research 
Network 2008). Further investigation by the same group using DNA, mRNA and 
microRNA analysis have led to subtypes being described (Verhaak et al. 2010). 
Characteristic alterations are listed in figure 1.2. It is hoped that over time these 
subtypes will help to establish a tailored treatment plan for each group of patients and 
improve survival outcomes. The importance of the molecular changes that define the 
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subtypes is recognised by their inclusion in the recently amended WHO classification 
system (Louis et al. 2016). As molecular profiling becomes a more routine component 
of diagnosis it will enable the use of the updated system. 
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Figure 1.2. An overview of astrocytoma grading and GBM subtypes. The brain consists of neurons and glial cells (astrocytes, oligodendrocytes, 
ependymal cells and microglia). The cell of origin of glial neoplasms (astrocytomas, oligodendrogliomas and ependymomas) is unknown but they are 
named according to resemblance. There are four grades of astrocytoma based on the WHO grading system; grade IV is known as GBM. Lower grade 
tumours that progress to GBM are referred to as secondary GBM. Subgroups of GBM have been established based on DNA, RNA and microarray 
analysis; classical, mesenchymal, neural and proneural. Typical characteristics are listed in the coloured boxes (Van Meir et al. 2010). 
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1.2.4   Brain anatomy and immune surveillance  
In order to understand the challenges faced when treating GBMs it is important to 
understand the anatomy and immune surveillance of the brain. 
1.2.4a   Meninges and the blood brain barrier 
The brain is a critical organ and thus has evolved unique defence mechanisms that are 
employed to protect it. Neurons reside in the brain parenchyma, a tissue that is 
subject to maximum security achieved by three encasing membranes known as 
meninges. Namely, the pia, arachnoid and dura maters lie sequentially from 
parenchyma to skull. The region between the pia and arachnoid membranes is known 
as the sub arachnoid space (SAS). CSF is found within the SAS, along with arachnoid 
trabeculae that entwine the two membranes (Figure 1.3b). This space is also occupied 
by arterial vessels that sink into the parenchyma to deliver nutrients to the brain 
(Figure 1.3c). As these vessels penetrate, so too do the arachnoid and pia maters, 
creating perivascular spaces that are continuous with the SAS (Ransohoff & Engelhardt 
2012). In order to prevent harmful agents from the blood entering the parenchyma, 
regulation is tightly controlled by the BBB. The BBB is a physical barrier that prohibits 
substances with a molecular weight of greater than 500 Da from entering the brain 
parenchyma (a five amino-acid peptide has a molecular weight of ~550 Da) (Daga et al. 
2011). It comprises three cellular components (Figure 1.4); endothelial cells held 
together by tight junctions form an impenetrable barrier, contractile pericytes help 
control the blood flow within the brain and astrocytes protrude foot-like processes 
that tightly enclose the vessel wall and are critical in the formation and maintenance of 
tight junctions (Ballabh et al. 2004). 
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Figure 1.3. Brain anatomy. 
a) A sagittal view of the brain and 
skull showing the routes taken by 
the CSF to enter the DCLNs. The 
majority of the CSF is produced in 
the ventricles. It circulates around 
the brain and is reabsorbed into 
the blood through the arachnoid 
villi. CSF is also trafficked to the 
DCLN either by dural lymphatic 
vessels or along olfactory rootlets 
through the cribriform plate to 
the nasal mucosa and eventually 
to the deep cervical lymph nodes 
(DCLN) via afferent lymphatic 
vessels. b) A coronal view of the 
meninges, dural sinus and the 
adjacent dural lymphatic vessels. 
The meninges (dura mater, 
arachnoid mater and pia mater) 
are concealed beneath the skull. 
Arachnoid villi protrude into dural 
sinuses. c) Astrocytic foot process 
provide a barrier that protects the 
brain parenchyma. See figure 1.4. 
d) A choroid plexus villi. CSF is 
made by the epithelial cells which 
filter fluid from the blood that has 
passed through the fenestrated 
endothelium. The epithelial layer 
is the blood-CSF barrier. Adapted 
from (Ransohoff & Engelhardt 
2012) and (Louveau et al. 2015). 
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Figure 1.4. The blood brain barrier (BBB). Endothelial cells (red) joined by tight 
junctions, pericytes (yellow) and astrocytic foot processes (green) make up the BBB. 
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1.2.4b   Blood-CSF barrier 
The blood-CSF barrier displays a different architecture to the BBB but is also a tightly 
controlled checkpoint of entry into the brain. The blood-CSF barriers are located in the 
four ventricles of the brain in regions known as the choroid plexus. The choroid plexus 
is organized into villi that consist of an outer epithelial layer embodying a fenestrated 
capillary, stromal cells and connective tissue (Figure 1.3d). The epithelial cells are 
closely conjugated by tight junctions and it is this layer that is termed the blood-CSF 
barrier (Lun et al. 2015). These epithelial cells are also responsible for the production 
of CSF. 
1.2.4c   Immune surveillance- CSF 
In addition to physical barriers, the immune system plays an important role in 
protecting the brain. For obvious reasons it is difficult to fully elucidate how the 
immune system functions in a healthy human brain and a lot of the current 
understanding has been based on animal models. Researchers using rodent models in 
the early 1920s reported the observation that antigens or tumours placed in the brain 
parenchyma failed to mount an immune response but this was not the case elsewhere 
in the body. These findings pioneered the conception of the idea in 1953 by Billingham 
and Boswell that the brain is ‘immunologically privileged’ (Galea et al. 2007). 
Anatomical observations supported this idea. For example the presence of the 
restrictive BBB (Galea et al. 2007) and, until 2015, the belief that the brain lacked 
conventional lymphatic vessels (Walker et al. 2002). However, this concept has been 
revised based on the existence of autoimmune diseases of the CNS, such as multiple 
sclerosis (Ransohoff & Engelhardt 2012), and that immune cells have been shown to 
infiltrate brain tumours and play a role in anti-tumour immunity (Brodbelt & Stoodley 
2007). Furthermore, with the newly discovered meningeal lymphatic vessels (Louveau 
et al. 2015), it is now more apparent than ever that immune regulation within the CNS 
is not absent, but is highly specialised. 
The CSF plays an important role in CNS immunity. In addition to the CSF made by 
choroid plexus epithelial cells mentioned above, a small proportion of the CSF 
originates from the interstitial fluid from the brain parenchyma via the perivascular 
spaces (Ransohoff & Engelhardt 2012). The CSF flows from the lateral ventricles, 
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through the third and into the fourth ventricle. From here some of the fluid continues 
to flow downwards and lubricate the spinal cord but the majority will exit the brain to 
the surrounding SAS via two lateral and one median apertures (Brodbelt & Stoodley 
2007). Once in the SAS, the CSF flows from posterior to anterior and is reabsorbed into 
the venous blood stream through the arachnoid villi (Hall 2006). The seminal discovery 
that lymphatic vessels are located within the brain has undoubtedly improved our 
knowledge of immune surveillance within the CNS. Lymphatic vessels were observed in 
a mouse model lining the dural sinuses and were shown to be the major route for CSF 
and cellular components into the deep cervical lymph nodes (DCLN). Similar structures 
were also identified in the human brain (Louveau et al. 2015). A proportion of CSF is 
also trafficked along olfactory rootlets through the cribriform plate to the nasal 
submucosa where it enters lymphatic vessels. Animal studies show that some of this 
subsequently drains to the DCLNs via afferent lymphatic vessels (Koh et al. 2005) 
(Figure 1.3a). These separate routes enable antigens from the parenchyma to reach 
secondary lymphoid tissue (SLT). In effect, the CSF acts as a component of the CNS’s 
lymphatic system.  
1.2.4d   Cellular surveillance 
The cellular components of the immune system operating in the brain are different in 
different anatomical regions. It is, perhaps, helpful to think of the brain as two 
sections; the parenchyma and everything exterior; the meninges, perivascular spaces 
and the ventricles. Microglia are the only immune cells routinely reported to be 
present in the healthy parenchyma. They help maintain homeostasis in the 
parenchyma, for example, by removing neurotransmitters (Shaked et al. 2005) and 
modifying and eliminating certain synapses (Tremblay et al. 2010). Immunologically, 
they are capable of antigen presentation and T cell activation in response to 
pathological insults (Ford et al. 1996). Myeloid cells outside the parenchyma include 
meningeal macrophages, perivascular macrophages and choroid plexus macrophages. 
The residence of these cells is indicated by their names. Their location is ideal to 
sample CSF from both parenchyma drainage and that originating within the ventricles. 
Mast cells are also present in the meninges and perivascular spaces. Perivascular 
macrophages are optimally positioned to activate extravasated lymphocytes by 
antigen presentation and also stringently control lymphocyte entry into the 
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parenchyma (Ransohoff & Engelhardt 2012). It is commonly reported that the most 
abundant cell type in CSF is T cells. However, there are conflicting accounts of the type 
and proportion of T cell present. This could be due to the method used to assess the 
composition, for example a lumbar puncture extracts CSF from the bottom region of 
the spine compared to autopsy tissue where CSF can be viewed in the SAS. It is also 
possible that the immune composition within the brain could change following death 
despite a lack of neurological disease. Some groups report a high proportion of CD4+ 
memory T cells (Kivisäkk et al. 2003). It is thought that these T cells predominantly gain 
access to the brain via the choroid plexus (Ransohoff et al. 2003). Here they can 
interact with the antigen presenting cell and traffic to the DCLN via the cribriform plate 
(Goldmann et al. 2006). 
The historic theory the brain is ‘immune privileged’ has now been revised and 
accounts for the differential surveillance in separate compartments. The new 
definition acknowledges that privilege is restricted to the parenchyma but is not 
absolute, it is not present in the meninges, choroid plexus or ventricles and it is not 
maintained during inflammation (Galea et al. 2007). The immune cell composition 
within the brain changes during disease, including cancer.
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1.2.5   Immune cell composite within glioblastoma multiforme 
Many studies have been undertaken to characterise immune cell infiltration within 
GBM and different results have been reported. This can partly be due to different 
markers used to define the cells and the techniques employed for identification, such 
as flow cytometry and immunohistochemistry, but it could also reflect the different 
response seen between patients. For example, within a study of just 9 patients the 
composition of macrophages in the tumour varied widely from 31-90% of total cells 
(Morantz et al. 1979). It is also feasible that the stage of disease progression correlates 
with the immune composition, as regulatory T cells (Tregs) have been shown to 
accumulate in a time dependent fashion in an animal model (Grauer et al. 2007). 
Another critical consideration to note is that the categorisation of certain infiltrates, 
such as tumour infiltrating lymphocytes (TILs) incorporates subsets of cells that have 
opposing roles in tumour biology; CD3+CD8+ T cells correlate with prolonged survival 
in GBM patients (Kmiecik et al. 2013), but CD4+CD25+ Tregs inhibit anti-tumour 
immune activation. Similarly, subpopulations of macrophages exist and whilst M1 
macrophages are linked with a pro-inflammatory response, M2 macrophages exhibit 
anti-inflammatory, pro-tumour behaviour (Mantovani & Sica 2010). In glioma patients, 
high levels of M2 macrophages correlated with higher WHO pathological grades and 
poor prognosis, whereas the opposite was true of M1 macrophages (Ding et al. 2014). 
It is widely reported that the most abundant immune cell within GBMs are myeloid 
derived macrophages (resident microglia and infiltrating macrophages) and they can 
constitute a high proportion of cells within the tumour mass (Dunn et al. 2007). In 
conjunction with M2 macrophages, microglia have also been implicated in tumour 
progression. Microglia have been reported to secrete anti-inflammatory molecules 
such as interleukin (IL)-10 (Seo et al. 2004) and prostaglandin E2 (Watters et al. 2005) 
which acts to reduce the expression of class II major histocompatibility complex (MHC) 
on antigen presenting cells (APCs) (Hishii et al. 1995), limiting antigen presentation to T 
cells. In addition to engaging an MHC complex, T cells must bind to costimulatory 
molecules such as CD86, CD80 and CD40. Microglia within GBM reportedly lacked the 
expression of such molecules (Hussain et al. 2006). Without sufficient costimulation, T 
cells can become anergic (Schwartz 2003) and fail to respond appropriately to tumour 
antigens. 
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Other immune cells of both myeloid and lymphoid origin have been reported in GBMs 
and either play a direct role in immune evasion or have been evaded by the tumour. 
Myeloid-derived suppressor cells (MDSCs) are thought to accumulate in tumours due 
to the presence of cytokines and growth factors, such as granulocyte macrophage 
colony stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), IL-2, 
and VEGF (Ostrand-Rosenberg 2010). They exhibit several methods to inhibit T cell 
activity, such as the production of arginase that reduces the availability of L-arginine, 
which is critical for T cell function (Rodríguez & Ochoa 2008), and the secretion of nitric 
oxide and reactive oxygen species that also act to repress T cell activation (Nagaraj & 
Gabrilovich 2007). Different numbers of TILs have been observed in GBMs (Dunn et al. 
2007) and numerous immune evasion strategies prevent tumour elimination by TILs. 
For example, expression of the Fas ligand (FasL) on tumour cells can induce T cell death 
by engaging with Fas receptor, a tumour necrosis factor (TNF) receptor superfamily 
member (Saas et al. 1997). Some tumour cells also lack the co stimulatory molecules 
required to effectively activate naïve T cells, such as CD80 and CD86 (Wintterle et al. 
2003). 
It is clear that both innate and adaptive immune cells play a role in tumour surveillance 
and many tactics are employed by the tumour to evade the onslaught of multiple 
cellular defence mechanisms. To develop successful cell based immunotherapies it is 
vital to improve our understanding of immune interactions within GBMs. 
1.2.6   Immunotherapies for GBM 
The last major advancement for the treatment of GBM patients occurred in 2005. 
Stupp and colleagues reported an increase in overall survival (OS) for patients who had 
undergone debulking surgery and were subsequently treated with radiotherapy and 
chemotherapy (specifically temozolomide) compared to radiotherapy alone (Stupp et 
al. 2005). Although this treatment trumps its predecessors and is now the current 
standard of care for patients in the UK, the reality is that a patient’s life has been 
extended by just 2.5 months; a survival prognosis of only 14.6 months. With a better 
understanding of the immunosuppressive microenvironment of GBM and the frequent 
mutations that occur, scientists have begun to develop immunotherapies that could 
improve their prognosis. The immune system can be manipulated in many different 
ways and as such there are different categories of immunotherapy; active 
 
17 
immunotherapy, passive immunotherapy, immunomodulator therapy and virotherapy. 
Numerous trials have been conducted within each category. Some of the more 
prominent are discussed below. 
1.2.6a   Active immunotherapies 
Active immunotherapies include cancer vaccines that aim to eliminate the tumour, 
primarily by activating cytotoxic T lymphocytes (CTLs). To prime the CTLs specifically 
against the tumour, tumour associated antigens (TAA) must be presented to them by 
APCs such as dendritic cells (DCs) (Bielamowicz et al. 2013). This can be achieved by 
loading the DCs outside of the body or by injecting the TAA into the body. Additional 
costs are associated with the former method. One TAA that has been the focus of 
many vaccine trials (reviewed in (Xu et al. 2014) is a mutant epidermal growth factor 
receptor (EGFR), EGFRvIII that has been shown to be overexpressed in 31% of GBM 
samples (Heimberger et al. 2005). The mutation involves a deletion in part of the 
extracellular domain of the growth factor receptor which causes it to become 
constitutively active (Prigent et al. 1996). Early clinical trials involved pulsing DCs with 
modified EGFRvIII peptides and delivering them to patients intradermally (Sampson et 
al. 2009). The vaccine was deemed safe and further trials revealed that the treatment 
successfully eliminated EGFRvIII positive cells (Sampson et al. 2008). A collective 
analysis of 3 phase II trials that used a synthetic EGFRvIII peptide, rindopepimut, 
resulted in a promising overall survival of 24 months from diagnosis (Zussman & Engh 
2015). However in March 2016, the subsequent double-blind phase III trial (ACT IV) 
was discontinued as the results showed no benefits over the placebo (NCT01480479). 
1.2.6b   Passive immunotherapes 
Passive therapies include adoptive cell therapies and monoclonal antibodies. During 
adoptive immunotherapy effector cells are introduced into the patient to induce anti-
tumour activity. In a recent phase II trial, lymphokine-activated killer (LAK) cells were 
placed directly into the tumour cavity by the surgeon after debulking surgery. These 
cells were generated by isolating peripheral blood mononuclear cells (PBMCs) from the 
patient and activating them with interleukin-2 (IL-2) for 3 to 5 days. The median 
survival from original diagnosis was 20.5 months and the 1-year survival rate was 75% 
(Dillman et al. 1997). Other cell therapies currently being investigated involve the use 
of genetically modified T cells (Bielamowicz et al. 2013). 
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As mentioned previously, antibodies are already used in the clinic to treat cancer. The 
first, rituximab which targets CD20 on B cells, was licensed by the FDA in 1997 to treat 
B cell non-Hodgkin lymphoma (Teo et al. 2016). GBM tumours are highly vascularised 
and the sprouting of new vessels (angiogenesis) is a key process in tumour progression 
(Jain et al. 2007). Angiogenesis is promoted by VEGF which is released by the glioma 
cells (Ahmed et al. 2014). Following promising early clinical trials, a monoclonal 
antibody targeting VEGF-A (bevacizumab) was given FDA approval for the treatment 
recurrent glioma in 2009. A number of further studies investigating the use of 
bevacizumab for newly diagnosed patients revealed worrying side effects, such as 
hypertension, thromboembolic events, intestinal perforation, and neutropenia, with 
no survival advantage (Gilbert et al. 2014). More concerning are reports that 
bevacizumab promotes invasion and metastasis in both animal models (Pàez-Ribes et 
al. 2009) and patients (Tuettenberg et al. 2009). Bevacizumab is not approved for 
treating GBM in the UK. 
Other antibody therapies currently in trials (for example NCT02017717 and 
NCT02617589) for GBM patients include the checkpoint inhibitors nivolumab and 
ipilimumab that target programmed cell death protein 1 (PD-1) and CTLA-4 
respectively. T cell activation is determined by the integration of both stimulatory and 
inhibitory signals. PD-1 is a membrane protein that is able to provide an inhibitory 
signal when it interacts with its ligands PD-L1 and PD-L2 (Nguyen & Ohashi 
2015)(Figure 1.5). CTLA-4 competes with the costimulatory receptor CD28 to bind the 
dual ligands CD80 and CD86; in doing so it helps to prevent T cell activation (McCoy & 
Le Gros 1999). Simultaneously blocking both of these inhibitory signals using 
antibodies has proved effective in the treatment of advanced melanoma in clinical 
trials (NCT01927419) and in June 2016 the treatment was approved by the National 
Institute for Health and Care Excellence (NICE). 
Lymphocyte activation gene 3 (LAG-3) is also an immune checkpoint receptor that is 
upregulated on Tregs and anergic T cells. It binds a region of MHC class II with greater 
affinity than CD4 and downregulated T cell proliferation. LAG-3 antibodies are being 
developed for cancer immunotherapy (He et al. 2016). 
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Figure 1.5. T cell regulation by PD-1. T cells are activated when their T cell receptors 
recognise a peptide presented on an MHC class I complex, in addition to CD28 binding 
a costimulatory protein such as CD80 or CD86. To prevent collateral damage to healthy 
tissue during chronic inflammation, suppression of T cells is required. PD-L1 and PD-L2 
interact with PD-1 to down regulate T cells. Tumour cells have exploited this 
mechanism by displaying these inhibitory ligands. Diagram based on (McDermott & 
Atkins 2013). 
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1.2.6c   Virotherapies 
The use of viruses to treat patients, virotherapy, is also being explored. Although the 
concept of virotherapy is more than 100 years old (Kelly & Russell 2007), no 
virotherapy has yet been approved for the treatment of GBM patients. A number of 
viruses are currently in clinical trials such as poliovirus, adenovirus, herpes simplex 
virus and reovirus (Koks et al. 2015). Originally it was thought that viruses exerted their 
effect by selectively replicating in tumour cells and thereby causing specific tumour cell 
lysis. However, given that non-virulent virus strains are also able to elicit an anti-
tumour response, it is now understood that the presence of the virus also acts as an 
adjuvant and helps to recruit and activate immune cells (Melcher et al. 2011). An 
ongoing phase I trial (NCT01491893) to treat recurrent GBM patients with a modified 
poliovirus has sparked excitement in America. The non-virulent virus is thought to gain 
entry into tumour cells via the CD155 surface protein. The group report a 23% 2 year 
survival rate compared to 13.7% in historical controls (Desjardins et al. 2016). A double 
blind study needs to be performed to establish if this treatment has a statistically 
significant survival advantage over the existing one. Paradoxically, the efficiency of the 
innate immune system has been implicated in hampering the efficacy of virotherapy in 
a murine model of GBM. NK cells, which have evolved to target viral infection, were 
shown to impede treatment with oncolytic Herpes simplex virus (oHSV) (Alvarez-
Breckenridge et al. 2012) but this has since been prevented by the administration of 
transforming growth factor beta (TGF-β) prior to oHSV administration (Han et al. 
2015). 
Evidently, a vast amount of research is being done to develop immunotherapies in 
order to improve the outlook for patients. However, very little progress has actually 
been made to advance the survival statistics and, as of yet, the great potential of 
immunotherapies is still to be harnessed for the treatment of patients with GBM. 
1.2.7   Cancer stem cells 
Cancer stem cells (CSCs) are defined as having the ability to self-renew, differentiate 
into different lineages within the tumour and recapitulate the original disease 
phenotype in animal models (Singh et al. 2003). The CSC hypothesis states that CSCs 
exist at the top of the cellular hierarchy within a tumour and can differentiate to form 
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the diverse progeny of the tumour bulk. Once differentiated, the cells lose the capacity 
to self-renew (Pointer et al. 2014). Glioma stem cells (GSCs) are CD133+ (Singh et al. 
2004) and are known to be resistant to current radio- and chemotherapies (Bao et al. 
2006; Liu et al. 2006). Their resistance to treatment implicates these cells in relapse 
and future therapies should target these cells with the aim of reducing recurrence. 
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1.3   NK cells 
1.3.1   Overview 
Natural killer (NK) cells are large granular lymphocytes that exhibit both cytotoxicity 
and cytokine-producing effector functions (Vivier et al. 2008). They were discovered in 
1975 by Rolf Kiessling whilst investigating cell mediated cytotoxicity against cancer 
cells. He identified a lymphocyte population isolated from mouse spleens that was 
able to ‘naturally kill’ mouse leukaemia cells in vitro without prior immunisation 
(Kiessling et al. 1975). It is now established that, in addition to transformed cells, NK 
cells are capable of recognising and killing virus infected cells and play a key role in 
regulating the adaptive immune system (Kruse et al. 2014). Accordingly, recurring virus 
infections and an increase in the incidence of some cancers are observed in patients 
with NK cell deficiencies (Orange 2013). 
Leukocytes are often defined according to the presence or absence of surface 
molecules that have been designated a ‘cluster of differentiation’ (CD) number which 
provides information about the cell’s function (Chan et al. 1988). NK cells originate 
from CD34+ hematopoietic progenitor cells (HPCs) (Freud & Caligiuri 2006) and 
constitute 2-18% of lymphocytes within human peripheral blood (Grégoire et al. 2007). 
NK cells are typically identified as lacking the T cell receptor complex (including 
CD3gamma and delta chains), but display neural cell adhesion molecule (CD56) or 
natural cytotoxicity triggering receptor 1 (NCR1, also known as NKp46 or CD335); CD3-
CD56+ or CD3-NKp46+ (Morvan & Lanier 2016). Broadly speaking, NK cells can be 
categorised as CD56bright and CD56dim cells. The CD56bright subset primarily function to 
release cytokines, but exhibit little or no cytotoxic activity (Cooper et al. 2001), 
whereas the opposite is true for CD56dim cells (Walzer et al. 2007). CD56dim cells also 
express CD16, a low affinity Fc receptor, allowing them to participate in ADCC when 
they encounter cells coated in IgG antibody. Therefore NK cells are important effectors 
in antibody therapies (Seidel et al. 2013). A more recent nomenclature system has 
been proposed to categorise innate lymphoid cells (ILCs) based on their cytokine 
secretion profile and transcription factors. NK cells are a prototypical group 1 ILC as 
defined by their ability to produce IFNɣ (Spits et al. 2013) that plays an important role 
in shaping the immune response. IFNγ can induce upregulation of MHC class I 
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expression on APCs (Wallach et al. 1982), induce macrophage killing of intracellular 
pathogens (Filipe-Santos et al. 2006) and prevent the division of aberrant cells (Maher 
et al. 2007). 
1.3.2   Mechanisms for killing 
Natural killer cells can kill target cells either by releasing the cytotoxic contents within 
their granules or by engaging death receptors such as Fas or the TNF-related 
apoptosis-inducing ligand (TRAIL) receptor on the surface of target cells (Caligiuri 
2008). 
1.3.2a   Granule exocytosis 
Activation or inhibition signals are generated at the site of contact between the NK cell 
and target cell known as the immunological synapse (IS). These synapses can be 
activating, inhibitory or regulatory depending on the receptor-ligand complexes 
present (Krzewski & Strominger 2008). Activating ISs are highly organised and contain 
an outer region known as the peripheral supramolecular activation cluster (pSMAC) 
and a central region; central supramolecular activation cluster (cSMAC) (Figure 1.6). 
Adhesion molecules such as LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) are located 
in the pSMAC whilst the NK cell activating receptors (see section 1.3.3b) occupy the 
cSMAC. Engagement of the activating receptors causes an intracellular signalling 
cascade that results in polarisation of the microtubule organising centre (MTOC) and 
the recruitment of lytic granules to the IS where the granules are exocytosed (Krzewski 
& Coligan 2012). The granules contain the pore-forming protein, perforin, that allows 
the entry of the proteolytic granzymes into the cytoplasm of the target cell (Catalfamo 
& Henkart 2003). Granzymes are serine proteases and, to date, five have been 
identified in humans; A, B, H, K and M. Once within the target cell cytosol, granzymes 
proteolytically cleave their target proteins, leading to apoptosis through activation of 
caspases, induction of mitochondrial damage, and DNA fragmentation (Figure 1.6) 
(Krzewski & Coligan 2012). 
1.3.2b   Death receptor 
Apoptosis of the target cell can also be induced by signalling through membrane-
bound death receptors. The interaction of NK cell Fas ligand or TRAIL with their 
corresponding receptors on target cells, Fas (CD95) or TRAIL receptors, causes the 
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activation of the caspase cascade. Ligand binding results in receptor oligomerization, 
recruitment of adaptor proteins such as Fas-associated death domain (FADD) and 
cleavage of procaspase 8 to the active form. The resulting cell death is similar to 
granzyme induced apoptosis (Figure 1.6) (Warren & Smyth 1999). 
 
 
 
Figure 1.6. Mechanisms of NK cell target killing. The left hand side depicts the 
exocytosis of NK cell cytotoxic granules leading to the apoptosis of the target cell. An 
activating immunological synapse (IS) causes the polarisation of the microtubule 
organising centre (MTOC) and the recruitment and release of lytic granules. Perforin 
allows the entry of granzymes into the cytosol of the target cell where they exert their 
proteolytic action. The right hand side details induction of the target cell apoptosis by 
the engagement of death receptors. Adapted from (Krzewski & Coligan 2012; Warren 
& Smyth 1999). 
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1.3.3   Regulation of NK cells 
With the ability to kill cells and induce an immune response, the activity of NK cells 
must be tightly regulated and this is achieved by the integration of signals from both 
activating and inhibitory receptors, including those for cytokines and chemokines. 
1.3.3a   Cytokines/chemokines 
There are many different cytokines that act to regulate NK cells. For example, 
interleukin 2 (IL-2), interleukin 15 (IL-15), type I IFN, interleukin 12 (IL-12) and 
interleukin (IL-18) are potent activators of NK cell effector function (Walzer et al. 2005; 
Trinchieri 1989) whereas molecules such as prostaglandin E2 (PGE2), indoleamine 2,3-
dioxygenase (IDO), adenosine and TGF-β are known to inhibit NK cells (Morvan & 
Lanier 2016). 
Two of the best characterised activating cytokines are IL-2 and IL-15 and they bind to 
membrane bound receptors, the IL-2 receptor (IL-2R) and IL-15 receptor (IL-15R) 
respectively. The receptors are heterotrimeric, of which 2 subunits are common to 
both receptors; the common cytokine-receptor γ-chain (γc or CD132) and the IL-2 
receptor β chain (CD122) (Waldmann 2006). The third subunits are the IL-2Rα and IL-
15Rα chains. These can either be membrane bound or presented together with the 
cytokine (Mishra et al. 2014). When IL-15Rα and IL-15 are displayed together by one 
cell to interact with the IL-15Rβ and γ subunits on another, it is called trans-
presentation. Trans-presenting cells include neutrophils, monocytes and dendritic cells 
(Stonier & Schluns 2010). Intracellular signalling of IL-15 leads to NK cell activation and 
uses Janus-associated kinases (JAK) and signal transducer and activator of transcription 
(STAT)(Johnston et al. 1995). The binding of IL-15 causes activation on JAK1 and 
subsequent phosphorylation of STAT3 that is mediated by the β chain (CD122). 
Likewise, the γ chain coordinates JAK3/STAT5 activation (Lin et al. 1995; Miyazaki et al. 
1994). Once phosphorylated, STAT5 and STAT3 form a complex that translocates to the 
nucleus and activates transcription of the anti-apoptotic protein bcl-2 and proto-
oncogenes c-myc, c-fos and c-jun (Mishra et al. 2014). IL-15 activation has also been 
reported to signal through the PI3K/AKT and Ras/MAPK pathways (Mishra et al. 2014). 
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The established immunosuppressive cytokine TGF-β is produced by tumour cells and is 
thought to promote cancer metastasis through its actions in the tumour 
microenvironment, including enhancement of tumour cell invasion and by inhibiting 
the function of immune cells (Flavell et al. 2010; Massagué 2008). TGF-β prevents NK 
cell effector functions by preventing IFNγ production and cytotoxic activity (Laouar et 
al. 2005; Rook et al. 1986). TGF-β signals through its tetrameric membrane receptor 
complex made up of two TGF-βRI chains and two TGF-βRII chains. When bound by 
TGF-β, the type I chains trans-phosphorylates the type II chains which enables the 
phosphorylation of transcription factors Smad2 and Smad3 (Smad2/3). The SMAD2/3 
complex is then able to translocate to the nucleus where it interacts with Smad4 and 
other proteins to regulate transcription (Derynck & Zhang 2003). 
1.3.3b   Activating and inhibiting receptors 
Following the discovery of NK cells in 1975, the next logical step was to discover how 
cytotoxicity was regulated. In 1981 Klas Kärre, PhD student of Rolf Kiessling, published 
his thesis which contained the first version of the, then somewhat controversial, 
‘missing-self’ recognition concept, whereby the absence or incomplete expression of 
host MHC class I molecules in a normal cell would be sufficient to render it susceptible 
to NK cells. The theory was postulated following the observed ‘hybrid resistance’ in 
animal transplant models; an (A x B) F1 recipient rejects A or B grafts of parental origin 
(A and B referring to MHC genotypes). The absence of some MHC class I genes in a 
parental to F1 graft led to rejection by NK cells (Kärre 2002). Further evidence 
supported the ‘missing-self’ theory; cells lacking MHC class I were susceptible to NK 
cell death (Stern et al. 1980) and interferon upregulated MHC class I expression 
reduced susceptibility to NK cell lysis (Trinchieri & Santoli 1978). NK cells complement 
T cell immune surveillance as the downregulation of MHC class I proteins, a strategy 
commonly employed by tumour and virally infected cells as a way of avoiding T cell 
recognition (Alcami & Koszinowski 2000; Algarra et al. 2004), will render cells 
susceptible to NK cell lysis. 
Although the ‘missing self’ theory was first coined in the early 1980s, it would be 
another 10 years before the inhibitory receptors that interact with MHC molecules 
were discovered. It is now known that there are both activating and inhibitory 
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receptors and NK cell activity depends on the integration of signals from both types of 
receptor (Long et al. 2013). There are many different NK cell receptors but two of the 
main groups, based on their structure, are the killer cell immunoglobulin receptors 
(KIRs) and the killer lectin like receptors (KLRs) (Lanier 2008). Perhaps confusingly, the 
groups contain activating and inhibitory receptors; the key difference occurs in the 
intracellular and membrane regions of the receptors that allow the recruitment of 
specific proteins and subsequent differential downstream effects. This section aims to 
give an overview of activating and inhibitory receptors, highlighting the importance of 
integrating signals with a key focus on receptors investigated as part of this PhD. 
The killer cell immunoglobulin-like receptor (KIR) genes are encoded on chromosome 
19 in a region known as the leukocyte receptor complex (LRC) (Barrow & Trowsdale 
2008). KIRs are monomeric type I glycoproteins (Lanier 2008) and consist of an 
extracellular region containing either two or three immunoglobulin domains (KIR2D or 
KIR3D), with either a long or short cytoplasmic tail. Long-tailed KIRs contain either one 
or two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and are inhibitory 
(Figure 1.7). Conversely, short-tailed receptors have a positively charged lysine residue 
within the membrane region of the protein that mediates coupling to DAP12, a protein 
containing an immunoreceptor tyrosine-based activation motif (ITAM). Inhibitory KIRs 
are better characterised than activation KIRs and, whilst many inhibitory KIRs have 
well-defined MHC class I ligands, activating KIRs show only weak binding (Rajagopalan 
& Long 2005). When inhibitory KIRs bind their ligands, the tyrosine residue within the 
ITIM is phosphorylated which leads to the recruitment of phosphatases that compete 
with kinases linked to activating receptors to prevent the phosphorylation of proteins 
within the activation cascade. For example, SHIP-1 dephosphorylates 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) to phosphatidylinositol-3,4-
bisphosphate (PIP2), whereas SHP-1 and SHP-2 dephosphorylate the guanine 
nucleotide exchange factor Vav1 (Figure 1.8). The inhibitory KLRs, such as CD94-
NKG2A, also signal using ITIMs (Figure 1.7) (Lanier 2008). 
In a similar fashion, the ITAM is used by many of the activation receptors including 
activating KIRs, the natural cytotoxicity receptors (NCRs; NKp30, NKp44 and NKp46)), 
CD16 and activating KLRs (Figure 1.7). In general, the receptor has a positively charged 
residue within the membrane domain through which it interacts with a negatively 
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charged residue within the membrane domain of a membrane anchored accessory 
protein that contains one or more ITAMs in the cytoplasmic domain. The exception is 
CD16 that has a negatively charged residue, aspartic acid (D) in the membrane region. 
The ITAM containing proteins include DAP12, FcεRI-γ and CD3-ζ (Lanier 2008; Long et 
al. 2013). An overview of the receptors, including their ITAM associated proteins and 
ligands are summarised in figure 1.7. Many of the receptors, including KIRs, NCRs and 
CD16, contain immunoglobulin domains in the extracellular region of the protein so 
belong to the immunoglobulin superfamily (Kruse et al. 2014; Mandelboim et al. 1999). 
CD16 is a strong activating receptor and recognises the constant region (Fc) of IgG 
antibodies (Long et al. 2013). CD16 mediates ADCC by NK cells in antibody therapies 
(Seidel et al. 2013). The NCRs were discovered in the late 1990s (Sivori et al. 1997) and, 
despite having different amino acid sequences and structures (Joyce & Sun 2011), they 
have been grouped together based on their functions. NKp46 (CD335) is present on NK 
cells, regardless of activation status (Sivori et al. 1997) and has been used in this study 
to facilitate NK cell identification. Many ligands have been suggested for the NCRs 
(Kruse et al. 2014; Morvan & Lanier 2016) but the only one that has been confirmed 
with a receptor-ligand co-crystal structure is NKp30 with B7-H6. B7-H6 is a surface 
transmembrane protein and is not detected in healthy tissue but is detected on many 
tumour cell lines (Brandt et al. 2009). When the receptors bind their ligands, the 
tyrosine residues within the ITAMs of associated proteins are phosphorylated, 
probably by Src family kinases (Lanier 2008). This allows the recruitment of kinases Syk 
and ZAP-70 via their Src homology 2 (SH2) domains and activation of downstream 
pathways including PI3K and phospholipase Cγ (Figure 1.8)(Long et al. 2013). 
NKG2D (CD314) is an activation receptor of the KLR family and the human form exists 
as a hexamer composed of an NKG2D homodimer and two DAP10 homodimers. 
NKG2D recognises stress induced proteins MHC class I polypeptide-related sequence 
A/B (MIC A/B) and the UL16 binding proteins (ULBPs) that are present on cancer cells 
(Raulet 2003). As with DAP12, DAP10 contains a signalling motif that results in the 
activation of signalling cascades. However, it is not an ITAM but a tyrosine-isoleucine-
asparagine-methionine (YINM) motif which when phosphorylated is able to recruit 
PI3K through the P85 subunit or Grb2 (Lanier 2008). 
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DNAM-1 (DNAX accessory molecule-1, CD226) is an immunoglobulin activation 
receptor found on both NK and CD8 T cells (Shibuya et al. 1996). It recognises related 
proteins Nectin-2 (CD112) and the poliovirus receptor (CD155) (Bottino et al. 2003), 
both of which are upregulated on tumour cells. The cytoplasmic domain of DNAM-1 
contains signalling motifs that enable the recruitment of tyrosine kinases Fyn and 
serine-threonine kinase PKC (Shibuya et al. 1998). DNAM-1 works in conjunction with 
LFA-1, which is important for the tyrosine phosphorylation by Fyn and subsequent 
downstream activation (Shibuya et al. 1999). 
2B4 is an immunoglobulin-like co-receptor of the signalling lymphocytic activating 
molecule (SLAM) receptor family that recognises CD48 (Veillette 2010). Although its 
positive cytolytic functions were originally identified (Garni-Wagner et al. 1993), 
subsequent studies have reported inhibitory functions (Schatzle et al. 1999; Dong et al. 
2009). Although some discrepancy exists as to the circumstances of activation or 
inhibition, Veillette proposes that associated proteins that interact with the 
immunoreceptor tyrosine-based switch motif (ITSM) within the cytoplasmic domain of 
2B4 are a key determinant of effector functions; SLAM associated protein (SAP) and 
Fyn confer activation, whereas EAT2 inhibits activation (Veillette 2010; Veillette et al. 
2007). 
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Figure 1.7. NK cell receptors and ligands. The activity of NK cells is regulated by the integration of signals from a repertoire of activation and 
inhibitory receptors. NK cell receptors that are part of the immunoglobulin (Ig) superfamily include killer cell immunoglobulin receptors (KIRs), CD16, 
natural cytotoxicity receptors (NCRs; NKp30, NKp44 and NKp46), DNAM-1 and 2B4. Both the Ig superfamily and killer lectin-like receptors contain 
activation and inhibitory receptors. Inhibitory receptors signal through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (red), whereas 
activation receptors interact with accessory proteins such as DAP12, FcεRI-γ and CD3-ζ which contain immunoreceptor tyrosine-based activation 
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motifs (ITAMs) (green rectangle) or DAP10 which contains a YINM (green triangle). Based on information in (Lanier 2008; Kruse et al. 2014; Long et al. 
2013). 
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Figure 1.8. The integration of signalling downstream of activation and inhibitory receptors. Inhibitory receptors have ITIMs within the cytoplasmic 
part of the protein. When the receptor is bound by its ligand, the tyrosine residue within the ITIM becomes phosphorylated which leads to the 
recruitment of phosphatases such as SHIP-1, SHP-1 or SHP-2 that lead to the dephosphorylation of PIP3 and Vav1 respectively. This opposes the 
downstream signalling of activation receptors that are coupled to proteins containing activation motifs such as DAP12 and DAP10 that harbour an 
ITAM and YINM respectively. Binding of the activation receptors leads to the activation of signalling cascades including PI3K, PLCγ and Ras/Raf/MEK 
pathways. Based on information in (Lanier 2008; Kruse et al. 2014; Long et al. 2013). 
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1.3.4   Detection within brain tumours 
When reviewing the literature of brain infiltrating NK cells it is important to consider 
how the NK cells were defined and the method used to detect them. In 1988, a study 
of immune cell infiltrates was performed on both primary and secondary brain 
tumours which included grade IV gliomas (Stevens et al. 1988). Immunohistochemistry 
was utilised and NK cells were identified as Leu7 (CD57) positive cells. No NK cells were 
detected within grade I and II gliomas and low levels of NK cells were detected within 
grade IV gliomas and those that were present were within perivascular cuffs. The study 
presents two issues; firstly, if the cells only constitute a small proportion of the total 
number there is a distinct possibility that they will not be detected and secondly, not 
only is CD57 only expressed on a subset of NK cells, it is also present on a large 
proportion of T cells (Lopez-Vergès et al. 2010). Other markers used are not without 
their problems either; Leu11b (CD16) was used to study NK cell infiltration within 
oligodendrogliomas (Rossi et al. 1991) but it is not expressed on all NK cells. Although 
each study comes with its own restrictions, these consistently find that NK cells make 
up only a very small proportion of infiltrating cells if they are detected at all (Kmiecik et 
al. 2014). 
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1.4   Rationale for using cell based immunotherapies  
The current standard treatment for GBM involves surgical resection, radiotherapy and 
the administration of the chemotherapeutic drug temozolomide (Stupp et al. 2005). 
However, the prognosis of GBM patients remains poor. Although surgical resection 
removes the visible tumour mass, it does not eliminate the diffuse, migratory cells that 
are characteristic of GBM and inevitably the tumour recurs. Temozolomide is an 
alklyating agent that adds methyl groups to the oxygen at position 6 of guanine. This 
causes DNA fragmentation that prevents DNA replication, leading to tumour 
suppression and apoptotic cell death (Zhang et al. 2012). Treatment with 
temozolomide eventually yields populations that have acquired resistance by 
upregulating the DNA repair enzyme O6-methylguanine-DNA methyltransferase 
(MGMT) (Bandres et al. 2005). Alongside acquired resistance, the use of 
chemotherapies can also be restricted by the BBB as it disrupts the efficient delivery of 
systemically administered drugs (Doolittle et al. 2005). These challenges reiterate the 
need for novel strategies to improve the outcome of patients with GBM. Cell based 
immunotherapies are an exciting prospect as immune cells identify cancer cells based 
on molecular surface properties so could potentially identify cells that have spread 
from the tumour bulk. Importantly, activated immune cells can cross the BBB (Sehgal 
& Berger 2000). 
NK cells are of particular interest when considering immunotherapies because they 
can kill transformed cells without prior sensitisation (Herberman et al. 1975), help 
prime the adaptive immune response by the release of regulatory cytokines such as 
GM-CSF and IFNγ (O’Connor et al. 2006) and are important responders in cancer 
antibody therapies (Caligiuri 2008). However, in order for this to be achieved for 
patients with GBM, the NK cells must be capable of homing to the tumour and, once 
there, they must have functional cytotoxic activities. 
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1.5   Glucocorticoids 
When considering the use of cell based immunotherapies for the treatment of GBM, 
and indeed other cancers, it is important to consider the effects of other clinical 
treatments on immune cells. GBM patients often experience cerebral oedema that is 
treated with synthetic glucocorticoids (GCs), such as dexamethasone (Kostaras et al. 
2014). 
Naturally occurring GCs are steroidal hormones that are synthesised in the adrenal 
cortex. The name glucocorticoid (glucose + cortex + steroid) reflects their role in 
regulation of glucose metabolism, site of synthesis and steroidal structure (De 
Bosscher 2010). GCs are also potent anti-inflammatory molecules. In fact, it was this 
property that led to the initial identification of adrenal cortex hormones by Edward 
Kendall, Philip Hench and Tadeus Reichstein for which they were awarded the Nobel 
Prize for Physiology and Medicine in 1950 (Hench 1950). The initial success observed 
with the administration of cortisone for the treatment of rheumatoid arthritis (Hench 
& Kendall 1949) lead to the development of related synthetic compounds such as 
dexamethasone and methylprednisolone that retained the anti-inflammatory 
properties, but reduced the associated side effects (Herzog et al. 1955; Bunim et al. 
1958). GCs are still widely used in current clinical practice to treat an array of 
inflammatory, immune and allergic disorders (such as arthritis and asthma), blood 
cancers, and are administered following transplant surgery to prevent rejection 
(Sundahl et al. 2015). The clinical use of GCs predates knowledge of the mechanism of 
action. For example, it was not until 1985 that the glucocorticoid receptor (GR) was 
shown to bind DNA and regulate transcription initiation (Yamamoto 1985). There is 
now evidence that GCs exert their effects in different ways, examples of which are 
discussed below. 
It is generally accepted that GCs are fat soluble and diffuse across the cell membrane 
to the cytosol where they are able to bind the GR (De Bosscher et al. 2003). GRs are 
made up of different functional domains including an N-terminal transactivation 
domain (NTD), a conserved DNA-binding domain (DBD) and a C-terminal ligand-binding 
domain (LBD) (Ratman et al. 2013). In the absence of ligand, the GR resides in the 
cytoplasm within a complex of chaperone proteins containing heat shock proteins 
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(HSP) and immunophilins (Echeverria & Picard 2010). The interaction of the GR with 
HSP70/HSP90 is important to ensure the steroid-binding cleft is available to ligands 
(Pratt et al. 2004). Once the ligand is bound, the activated receptor is able to 
translocate to the nucleus where it can bind to both positive and negative GR response 
elements (GREs) (Franchimont 2004). Positive GREs are palindromic sequences within 
the promoter regions of genes that are bound by a homodimeric activated GR to 
promote gene expression (De Bosscher et al. 2008). Transcription can also be 
negatively regulated, a process known as transrepression, and this can involve DNA 
binding of the GC receptor/ligand complex or by blocking the binding of other 
transcription factors by direct protein-protein interaction, a process referred to as 
squelching (Ratman et al. 2013). Originally it was believed that the anti-inflammatory 
actions of GCs were due to transrepression of key transcriptional regulators of pro-
inflammatory genes such as NF-κB and AP-1 but it is now known that some anti-
inflammatory effects also occur through transcriptional activation (Clark 2007). These 
include the transcription of the NF-κB inhibitor (IκBα), IL-10, IL-4, TGF-β and mitogen-
activated protein kinase (MAPK) phosphatase 1 (De Bosscher et al. 2003; Auphan et al. 
1995; Scheinman et al. 1995; Abraham et al. 2006). 
More recently it has been discovered that GCs also exhibit non-genomic effects. 
Although the rapid action of GCs, within minutes, indicates that there are non-genomic 
effects, the research is very much in its infancy compared to the genomic actions. For 
example, a study using two commonly administered GCs, beclomethasone 
dipropionate (BDP) and prednisolone acetate (PDNA), showed that GCs increased the 
maximum isometric force produced by mouse slow-twitch muscle fibre bundles (Pérez 
et al. 2013). Experiments using an inhibitor of the GR or an antibody that binds to the 
GR prevented the observed increase in force. From this, the authors concluded that 
the GR is located within the membrane and somehow leads to the activation of focal 
adhesion kinase (FAK), Grb2 and ERK. However, it could be the case that the antibody 
also binds GCs which would result in a reduced concentration, mimicking the effect of 
blocking the interaction. More research is required to confirm the membrane bound 
protein. 
Non-genomic actions have also been reported in T cell signalling. When the T-cell 
receptor (TCR) is activated, Src kinases such as Lck and Fyn are activated and play a 
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critical role in TCR-mediated signal transduction (Zamoyska et al. 2003). 
Dexamethasone has been shown to prevent early events in T cell activation such as the 
formation of the T-cell-receptor-associated protein complex that contains Lck and Fyn 
(Löwenberg et al. 2006), preventing phosphorylation of Lck and Fyn targets 
(Löwenberg et al. 2005), thus inhibiting signalling through the TCR. 
These examples further highlight the complexity of the behaviour of GCs, in that they 
have tissue specific actions. Although the GR is expressed in most tissues (Ballard et al. 
1974), regulation is dependent on other factors such as the bioavailability of GCs, the 
topology of the DNA and tissue specific expression of certain histone modifying 
proteins that mediate access to the receptor/ligand complex (De Bosscher et al. 2003). 
Most commonly used for its anti-inflammatory properties, dexamethasone is likely to 
reduce the effectiveness of immunotherapies for patients with GBM. Indeed, 
dexamethasone was shown to inhibit the immune-stimulatory activities of 
lenalidomide on NK and T cells against multiple myeloma (MM) (Gandhi et al. 2010). 
However, when used in a mouse model of melanoma, dexamethasone was found to 
cause lymphopenia but did not inhibit the anti-tumour activity of activated CD8+ T 
cells (Hinrichs et al. 2005). 
More research into the actions of GCs on NK cells will help to integrate 
immunotherapies with the current use of glucocorticoids that are essential for treating 
brain tumour induced cerebral oedema. 
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1.6   Aims 
The prognosis for patients with glioblastoma multiforme remains poor and alternative 
therapies are clearly required. Cell based immunotherapy could prove an exciting 
avenue for new treatment options. The properties of NK cells, eliminating transformed 
cells without prior sensitisation, make them ideal candidates for therapeutic 
manipulation. However, the existence of GBM as a clinical entity indicates that they 
have already undergone the immunoediting process and are resistant to NK cell lysis. A 
limited number of studies exist that assess the amount of NK cell infiltration into 
human GBM tumours and no studies exist that extensively characterise the infiltrating 
NK cells. 
The aim of this study was to analyse the NK cells located within human GBM tumours 
and to establish their phenotype. Defining the phenotype is crucial to help elucidate 
mechanisms deployed by the tumour to inhibit NK cell function, which could be 
targeted for treatment. Glucocorticoids are frequently administered to GBM patients 
to reduce brain oedema; a second aim of this work was to investigate the effects that 
glucocorticoids have on NK cell function. This will help predict the impact that 
glucocorticoids have on any future NK cell based immunotherapies. 
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Chapter 2 Materials and Methods 
2.1   Cell culture 
2.1.1   Adherent cells 
GBM1, GBM4, GBM11, GBM13 and GBM20 are tumour stem-like cells derived from 
patients with GBM. The primary lines, GBM1 and GBM4, were generated at the Scripps 
Institute by Dr Heiko Wurdak in the laboratory of Professor Peter G. Schultz (Wurdak 
et al. 2010). GBM11, GBM13 and GBM20 were derived by Dr Anjana Patel and Dr 
Heiko Wurdak at the University of Leeds using the same method. The cells were a kind 
gift from Dr Anjana Patel and Dr Heiko Wurdak. Cells were grown on laminin (Sigma-
Aldrich, UK)-coated flasks (Corning, MA USA) in Neurobasal Medium (Gibco, 
Invitrogen, UK) supplemented with 0.5 % B27 Serum-Free Supplement (Gibco), 0.5 % 
N2 Supplement (Gibco), 40 ng/mL recombinant human EGF (R&D Systems), 40 ng/mL 
recombinant human bFGF (PeproTech, New Jersey, USA). Cells were incubated at 37C 
in a humidified atmosphere containing 5% CO2. No antibiotics were used.  
The neural progenitor cells (NP1) were isolated by the Wurdak group from a patient 
who had a section of brain removed to treat epilepsy. Cells were grown on laminin-
coated surfaces in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM-
F12) (Gibco) supplemented with 0.5 % B27 Serum-Free Supplement, 0.5 % N2 
Supplement, 20 ng/mL recombinant human EGF, 20 ng/mL recombinant human bFGF, 
1 % glutamine (Gibco) and 5% foetal bovine serum (FBS) (Gibco). Cells were incubated 
at 37C in a humidified atmosphere containing 5% CO2. No antibiotics were used. 
Adherent cells were harvested using 0.25% trypsin (Sigma-Aldrich)/EDTA (Sigma-
Aldrich) (0.25 % w/v trypsin and 0.2 % w/v ethylenediaminetetraacetic acid (EDTA) in 
PBS (Sigma-Aldrich)). Culture medium was discarded, cells were washed with PBS 
(phosphate buffered saline; 137 mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4, 10 mM 
Na2HPO4 pH 7.4), and incubated with 1 mL of trypsin/EDTA solution at 37C until they 
detached. Growth medium was added to dilute the trypsin and the cells were pelleted 
by centrifugation at 350 g for 5 minutes at room temperature (RT). 
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2.1.2   Suspension cells 
K562 is a well-known tumour target cell used to examine NK cell effector function. It 
originates from a 53-year-old female chronic myeloid leukaemia (CML) patient in blast 
crisis. Cells were cultured in RPMI (Sigma-Aldrich, UK) supplemented with 10% FBS. 
Cells were maintained at approximately 1 x 106 cells/mL and incubated at 37C in a 
humidified atmosphere containing 5% CO2. No antibiotics were used. 
2.2   Primary NK cells 
2.2.1   Peripheral blood mononuclear cell isolation 
Peripheral blood mononuclear cells (PBMCs) were either obtained from an apheresis 
cone or from the blood of a healthy donor. Blood from the apheresis cone was diluted 
four-fold with PBS, whereas blood from a donor was diluted two-fold. Approximately 
30 mL of diluted blood was carefully layered onto 15 mL Ficoll (Axis-Shield PoC, Oslo, 
Norway) in a 50 mL falcon tube (Corning). PBMCs were separated by density gradient 
separation at 800 g for 20 minutes and disabling the brake function. The PBMC fraction 
lies at the interface between the Ficoll and plasma layers (Figure 2.1). The PBMCs were 
removed using a Pasteur pipette (Thermo Fisher Scientific, USA), washed in a five-fold 
volume of PBS and collected by centrifugation at 220 g for 15 minutes. PBMCs were 
resuspended in cold MACS buffer (0.5% w/v bovine serum albumin (BSA) and 2mM 
sodium EDTA in PBS) and counted using a haemocytometer. 
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Figure 2.1. Peripheral blood mononuclear cell isolation by density gradient 
centrifugation. Diluted peripheral blood was layered onto Ficoll and centrifuged at 800 
g for 20 minutes without the brake. The PBMC layer can be seen post centrifugation 
between the Ficoll and plasma layers. 
 
2.2.2   NK cell isolation 
Untouched NK cells were isolated from PBMCs using an NK cell isolation kit (Miltenyi 
Biotec, Bergisch Gladbach, Germany) in line with the manufacturer’s protocol. A 
cocktail of biotin-conjugated monoclonal antibodies against non-NK cell antigens is 
used to negatively select the NK cell population. Magnetically labelled anti-biotin 
antibodies were added. The cells were passed through a MACS cell separation column 
within a magnetic field and the non-NK cells were retained on the column. The eluted 
NK cell fraction was washed with PBS and pelleted at 300 g for 10 minutes. NK cells 
were cultured in DMEM supplemented with 10% FBS and 10% heat inactivated human 
AB serum at approximately 1 x 106 cells/mL. 
2.2.3   NK cell cytokine and drug treatments 
Freshly isolated NK cells were activated with 100 IUmL-1 of IL-15 (Miltenyi Biotec). 
NK cells were seeded at approximately 1 x 106 cells/mL in a 24-well plate. Drug 
concentrations of 2 x 10-7 M dexamethasone (Sigma-Aldrich), 2 x 10-6 M 
methylprednisolone (Sigma-Aldrich), 1 x 10-4 M c-Myc inhibitor 10074-G5 (Sigma-
Aldrich) or 5 ng/mL TGF-β (Miltenyi Biotec) were added to the cells and mixed 
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thoroughly. For dual treatments, the glucocorticoids, TGF-β or c-Myc inhibitor was 
added immediately before the IL-15. 
2.3   Matched GBM tumour and blood sample 
2.3.1   Ethical approval 
Ethical approval to collect blood and tumour samples after informed consent was 
obtained from the ethics committee at the Leeds Teaching Hospitals NHS Trust (REC 
number 10-H1306-7). 
2.3.2   Tumour Processing 
After ethical approval and patient consent had been given, the tumour samples were 
taken from astrocytoma patients as part of resection surgery. Samples either arrived 
as a solid lump of tissue (varied in size but were approximately 2 cm3) in a specimen 
tube containing PBS or within the sterile suction trap of a cavitron ultrasonic surgical 
aspirator (CUSA). A study assessing the use of CUSA trap samples as a source of 
material for histopathological study and tissue culture concluded that the CUSA trap 
provides viable cells that are a representative sample of tumour histology, as well as 
an adequate and sterile biosource of material for tissue culture studies (Schroeteler et 
al. 2014). Upon arrival, the solid sample was placed in a petri dish and washed in PBS. 
The sample was pushed through a 40 µm cell sieve (Thermo Fisher Scientific) using the 
plunger part of a 10 mL syringe and collected in a 50 mL falcon tube (Figure 2.2). The 
filter was washed using PBS until a final volume of 50 mL had been collected. The cells 
were collected by centrifugation at 400 g for 5 minutes. The supernatant was removed 
and the remaining pellet was washed twice by resuspending in 50 mL of PBS. After the 
second wash, the cell pellet was resuspended in fluorescence-activated cell sorting 
(FACS) buffer (PBS with 0.5% BSA (Sigma-Aldrich) and 0.05% sodium azide (Sigma-
Aldrich) and stained with appropriate antibodies (see antibody staining section). 
Approximately 1 x 107 cells/tube were stained. Data was acquired using the BD LSRII 
machine fitted with 4 lasers. Approximately 2 x 106 events were collected. 
2.3.3   Blood Processing 
Between 4 and 12mL of blood sample were collected from the same patient. The 
blood sample was diluted with PBS to a final volume of 35 mL. PBMCs were extracted 
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using Ficoll as detailed above. As with the cells from the tumour sample, PBMCs were 
resuspended in FACS buffer, stained with antibodies (section 2.4) and analysed on the 
BD LSRII machine. Approximately 3 x 104 events were collected.
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Figure 2.2. Flow diagram of 
sample processing. (Top) 
The patient blood sample 
was diluted with PBS to a 
final volume of 35 mL. 
PBMCs were isolated on a 
ficoll gradient, washed and 
stained. (Bottom) The 
tumour sample was pushed 
through a 40 µm filter, 
washed and stained. 
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2.4   Antibody staining 
Cells were washed with PBS and resuspended in ice-cold FACS buffer with a maximum 
density of 1 x 107 cells/mL. An optimised concentration of antibody was added (Table 
2.1) and incubated in the dark, on ice for 20-30 minutes. Isotype control antibodies 
were used to exclude unspecific antibody binding. When assessing the percentage of 
cells positive for a particular antigen an isotype binding of 2% was used as a baseline. 
Subsequently cells were washed with PBS, pelleted by centrifugation at 350 g, 4 C for 
5 minutes and stained with a dead cell discriminator, Zombie NIR: PBS 1:200 PBS for 15 
minutes in the dark. Cells were washed with FACS buffer before being analysed using a 
LSRII flow cytometer. Details of the antibodies are listed in Table 2.1. 
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Table 2.1. Details of antibodies used for flow cytometry.  
 
CD number or specificity Conjugate Clone Manufacturer, product 
number 
Host Target Class Optimised concentration 
(Volume(μL) per 100 μL 
or 1 x 106 cells) 
CD2 PE RPA-2.10 BD Biosciences, 555327 Mouse Human IgG1k 5 
CD3 PerCP BW264/56 Miltenyi Biotec, 130-094-965 Mouse Human IgG2a 8 
CD9 PE M-L13 BD Biosciences, 555372 Mouse Human IgG1 5 
CD24 PE 32D12 Miltenyi Biotec, 130-095-953 Mouse Human IgG1 10 
CD45 FITC HI30 BD Biosciences, 555482 Mouse Human IgG1k 5 
CD48 FITC BJ40 BioLegend, 336707 Mouse Human IgG1k 5 
CD69 BV421 FN50 BioLegend, 310929 Mouse Human IgG1k 3 
CD69 FITC FN50 BioLegend, 310904 Mouse Human IgG1k 3 
CD90 VioBlue DG3 Miltenyi Biotec, 130-099-271 Mouse Human IgG1 5 
CD107a PE H4A3 BD Biosciences, 555801 Mouse Human IgG1k 5 
CD112 (Nectin-2) PE R2.525 BD Biosciences, 551057 Mouse Human IgG1k 10 
CD132 (IL-2 Rγ) PE AG184 BD Biosciences, 555900 Mouse Human IgG1k 3 
CD152 (CTLA-4) PE BNI3 Miltenyi Biotec, 130-097-684 Mouse Human IgG2a 10 
CD184 PEVio770 12G5 Miltenyi Biotec, 130-103-798 Mouse Human IgG2a 10 
CD223 (LAG-3) PE REA351 Miltenyi Biotec, 130-105-452 Mouse Human   10 
CD226 (DNAM-1) PE DX11 Miltenyi Biotec, 130-092-476 Mouse Human IgG1 5 
CD244 (2B4) PE REA112 Miltenyi Biotec, 130-099-051 Mouse Human   10 
CD273 (PD-L2) PE MIH18 BD Biosciences, 558066 Mouse Human IgG1k 5 
CD274 (PD-L1) PE MIH1 BD Biosciences, 557924 Mouse Human IgG1k 5 
CD279 (PD-1) PE PD1.3.1.3 Miltenyi Biotec, 130-096-164 Mouse Human IgG2b 5 
CD314 (NKG2D) PE 1D11 BD Biosciences, 557940 Mouse Human IgG1k 5 
CD317 (Tetherin) PE REA202 Miltenyi Biotec, 130-101-707 Mouse Human  5 
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CD335 (NKp46) APC 9E2/NKp46 BD Biosciences, 558051 Mouse Human IgG1k 5 
CD336 (NKp44) PE 2.29 Miltenyi Biotec, 130-092-480 Mouse Human IgG1 10 
CD337 (NKp30) PE P30-15 BD Biosciences, 558407 Mouse Human IgG1k 5 
B7H6 APC 875001 R&D Systems, FAB 7144 Mouse Human IgG1 5 
HLA-A,B,C APC W6/32 BioLegend, 311410 Mouse Human IgG2a 5 
MIC A/B PE 6D4 BD Biosciences, 558352 Mouse Human IgG2ak 10 
ULBP1 PE 170818 R&D Systems, FAB 1380P Mouse Human IgG2a 10 
mTOR (pS2448) PE O21-404 BD Biosciences, 563489 Mouse Human IgG1k 5 
SMAD2 (pS465/pS467)/ 
SMAD3 (pS423/pS425) 
PE O72-670 BD Biosciences, 562586 Mouse Human IgG1k 5 
STAT5 (pY694) PerCP 
Cy5.5 
47/Stat5(pY694) BD Biosciences, 560118 Mouse Human IgG1k 20 
S6 (pS235/pS236) PE N7-548 BD Biosciences, 560433 Mouse Human IgG1k 20 
Isotype APC MOPC-21 BD Biosciences, 555751 Mouse  IgG1k  
Isotype BV421 MOPC-21 BioLegend, 400157 Mouse  IgG1k  
Isotype FITC MOPC-21 BD Biosciences, 555748 Mouse  IgG1k  
Isotype PE MOPC-21 BD Biosciences, 559320 Mouse  IgG1k  
Isotype PE G155-178 BD Biosciences, 555574 Mouse  IgG2ak  
Isotype PerCP 
Cy5.5 
MOPC-21 BD Biosciences, 552834 Mouse  IgG1k  
Isotype PEVio770 S43.10 Miltenyi Biotec, 130-096-638 Mouse  IgG2a  
Isotype APC IS5-21F5 Miltenyi Biotec, 130-092-214  Mouse  IgG1k  
Isotype VioBlue IS5-21F5 Miltenyi Biotec, 130-094-670 Mouse  IgG1  
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2.5   NK cell functional assays 
2.5.1   Cytotoxicity assay 
The target cells were harvested using 0.25% trypsin/EDTA and resuspended in media 
containing a cell tracker dye (see multiplex screen section, 2.6) at a concentration of 1 
x 106 cells/mL. The cells were incubated in the staining solutions for 1 hour at 37C and 
5% CO2. Once stained, the cells were washed with PBS and resuspended in media. NK 
cells (the effectors) were pelleted by centrifugation at 300 g for 5 minutes and co-
cultured with a total of 2 x 105 cells per well in a 100 l reaction volume with the 
stained targets in a U-bottomed 96-well plate for five hours at 37C and 5% CO2. 
Different concentrations of effector to target ratios were used ranging from 1:1 to 5:1. 
A zero hour control was set up alongside each reaction that included the same number 
of effector and target cells and was mixed immediately before staining with the dead 
cell discriminator. This allowed the background level of death to be established. After 
five hours the cells were pelleted and the supernatant was removed. The cells were 
resuspended in ice-cold Zombie near infrared (NIR) (Biolegend, UK) dead cell 
discriminator in PBS (1:200 v/v) and incubated on ice, in the dark for 10 minutes. 
Zombie NIR reacts with the primary amine group on proteins. Although Zombie NIR 
has access to the proteins on the surface of the cell, when the cell is dead the 
membrane becomes compromised and the dye can additionally bind to cytoplasmic 
proteins. Therefore, the dead cells stain more brightly. After a 10 minute incubation 
with the dead cell discriminator, the cells were washed with ice-cold FACS buffer, 
resuspended in FACS buffer and analysed using a LSRII Flow cytometer (BD Bioscience). 
Approximately 5 x 104 events were collected. 
2.5.2   Cytotoxicity assay with two targets 
The target cells were harvested separately using 0.25% trypsin/EDTA and resuspended 
in media containing either cell tracker violet or cell tracker green (see multiplex screen 
section) at a concentration of 1 x 106 cells/mL. The cells were incubated in the staining 
solutions for 1 hour at 37°C and 5% CO2. Once stained, the cells were washed with PBS 
and resuspended in media. The cells were mixed in a 1:1 ratio and collectively used as 
the targets. The assay was then carried out as described in method 2.5.1. 
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2.5.3   Degranulation assay 
Prior to the assay NK cells were stained with 0.4 µM cell tracker green-CMFDA 
(Invitrogen) for 1 hour at 37C and then washed with PBS. NK cells were co-cultured 
with K562 target cells at an E:T ratio of 1:1 for 5 hours. After an hour of incubation 
GolgiStop (BD Biosciences) was added at 1:1000 to prevent the internalisation of 
CD107a after degranulation. At the end of the 5 hour incubation, the cells were 
pelleted, resuspended in ice-cold FACS buffer and stained with anti-CD107a-PE, anti-
CD56-APC or the correct isotype control (Table 2.1) for 20 minutes on ice. Cells were 
then washed with ice-cold PBS and resuspended in ice-cold Zombie NIR :PBS 1:200 and 
incubated on ice, in the dark for 10 minutes. Cells were washed with ice-cold FACS 
buffer, resuspended in FACS buffer and analysed using a LSRII Flow cytometer (BD 
Bioscience). Approximately 5 x 104 events were collected. 
2.6   Multiplex screen 
The antibody panel used was the ‘Human Cell Surface Marker Screening Panel’ from 
BD Bioscience. The panel is supplied as three ninety-six well plates with lyophilised rat 
or a mouse primary antibodies against two hundred and forty two human cell surface 
antigens and a panel of appropriate isotype controls. The lyophilised antibodies were 
reconstituted in 100 μL of PBS. The multiplex surface antigen screen allowed four cell 
lines to be analysed at a time. The screen was repeated to gather data on 5 GBM stem 
cell lines (GBM1, GBM4, GBM11, GBM13 and GBM20). Cells were harvested using 
0.25% trypsin/EDTA, washed with PBS and counted using a haemocytometer. The cells 
were stained by resuspending in media containing the appropriate dye; GBM1 with 5 
μM calcein blue-AM (Invitrogen), GBM4 with 2μM cell tracker violet-BMQC 
(Invitrogen), GBM11 with 2 μM cell tracker orange-CMRA (Invitrogen), GBM13 with 5 
μM calcein blue-AM (Invitrogen) and GBM20 with 0.4 µM cell tracker green-CMFDA 
(Invitrogen). Cells were incubated in the staining solutions for 1 hour at 37C and 5% 
CO2. Once stained, the cells were washed with PBS, resuspended in FACS buffer, 
pooled together and aliquoted at 100 µl/well into 4 U-bottomed 96-well plates. 20 μL 
of unlabelled primary antibody was added to the appropriate well and incubated on 
ice in the dark for 30 minutes. The cells were washed with FACS buffer, resuspended in 
the appropriate AlexaFluor 647 conjugated goat anti-mouse or goat anti-rat secondary 
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antibody and incubated on ice for 20 minutes in the dark. The cells were subsequently 
washed with PBS and resuspended in 100 μL of 1:100 Zombie NIR:PBS to stain the 
dead cells. A final wash step was completed before collecting the data using a LSRII 
(BD) Flow cytometer (4 laser) with a 96 well plate reader. Analysis and compensation 
was done using FACS Diva (BD) and Kaluza (Beckman Coulter, High Wycombe UK) 
software. The fluorophores used in the screen were selected based on their excitation 
and emission values and could be compensated to give a clear signal for the individual 
fluorophores. 
2.7   Cell cycle analysis 
NK cells were isolated and treated (see methods 2.2.2-2.2.3) for 24-72 hours. A 
minimum of 1.5 x 106 cells/treatment was used. BrdU (Sigma-Aldrich) was added to a 
final concentration of 50 μM. The experiment was performed in two different ways; 
BrdU was either added immediately after treatment or 1 hour before collection. After 
incubation, cells were washed with ice-cold PBS and collected by centrifugation at 450 
g for 10 minutes at 4°C. The pellet was resuspended in 2 mL of ice-cold PBS and fixed 
by adding 8 mL 100% EtOH in a dropwise fashion, whilst vortexing. Fixed cells were 
stored at -20°C at least overnight before staining. Cells were centrifuged for 10 
minutes at 600 g at 4°C and the supernatant was discarded. The pellet was 
resuspended in 1.5 mL of pepsin solution (0.5 mg/mL pepsin (Fisher Scientific, UK), 30 
mM HCl). Cells were incubated in a water bath at 37°C for 20 minutes and vortexed 
every 5 minutes. Cells were centrifuged for 10 minutes at 600 g. The supernatant was 
carefully removed using a needle and syringe. The cells were resuspended in 1 mL of 2 
M HCl and incubated at RT for 20 minutes. Cells were diluted with 0.5 mL of PBS and 
centrifuged for 10 minutes at 600 g. The supernatant was removed and the cells were 
washed with 1.5 mL PBS. Cells were resuspended in 100 μL of anti-BrdU (BD 
Biosciences) antibody solution; 1:4 anti-BrdU: Bu buffer (0.5 % FCS, 0.5 % Tween 20, 20 
mM Hepes in PBS). Cells were stained for 1 hour at RT, then diluted with 1.5 mL PBS 
and stored at 4°C overnight. Cells were centrifuged for 10 minutes at 600 g and 
resuspended in 100 μL of the first secondary antibody; 1:49 rabbit anti-mouse AF594 
(Invitrogen): Bu buffer. After a 1-hour incubation at RT the cells were diluted with 1.5 
mL PBS and stored at 4°C overnight. Cells were centrifuged for 10 minutes at 600 g and 
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resuspended in 100 μL of the second secondary antibody; 1:49 donkey anti-rabbit 
AF594 (Invitrogen): Bu buffer. Cells were incubated at RT for 1 hour and washed with 
PBS. Cells were resuspended in 300 μL Hoechst solution; 2.5 μM Hoechst 33342 
(Biotium, California, USA) in PBS, 0.05% Tween. Data was collected using a LSRII flow 
cytometer. 
2.8   Preparation of NK cell lysates 
NK cells were diluted five-fold with ice-cold PBS and centrifuged at 450 g for 5 minutes 
at 4°C. The supernatant was discarded and the cells were resuspended in 50 μL RIPA 
buffer (10 mM Tris-HCl pH 8, 1 mM EDTA, 0.5 mM EGTA, 140 mM NaCl, 1 % Triton X-
100, 0.1 % sodium deoxycholate, 0.1 % v/v SDS, dH20) supplemented with protease 
inhibitor (Roche, Basel, Switerland) and phosphatase inhibitor (Roche) according to the 
manufacturer’s guidelines. Cells were incubated on ice for 10 minutes and either used 
immediately or frozen at -20°C. 
2.9   SDS PAGE 
A discontinuous protein gel was made consisting of a 5% stacking gel (5% acrylamide, 
0.125 M Tris-HCl pH 6.8, 0.1% SDS, 0.1% APS, 0.001% TEMED) and either a 10% or 15% 
resolving gel (10% or 15% acrylamide, 0.375 M Tris-HCl pH 8.8, 0.1% SDS, 0.1% APS, 
0.001% TEMED). An equal volume of protein sample buffer (100 mM tris-HCl, 4% SDS, 
20% glycerol, 0.2% bromophenol blue, 10% β-mercaptoethanol) was added to the 
samples and boiled for 5 mins at 95 °C to denature and reduce the protein. The lysates 
were loaded onto the gel along with molecular weight markers. Equal numbers of cells 
were analysed. Laemmli running buffer (25 mM tris, 192 mM glycine, 0.1% SDS) was 
used. The gel was run at 120V until the running front reached the bottom of the gel.  
2.10   Western blot 
Western blot was performed by sandwiching the gel between a sheet of polyvinylidene 
difluoride (PVDF) and three pieces of Whatman 3 MM Chr paper that had been pre-
soaked in transfer buffer (25 mM tris, 192 mM glycine, 20 % MeOH). The proteins were 
transferred at 15 V for 1 hour using a semi-dry transfer apparatus (Bio-Rad, UK). 
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2.11   Probing 
Following the transfer, membranes were blocked for 1 hour at RT with blocking buffer; 
TBST (25 mM Tris base, 134 mM sodium chloride, pH 7.5, 0.1 % v/v Tween-20) 
containing 5 % w/v BSA. The blots were probed with a primary antibody (Table 2.2) 
diluted 1:1000 in blocking buffer for 2 hours at RT or overnight at 4°C on a shaker. The 
membrane was washed three times for 5 minutes with TBST, with continuous rocking. 
A secondary HRP-conjugated antibody was added diluted in blocking buffer and 
incubated at RT for 1 hour or at 4°C overnight, with continuous rocking. The 
membrane was washed again three times with TBST and protein was detected using a 
chemiluminescence reagent (GE Healthcare, UK), a light proof cassette, CL-XPosure 
film (Thermo-Fisher Scientific) and a Konica SRX-101A Tabletop X-ray Film Processor 
(Konica, UK). The expression of β-actin was used to assess the equal loading of protein 
samples. 
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Table 2.2. Details of antibodies used for Western blots.  
 
 
Specificity Conjugate Manufacturer, product number Blocking buffer Host Size (KDa) % gel 
c-Myc Purified Cell Signaling Technology, 9402 TBST 5%BSA Rabbit 57-70 10 
Total S6 Purified Cell Signaling Technology, 2217 TBST 5%BSA Rabbit 32 15 
pS6 235/236 Purified Cell Signaling Technology, 4858 TBST 5%BSA Rabbit 32 15 
pS6 240/244 Purified Cell Signaling Technology, 5364 TBST 5%BSA Rabbit 32 15 
phospho p70S6K 389 Purified Cell Signaling Technology, 9234 TBST 5%BSA Rabbit 70,85 10 
4EBP1 Purified Cell Signaling Technology, 9644 TBST 5%BSA Rabbit 15-20 15 
p4EBP1 T37/40 Purified Cell Signaling Technology, 2855 TBST 5%BSA Rabbit 15-20 15 
non phospho 4EBP1 T46 Purified Cell Signaling Technology, 4923 TBST 5%BSA Rabbit 15-20 15 
Granzyme B Purified BD Biosciences, 550558 TBST 5%BSA Mouse 32 10 
Rabbit Peroxidase Cell Signaling Technology, 7074 TBST 5%BSA Goat   
Mouse Peroxidase Sigma-Aldrich, a4416 TBST 5%BSA Goat   
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2.12   Microarray 
NK cells from healthy donors were isolated (method 2.2.2) and treated under six 
different conditions (method 2.2.3-2.2.3) for 48 hours; untreated (resting) or addition 
of dexamethasone, TGF-β, IL-15, IL-15+dexamethasone and IL-15+TGF-β. A minimum 
of 5 x 106 cells were treated for each condition. Both the morphology of the cells and 
the cell surface expression of CD69 and NKp30 were used to assess the donor response 
(described in Chapter 5). Cells were diluted in a five-fold volume of PBS and 
centrifuged at 450 g, 5 minutes. The supernatant was discarded and the cell pellet was 
resuspended in 300 μL RNAprotect cell reagent (Qiagen, Hilden, Germany) and 
vortexed. The samples were transferred to barcode (provided by the company) 
labelled Eppendorf tubes and stored at -20°C. The samples from all donors were 
collectively sent to an external service provider (Hologic, Manchester, UK) who 
processed the samples and performed the microarray. Standard techniques were used 
to isolate mRNA, synthesize complementary DNA (cDNA), fluorescently label the cDNA, 
hybridise it to the array (GeneChip® Human Transcriptome Array 2.0, Affymetrix, 
California, USA) and acquire the data. The raw intensity files were received and 
analysed using the Affymetrix expression and transcript analysis consoles. Dr Alastair 
Droop facilitated the initial stages of the analysis using the computer programming 
language R. 
 
2.13   Statistics 
T tests were performed using GraphPad Prism (GraphPad). 
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Chapter 3 Lymphocyte infiltration of human GBM 
tumours 
3.1   Introduction 
The successful implementation of NK cell based immunotherapy of GBM requires the 
NK cells to enter the tumour. Previous studies have shown that NK cells account for a 
very small proportion of infiltrating cells within high grade gliomas (Kmiecik et al. 
2014). However, in some cases these analyses were not restricted to GBM (and 
included other types of brain tumours) and the markers used to identify NK cells were 
restricted to certain subsets of NK cells or not unique to NK cells. During one study that 
focused on T cell characterisation, it was noted that NK cells account for less than 3% 
of infiltrating lymphocytes in GBM (Kmiecik et al. 2013). The lack of detailed 
characterisation of NK cell infiltration into GBM prompted a more in depth analysis. 
NK cell infiltration alone is insufficient for anti-tumour activity as the NK cell must be 
activated to exert its effector functions. For example, activation receptors must be 
displayed on the NK cell surface where they can engage and respond to tumour 
expressed ligands. Immunosuppressive mechanisms operating in other tumour 
microenvironments have been reported to reduce expression of activation receptors 
such as NKp30, NKG2D, DNAM-1 (Mamessier et al. 2011; Rocca et al. 2013) and tilt the 
balance in favour of NK cell inhibition. 
To date, there are no reports detailing the phenotype of NK cells within human GBM 
tumours. Therefore, not only was it necessary to assess the extent of NK cell 
infiltration into human GBM tumours, it was as essential to characterise their cell 
surface phenotype. An understanding of how GBM tumours are able to evade the 
cytotoxic effects of NK cells (be it by preventing recruitment or activation) will enable 
the development of immunotherapies that target the appropriate evasion strategy. 
3.2   NK cells are present within the tumour 
Patients undergoing tumour resection surgery gave their consent for the extracted 
tissue and a peripheral blood sample to be used for research. A tumour dissociation 
method and a staining panel to phenotype NK cells using flow cytometry was 
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optimised (data not shown). The samples were processed and data collected on the 
same day as the surgery. Briefly, the tumour sample was reduced to a single cell 
suspension and the PBMCs were isolated from the blood sample using a density 
gradient. The samples were subsequently stained with fluorescently labelled 
antibodies and a dead cell discriminator, and analysed by flow cytometry. The 
lymphocyte population was identified within the blood sample according to its size and 
granularity (FSC and SSC respectively, Figure 3.1). Within this population the live, 
CD45+ cells (pan-leukocyte marker) were selected. NK cells were then defined as 
CD3negNKp46+ and T cells as CD3+NKp46neg. The same gating strategy was applied to 
evaluate both blood and tumour samples. Note that studies of human NK cells 
frequently define NK cells as CD56+CD3neg cells. However, CD56 (also known as 
Neural Cell Adhesion Molecule 1) is highly expressed by cells in the brain and cannot 
be used to identify NK cells.  
Tumour and blood samples from 11 patients were analysed for the presence of NK and 
T cells, both subsets were found within the tumour. NK cells and T cells accounted for 
3.6±3.1% and 37.8±24.4% of CD45+ cells within the tumour respectively, compared to 
12.3±12.5% and 64.9±13.3% within the blood (Table 3.1). However, the CD45+ 
populations in healthy blood and brain have quite different compositions (for example, 
the brain contains large numbers of CD45+ microglia). Therefore, the ratio of NK cells 
to T cells in blood and brain was used to assess the selective infiltration of these two 
subsets. 
There was no significant difference in the NK:T cell ratio between the patient blood 
and tumour samples, nor compared to healthy blood donor samples (Figure 3.2). This 
suggests that both NK cells and T cells are recruited into the tumour and that 
infiltration of neither NK cells nor T cells is favoured. 
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Figure 3.1. The gating strategy used to identify NK and T cells. Samples were processed and analysed by flow cytometry. The same gating strategy 
was applied to both the peripheral blood (top panel) and tumour sample (bottom panel). The lymphocytes were identified by their forward scatter 
(FSC) and side scatter (SSC). These are measures of size and granularity respectively. Within this gate the live cells were defined as negatively stained 
with the dead cell discriminator. The CD45 positive cells were selected. NK cells and T cells were identified as CD3negNKp46+ and CD3+NKp46neg 
respectively.
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Figure 3.2. NK cell infiltration. PMBCs isolated from blood samples and a single cell 
suspension of tumour cells were stained and analysed by flow cytometry. Within the 
CD45+, live, lymphocyte gates NK cells and T cells were identified as CD3negNKp46+ 
and CD3+NKp46neg respectively. A ratio of the number of NK cells to T cells was 
calculated for each sample within each group (left-right); control blood, patient blood 
and tumour. Each dot represents a single sample (n=6 control blood, n=11 patient 
samples); the bar indicates the mean± s.d. Statistical analysis was performed by ratio t-
tests (paired or unpaired where appropriate). ns: not significant. 
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3.3   Peripheral blood and tumour lymphocytes are 
phenotypically distinct 
Brain tumours are highly vascularised and it was possible that the NK:T cell ratios in 
the peripheral blood and tumour samples were the same because I simply sampled 
blood-resident lymphocytes within the tumour vasculature. However, analysis of the 
cell surface phenotype revealed significant differences between the blood and tumour-
resident lymphocytes. 
The lymphocyte activation marker CD69 (Ziegler et al. 1993) was expressed on a 
significantly higher proportion of both NK and T cells within the tumour compared to 
those in the peripheral blood of the same patient (Figure 3.3 and figure 3.4); the 
average percentage of NK cells expressing CD69 in the patients’ peripheral blood 
samples was 13.1% compared to 49.3% in the tumours (p< 0.001). A similar pattern is 
seen on T cells where 9.1% express CD69 in the blood compared to 74.6% in the 
tumour (p< 0.0001). 
This result indicated that the sampling method was effective and could be used to 
study the phenotype of tumour infiltrating lymphocytes in more detail. 
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Figure 3.3. CD69 expression on NK and T cells within the blood and tumour. Flow 
cytometry was used to evaluate the expression of activation marker CD69 on NK cells 
(left) and T cells (right) within the patient’s peripheral blood (middle row) and tumour 
(bottom row). Data is representative of 8 samples. An isotype control antibody (top 
row) was used to exclude non-specific binding. 
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3.4   NK cell activation receptors are down regulated on GBM 
infiltrating NK cells 
A panel of surface proteins was chosen to compare the phenotype of the lymphocytes 
within the blood and tumour samples (Figure 3.4). These included the prototypic 
activation marker CD69, activation (or coactivation) receptors such as NKp30, NKG2D, 
DNAM-1, CD2, and 2B4 and the checkpoint inhibitors PD-1, CTLA-4 and LAG-3. 
Expression of tetherin was also analysed as it is induced by type I interferons and IL-15 
so is a marker of activation (Neil et al. 2008; Homann et al. 2011; El-Sherbiny et al. 
2015). In contrast, CD9 is upregulated by TGF-β (Keskin et al. 2007) and might indicate 
the presence of this immunosuppressive cytokine within the tumour 
microenvironment. The expression of CD69 on the tumour infiltrating NK cells suggests 
that a proportion of NK cells are activated when they enter the tumour 
microenvironment. 
In contrast, the activation receptors NKp30, NKG2D and DNAM-1 were down regulated 
on NK cells located within the tumour compared to the peripheral blood (Figure 3.4 
and table 3.2). Approximately 10% fewer tumour infiltrating NK cells expressed these 
activation receptors (Table 3.2). This suggests that tumour-resident NK cells are less 
likely to respond to ligands expressed by the tumour. The cell surface molecule CD2 is 
essential for the development of NK cytotoxicity and cytokine secretion (Kim et al. 
2010) and also showed the same pattern of down regulation as the activation 
receptors (Figure 3.4 and table 3.2). This supports the hypothesis that tumour resident 
NK cells have a reduced capacity for anti-tumour activity due to the reduced 
expression of these key activation receptors.  
The upregulation of CD9 on tumour infiltrating NK cells suggests that TGF-β is present 
within the tumour microenvironment. TGF-β suppresses NK cell activity (Rook et al. 
1986) and this might be one mechanism by which the tumour evades immune 
destruction. Tetherin is constitutively expressed by NK cells and further upregulated by 
type I interferons and activating cytokines such as IL-15 (El-Sherbiny et al. 2015). 
However, tetherin expression was significantly downregulated on the tumour 
infiltrating NK cells compared to NK cells in the blood. This suggests that NK cells are 
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inhibited within the tumour microenvironment, demonstrated by the down-regulation 
of multiple activatory receptors. 
Previous reports have demonstrated NK cell expression of checkpoint inhibitors such 
as PD-1 (Norris et al. 2012) and CTLA-4 (Stojanovic et al. 2014). However, I found no 
evidence of their expression in any of the groups (control blood, patient blood nor the 
tumour infiltrating NK cells). 
Though there were statistically significant differences in expression of activation 
receptors between matched NK cells within the patients’ blood and tumour, I found no 
evidence for significant differences between the blood of patients and those of healthy 
controls (Figure 3.4). This indicates that it is the tumour microenvironment that 
specifically causes the immunosuppressed NK cell phenotype. 
A similar study investigating NKG2D expression on NK and T cells in patients with 
gliomas found NKG2D was downregulated on peripheral NK cells from GBM patients 
compared with those isolated from patients with meningioma or other benign tumors 
(Crane et al. 2010). The group showed that the reduced expression of NKG2D in the 
peripheral blood of GBM patients correlated with serum TGF-β levels. The expression 
of NKG2D on peripheral NK cells was reassessed post resection surgery and was found 
to be increased to around 70%, still much less than the 90% observed within my 
patient blood cohort. A key difference is that their study was based on recurrent GBM 
patients. Presumably, the patients analysed in their study had a higher tumour burden 
than those analysed here hence the main effects observed in my study were restricted 
to the tumour microenvironment. 
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Figure 3.4. NK cell phenotype within the patient peripheral blood and tumour. NK cells (CD45+CD3negNKp46+) from control blood (CB), patient’s 
peripheral blood (PB) or tumour (T) were analysed by flow cytometry for the expression of the surface proteins listed. The gates were set at 2% of 
the isotype control stain. The number of patient samples analysed is adjacent to each graph. Each dot represents a single sample and the bar 
indicates the mean± s.d. Statistical analysis was performed using t-tests (paired or unpaired where appropriate). *P<0.05, **P<0.01; ***P<0.001; n.s: 
not significant. 
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3.5   T cell inhibitory receptors are upregulated on GBM 
infiltrating T cells 
The use of anti-CD3 antibody (to identify NKp46+CD3neg NK cells) also allowed the 
phenotype of T cells (CD3+) to be examined (Figure 3.5). Limitations due to the sample 
size prevented the incorporation of additional markers, such as CD4 and CD8, into the 
panel so information about specific subsets of T cells could not be ascertained. 
However, phenotyping the bulk population of tumour resident T cells provided 
additional insight into the immune status within the tumour. 
As witnessed in the NK cell analysis, DNAM-1, tetherin and CD2 were all 
downregulated on T cells within the tumour compared to those in the peripheral blood 
(Figure 3.5 and table 3.3). Furthermore, similar to the data with NK cells, CD69 was 
upregulated in the tumour infiltrating T cells compared to the matched blood (Figure 
3.5 and table 3.3). Hence, the tumour microenvironment influences the phenotype of 
T cells and NK cells in a similar manner. 
One of the major differences observed between NK cells and T cells is the upregulation 
of checkpoint inhibitors on T cells within the tumour. Both PD-1 and LAG-3 are 
significantly upregulated on tumour T cells compared to the peripheral blood T cells 
and a similar trend is seen for CTLA-4. These checkpoint inhibitors are not expressed 
by NK cells. It appears that T cell suppression within the tumour microenvironment is 
twofold; activation receptors (e.g DNAM-1 and CD2) are down regulated and 
checkpoint inhibitors (PD-1 and LAG-3) are upregulated. 
As with NK cells, the phenotype of the T cells is not significantly different between the 
blood of a healthy controls and the patients. 
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Figure 3.5. T cell phenotype within the patient peripheral blood and tumour. T cells (CD45+CD3+NKp46neg) from the control blood (CB), patient’s 
peripheral blood (PB) or tumour (T) were analysed by flow cytometry for the expression of the surface proteins listed. The gates were set at 2% of 
the isotype control stain. The number of patient samples analysed is adjacent to each graph. Each dot represents a single sample and the bar 
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indicates the mean± s.d. Statistical analysis was performed using t-tests (paired or unpaired where appropriate). *P<0.05, **P<0.01; ***P<0.001; n.s: 
not significant. 
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 Peripheral blood Tumour 
NK cells 12.3 ± 12.5%  3.6 ± 3.1% 
T cells 64.9 ± 13.3% 37.8 ± 24.4% 
 
Table 3.1 Proportion of NK and T cells out of CD45+. NK (CD45+CD3negNKp46+) and T 
cells (CD45+CD3+NKp46neg) were identified within the peripheral blood and tumour 
using flow cytometry. The proportion of NK and T cells out of CD45+ cells was 
calculated. n=11. Numbers represent mean± s.d. 
 
 Control blood Peripheral blood of patient Tumour 
CD69 11.8 ± 11.7% 13.1 ± 12.7% 49.3 ± 20.2% 
NKp30 86.8 ± 13.1% 86.5 ± 10.1% 77.9 ± 16.1% 
NKG2D 91.1 ± 6.9% 90.3 ± 6.0% 80.3 ± 9.9% 
DNAM-1 79.2 ± 15.6% 79.8 ± 18.0% 63.5 ± 21.3% 
CD9 4.8 ± 4.9% 5.9 ± 4.4% 16.2 ± 8.0% 
Tetherin 86.9 ± 12.2% 92.7 ± 6.9% 86.6 ± 6.3% 
CD2 67.9 ± 9.8% 66.7 ± 15.7% 55.7 ± 12.5% 
 
Table 3.2 Proportion of NK cells expressing surface protein. Flow cytometry was used 
to analyse the proportion of NK cells (CD45+CD3negNKp46+) that were stained with 
antibodies for the particular antigens. The gates were set at 2% of the isotype control 
antibody stain. Numbers represent mean± s.d, number of patient samples analysed is 
given in figure 3.4. 
 
 Control blood Peripheral blood of patient Tumour 
CD69 12.5 ± 18.7% 9.1 ± 12.9% 74.6 ± 10.0% 
PD-1 48.4 ± 12.5% 45.7 ± 12.5% 83.2 ± 7.8% 
LAG-3 14.3 ± 14.3% 15.3 ± 5.9% 33.9 ± 16.8% 
CTLA-4 5.8 ± 6.6% 8.6 ± 5.4% 15.1 ± 12.0% 
DNAM-1 72.9 ± 10.9% 82.0 ± 9.1% 72.0 ± 11.5% 
Tetherin 75.5 ± 13.5% 81.7 ± 11.5% 68.0 ± 12.5% 
CD2 97.9 ± 1.0% 98.2 ± 0.8% 94.5 ± 3.3% 
 
Table 3.3 Proportion of T cells expressing surface protein. Flow cytometry was used 
to analyse the proportion of T cells (CD45+CD3+NKp46neg) that were stained with 
antibodies for the particular antigens. The gates were set at 2% of the isotype control 
antibody stain. Numbers represent mean± s.d, number of patient samples analysed is 
given in figure 3.5. 
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3.6   Discussion and conclusion 
NK cells, defined as CD3negNKp46+, were identified within human GBM tumours, 
accounting for 3.6±3.1% of CD45+ cells. This agrees with a previous study that 
reported NK cells (defined as CD3−CD14−CD56+) accounted for 2.11% ±0.54 of CD45+ 
cells (Kmiecik et al. 2013). To assess whether T cells or NK cells selectively infiltrated 
the tumour, I compared the proportion of NK cells in both the blood and tumour 
sample. As previously mentioned, the presence of CD45+ microglia in the tumour 
sample means that the comparison cannot be made using the proportion of CD45+ 
cells. The ratio of NK to T cells was used and no infiltration preference was observed 
between these two cell types. It is important to realise that no information about the 
infiltration of specific T cell subsets can be obtained using this ratio; knowledge of CD4 
and CD8 T cell infiltrates will likely be more relevant to patient prognosis. For example, 
conflicting historical reports exist that correlate gross lymphocyte infiltration and 
prognosis (Safdari et al. 1985; Brooks et al. 1978; Böker et al. 1984). However, the use 
of subset markers has linked the levels of CD3+ and CD8+ cells with prolonged survival 
in GBM patients (Kmiecik et al. 2013) and Treg accumulation (scored using the FOXP3 
molecule as a marker) increases with tumour grade (El Andaloussi & Lesniak 2006). 
For several other cancers the number of NK cells present in the tumour positively 
correlates with patient survival. For example, in squamous cell lung carcinoma patients 
with low levels of tumour infiltrating NK cells had a 2.5 fold increase in the risk of 
death (Villegas et al. 2002). However, these studies were performed using 50 patients 
and a much larger GBM cohort would be required to carry out similar studies. 
Tumour infiltrating immune cells often show an altered phenotype which is associated 
with a loss of an antitumor activity and, in some cases, pro-tumour activities (de Visser 
et al. 2006). This process is known as tumour-induced polarisation and has been well 
documented for macrophages (Mantovani & Sica 2010), dendritic cells, mast cells, B 
cells and T cells (Coffelt et al. 2010; DeNardo et al. 2010). It has also been proposed for 
NK cells (Noonan et al. 2008) as the CD56brightCD16neg subset, that are known to 
produce angiogenic factors such as VEGF, PIGF and IL-8, are predominant in human 
non-small cell lung cancer (NSCLC) (Carrega et al. 2008). Having established that NK 
cells were able to gain entry into the GBM tumour, it was important to analyse their 
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cell surface phenotype to assess any tumour-induced polarisation and evidence of 
immunosuppression. 
The upregulation of CD69 on tumour infiltrating NK and T cells suggests that the cells 
are or have been active. When considering the development of immunotherapies for 
these patients, the upregulation of CD69 is promising because it suggests that the 
immune cells are capable of recognising and responding to the tumour cells. However, 
when NK cells are treated with the activating cytokine IL-15 a far greater proportion of 
cells (typically 60-70%; see chapter 5), express CD69. In contrast, the bimodal CD69 
histogram (Figure 3.3) shows that a minority of the tumour infiltrating NK cells are 
activated and the majority of NK cells within the tumour are CD69 negative. This 
suggests that, whilst NK cell activation can occur in the tumour microenvironment, the 
majority of NK cells are not activated and are unlikely to be contributing to an anti-
tumour response. The ability to therapeutically activate these CD69neg NK cells has 
the potential to enhance the anti-tumour activity, for example using a TGF-β blocking 
antibody could prevent the down regulation of activation receptors (see below). 
A down regulation of activation and coactivation receptors NKp30, NKG2D, DNAM-1 
and CD2 was observed on NK cells located within the tumour compared to the 
peripheral blood (Figure 3.4). This has been reported for NKp30, NKG2D, DNAM-1 in 
other tumours such as breast (Mamessier et al. 2011) and colon cancer (Rocca et al. 
2013). In both cases these NK cells had an impaired cytotoxicity. This is not surprising 
as reducing the amount of receptor available at the surface means that activation 
signals cannot be relayed. In fact, a direct association has been made between the 
surface density of NCRs such as NKp30 and NK cell cytotoxic activity (Sivori et al. 1999). 
Although the cytotoxic ability of the GBM infiltrating NK cells identified in this study 
was not tested (as the numbers present in the samples preclude such an analysis), I 
would predict that it is reduced. 
Similarly, evidence of immunosuppression is seen when examining the GBM infiltrating 
T cell population; inhibitory receptors PD-1 and LAG-3 were significantly upregulated 
and the same trend is shown for CTLA-4 (Figure 3.5). A study analysing malignant brain 
tumours found a 3.3 fold increase of CTLA-4 on T regs (defined as 
CD4+FoxP3+CD25highCD127low) infiltrating brain metastases compared to those within 
the blood (Jacobs et al. 2009). Although the figures given reflect an increase in the 
amount of CTLA-4 rather than the proportion of cells that display the antigen, the 
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same trend is observed in my data that shows approximately 2 fold more cells 
expressing CTLA-4 within the tumour compared to the patients’ blood. The same study 
also reported that PD-1 was expressed on CD4+ cells present in 26% of tumours but no 
indication was given as to the of proportion of T cells expressing PD-1. My research 
concludes that the average proportion of T cells within the tumour expressing PD-1 
was 83.2 ± 7.8%, comparatively much higher. However, this could be due to 
differences in the types of tumour analysed as the study mentioned included different 
types of brain tumours. Although the expression of LAG-3 has not been analysed 
previously on GBM infiltrating lymphocytes, its expression is enriched on CD8+ 
epithelial ovarian cancer (EOC) infiltrating T cells compared to those in the peripheral 
blood (Matsuzaki et al. 2010).Overexpression of inhibitory receptors is a feature of 
exhausted T cells which have reduced effector functions (Jiang et al. 2015). Exhausted 
T cells are no longer able to produce granzyme B that is a key component of lytic 
granules found in cytotoxic T cells (Wherry et al. 2003). A reduced cytokine and 
cytotoxic response by T cells leads to the failure of cancer elimination (Jiang et al. 
2015). Restoring this function using immunotherapies has shown real clinical promise. 
A recent clinical trial targeting CTLA-4 and PD-1 in GBM patients showed tumour 
regression (Nduom et al. 2016). Antibodies are being used in trials in GBM, combining 
that with second generation checkpoint inhibitors (e.g. LAG-3) and other e.g. anti-TGF-
β strategies might prove successful. 
CD9 is known to be induced by TGF-β (Keskin et al. 2007) and was significantly 
upregulated on NK cells within the tumour compared to those in the peripheral blood 
(Figure 3.4). Interestingly, not only is TGF-β known to reduce the expression of 
activation receptors NKp30 and NKG2D (Castriconi et al. 2003), it is also a crucial factor 
during T cell exhaustion (Massagué 2008). TGF-β is expressed by GBM cells, astrocytes 
and microglia (Constam et al. 1992). Whilst CD9 might be induced by many factors, the 
presence of CD9 on tumour infiltrating NK cells is consistent with the presence of TGF-
β in the tumour microenvironment. In addition to tumour-induced polarisation, TGF-β 
acts directly on the tumour cells themselves and has been implicated in tumour 
progression and metastasis (Ikushima & Miyazono 2010). 
CD9 is a characteristic marker of decidual NK cells (dNKs). These are specialised NK 
cells in the gravid uterus that play a role in preventing rejection of the foetal hemi-
allograft and placental angiogenesis (Sharma 2014). Within the decidua, NK cells are 
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the most abundant lymphocyte and they have a different phenotype and function to 
peripheral blood NK cells. The dNKs are CD56superbrightCD16negCD9+, poorly cytotoxic, 
and associated with induction of CD4+ Tregs and produce IL-10 that potentially 
contributes to the immunosuppressive nature of the placenta. Indeed, low levels of 
dNKs are linked to miscarriage (Santoni et al. 2007). The origin of dNKs is controversial 
but it has been proposed that peripheral NK cells are converted when they enter the 
decidua and decidual stromal cells are known to produce high levels of TGF-β (Bruno 
et al. 2014). Perhaps TGF-β within the tumour microenvironment induced a 
proangiogenic NK cell phenotype that is characteristic of dNKs. Supporting this theory 
is the finding that dNKs introduced to tumour cell xenografts enhanced tumour growth 
(Hanna et al. 2006) and that TGF-β contributes to the proangiogenic polarisation of NK 
cells in NSCLC (Bruno et al. 2013). 
Tetherin was also down regulated on the tumour infiltrating NK cells compared to 
those in the peripheral blood. Tetherin is upregulated in response to type I interferons 
and is important in controlling viral infections (Jiang et al. 2010; Brass et al. 2009). 
Down regulation could signify a global suppression of NK cell function. However, little 
is known of the mechanisms that regulate tetherin beyond IFN and the significance of 
tetherin downregulation is currently unclear. As well as its role in tethering budding 
virus particles to the cell membrane, tetherin has a pro-inflammatory signalling role; 
DCs from virus infected tetherin knock out mice had a significantly reduced expression 
of MHC class II and co-stimulatory molecule CD80 than wild type mice (Li et al. 2016). 
Reduced tetherin expression in the tumour may thus have consequences for NK cell 
effector function. 
Flow cytometry proved to be an incredibly powerful method for identifying and 
phenotyping rare populations of cells. However, it is also important to realise its 
limitations. One of the main drawback of this technique is that spatial information is 
lost. It would be interesting to see if NK cells could penetrate the tumour, or if they are 
paralysed upon entry. Immunofluorescence microscopy using tumour sections would 
help to provide answers. Nonetheless, it could prove difficult given the low proportion 
of NK cell infiltration. 
Results show that NK and T cells are present in the tumour, albeit at low numbers. 
There is evidence of immunosuppression of tumour infiltrating cells but not on 
peripheral lymphocytes, suggesting that the blood resident cells are ‘normal’ until they 
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encounter the tumour microenvironment. Not only does this suggest that this is part 
of the tumour’s evasion strategy, it also suggests that restoring the immune function 
within the tumour using immunotherapies could prove an effective treatment for 
these patients. 
In order for NK cell based therapies to be effective, the NK cells must be capable of 
responding to transformed cells. The results demonstrating CD69 expression on some 
tumour resident NK cells suggests that some NK cells are activated by a stimulus 
present in the tumour microenvironment. However, it is unclear whether the NK cells 
are responding directly to the tumour. Experiments described in the next chapter are 
aimed at investigating the outcome of NK cell-GBM interactions in vitro, outside of the 
immunosuppressive environment of the tumour.  
 
 
73 
Chapter 4 NK and target cell interactions 
4.1   Introduction 
Tumours progress partly because they are not eliminated by the immune system. In 
the previous chapter I showed that the GBM tumour microenvironment alters the cell 
surface phenotype of NK cells and T cells, with expression of NK cell activation 
receptors reduced and T cell inhibitory receptors increased. This is consistent with the 
hypothesis that NK cell and T cell activity is inhibited in the tumour and that this 
evasion activity has contributed to tumour progression, a hallmark of cancer (Hanahan 
& Weinberg 2011). With their ability to recognise and eliminate tumour cells, NK cells 
have great potential as key effector cells of immunotherapies. However, translating 
this to the clinic requires that NK cells have the ability to kill GBM cells when they are 
not subject to the immunosuppressive cues within the tumour microenvironment. 
Work reported in this chapter aims to address this by analysing GBM cell susceptibility 
to NK cell mediated death in vitro. 
Glioma stem cells (GSCs) are resistant to radio- and chemotherapies (Bao et al. 2006; 
Liu et al. 2006) and repopulate the tumour after treatment, leading to the formation of 
a recurrent tumour. Therefore, it is critical that we assess how well NK cells target 
GSCs if they are to be used as an immunotherapy. Patient derived brain tumour-
initiating cells (BTICs, also known as cancer stem cells) were used for the in vitro assays 
carried out in this chapter. Four of the primary cell lines were derived from GBM 
patients undergoing initial resection surgery (GBM1, GBM4, GBM11 and GBM13) 
whilst GBM20 is from a recurrent GBM tumour. The BTICs, which I will refer to as GBM 
stem cells, were characterised by Dr Heiko Wurdak (Wurdak et al. 2010) and members 
of his group, Dr Euan Polson and Dr Anjana Patel. They exhibit an undifferentiated 
phenotype and are characterised by expression of neural markers such as Nestin and 
Sox2, the proliferation marker Ki67 and low levels of the astroglial marker GFAP and 
the neuronal marker TuJ1 (which are characteristic of differentiated cells). They are 
also able to recapitulate high-grade gliomas in vivo using a mouse model, including 
high cellularity, tumour heterogeneity, proliferation, and massive infiltration into areas 
adjacent to the implantation site and even into relatively distant brain areas. 
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I therefore assessed the ability of the GBM cells to alter the surface phenotype of 
activated NK cells, the ability of NK cells to recognise and kill GBM stem cell tumour 
targets and characterised the surface landscape of these cells to understand how the 
targets might influence the immune response. 
4.2   GBM stem cells instigate an immunosuppressed NK cell 
phenotype 
GBM infiltrating NK cells analysed in chapter 3 exhibited reduced cell surface 
expression of NKG2D, NKp30 and DNAM-1. To assess the ability of GBM stem cells to 
downregulate the expression of NK cell activation receptors, co-culture experiments 
were carried out. 
This type of experiment has previously been used to analyse the interaction between 
ovarian cancer and NK cells and colorectal cancer and NK cells (Wilson et al. 2011); co-
culture using an excess of tumour cells causes TGF-β-dependent changes in the NK cell 
phenotype, including the downregulation of NKp30, NKG2D and DNAM-1, similar to 
that observed on the GBM infiltrating NK cells (chapter 3). 
I hypothesised that the changes observed in vivo might also be due to GBM expressed 
TGF-β. To test this, NK cells were isolated from healthy donors and activated for 24 
hours with IL-15. They were then washed and co-cultured with 80% confluent GBM 
stem cells (GBM4, GBM11 and GBM20) for between 24 and 72 hours (specifically, 
donor 1 24 hours; donor 2, 72 hours; donor 3, 48 hours). Activated NK cells incubated 
in GBM media were included as a control to account for changes in phenotype 
attributable to the different media used for culturing NK cells and GBM. The effect of 
co-culture on the expression of the activation marker CD69 and the activation 
receptors NKp30, NKG2D, DNAM-1 and NKp44 was analysed using flow cytometry 
(Figure 4.1). The results indicate that CD69 is expressed at high levels on IL-15 treated 
NK cells and that this expression was largely unaffected by co-culture with GBM (a 
slight downregulation of CD69 is seen for donor 2 and 3 when the NK cells are cultured 
with GBM4 and GBM20, Figure 4.1 top row). 
However, more marked changes in expression of activation receptors was observed 
following co-culture; NK cells from all three donors showed downregulation of 
activation receptors to varying degrees when co-cultured with the GBM stem cells. The 
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most pronounced effect is seen in donor 1 whereby co-culture with all GBM cells leads 
to the decreased expression of NKp30, NKG2D and DNAM-1 (Figure 4.1 left column). 
This mimics the effects of the tumour microenvironment on NK cells observed in the 
patient samples (Figure 3.4). 
Interestingly, not only do the donor NK cells show different levels of downregulation of 
activation receptors in response to the GBM cells, but they are also influenced in 
distinct ways by the individual GBM cells. For example, NK cells from donor 2 showed a 
down regulation of NKG2D, DNAM-1 and NKp44 when co-cultured with GBM11 cells 
but there was no expression change in NKp30 when compared to the IL-15 treated 
cells. In contrast, NK cells from the same donor co-cultured with GBM20 resulted in 
downregulation of NKp30, but the downregulation of NKG2D and DNAM-1 was not to 
the same extent as that seen with GBM11 co-cultured NK cells (Figure 4.1 middle 
column). Incubation of NK cells from donor 3 with any of the GBM cells caused a 
downregulation of NKG2D. 
These experiment show that GBM stem cells are capable of modifying the NK cell 
surface phenotype ex vivo, and that the resultant phenotype broadly resembles that 
observed for GBM infiltrating NK cells (chapter 3). 
However, inclusion of anti-TGF-β antibody or the TGF-β signalling inhibitor (SB431542) 
in similar co-cultures with the GBM cell line U87 (data not shown) failed to 
demonstrate a role for TGF-β in these effects and, coupled with the donor variation, 
the mechanistic basis for this modulation was not pursued further. However, this type 
of co-culture experiment has the future potential to uncover the mechanism by which 
GBM cells influence the NK cell phenotype. 
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Figure 4.1. Phenotype of NK cells co-cultured with GBM stem cells. NK cells were activated with IL-15 and incubated with GBM stem cells for 
between 24 and 72 hours. NK cells were analysed using flow cytometry for the expression of the activation receptors shown. Isotype staining 
(shaded) shows nonspecific binding. Expression of each receptor is shown for cells treated with IL-15 alone (blue) or subsequently co-cultured with 
GBM4 (orange), GBM11 (pink) or GBM20 (green). Data from 3 experiments using 3 individual donors is presented. 
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4.3   Patient derived GBM stem cells are susceptible to activated 
NK cell killing 
Having established that the GBM stem cells were capable of modulating the 
phenotype of activated NK cells, it was important to establish if their cytolytic function 
was also impaired. Three patient-derived GBM stem cell lines (GBM1, GBM4 and 
GBM20) were used as targets in cytotoxicity assays to assess the ability of NK cells to 
recognise and kill GBM cells in the absence of the immunosuppressive 
microenvironment. NK cell activation is dependent on the integration of both 
activating and inhibitory signals. To shift this balance to favour NK cell activation, 
freshly isolated NK cells from healthy donors were cultured with IL-15 prior to the 
assay. This treatment induces the cell surface expression of activation receptors 
NKp30, NKG2D and DNAM-1 (See chapter 5); receptors that were shown to be 
downregulated on the tumour infiltrating NK cells in the GBM resection samples 
(chapter 3). 
Target cells were stained with a cell tracker dye and incubated with different ratios of 
activated NK cells (effectors). After 5 hours, the level of target cell death was assessed 
using a dead cell marker and flow cytometry (Figure 4.2a). A zero-hour time point was 
used as a control to account for non-NK mediated cell death. The experiment was 
repeated 3 times using NK cells derived from 3 individual donors. All primary GBM 
stem cells tested (GBM1, GBM4 and GBM20) were susceptible to NK mediated cell 
death (Figure 4.2b). A higher effector to target ratio correlated with an increase in 
target cell death. The results also exhibit different donor responses. For example, one 
donor (red dots on graphs in figure 4.2b) was able to kill a higher proportion of GBM1 
and GBM4 cells compared to GBM20 cells and also compared to the other two donors. 
This variation in donor response can be explained by the fact that NK cells from 
different individuals can display different inhibitory KIRs (Valiante et al. 1997; Uhrberg 
et al. 2002). 
These experiments demonstrate that activated NK cells are capable of killing primary 
GBM stem cells and suggests that immunotherapies that enhance NK cell activity might 
be beneficial for GBM patients. 
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Figure 4.2. Cytotoxic assays. Effectors (activated primary NK cells) were incubated with stained targets (patient derived GBM stem cells) for 5 hours. 
After the 5 hour incubation period the cells were stained with a dead cell discriminator and assessed by flow cytometry. a) Cell tracker positive 
targets were identified (left) and cell death was analysed. The histograms show (from left to right) the 0 hour (control) and 5 hour time points with 
the increasing effector to target ratios; dose dependent killing was observed. b) GBM stem cells (GBM1, GBM4 and GBM20) were assessed for NK cell 
mediated cytotoxicity. The experiment was repeated with NK cells from 3 individual donors. Dots of the same colour (red, orange and blue) 
represent data for each donor. The bar indicates the mean± s.d. Statistical analysis was performed using paired t-tests. *P<0.05, **P<0.01. 
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4.4   GBM stem cell surface antigen screen 
The results in figure 4.2 indicate that NK cells can detect (and kill) GBM cells. This 
implies that GBM cells express ligands for NK cell receptors and presumably ligands of 
other immune cell types. Furthermore, knowledge of cell surface phenotype of GBM 
cells could greatly improve our understanding of potential immune evasion strategies 
employed by the tumour that could underpin development of immunotherapies. 
To analyse the GBM cell surface phenotype in detail, I performed a multiplex cell 
surface antigen screen using five patient-derived glioma stem cell lines (GBM1, GBM4, 
GBM11, GBM13 and GBM20). The multiplex screen utilises cell tracker dyes to label 
different cell types in a mixed population (Figure 4.3a). In this way, four cell types 
could be distinguished (Figure 4.3b) and simultaneously stained for 242 different 
surface antigens (Figure 4.3c). The screen was performed twice to allow five lines to be 
analysed. Cell lines screened on both occasions showed that the assay was 
reproducible (data not shown). Prior to the screen, optimisation was carried out to find 
the best combination of cell tracker dyes, antibody staining protocol and flow 
cytometer settings (data not shown). Data was acquired using an LSRII flow cytometer 
and analysed using BD FACSDiva and Beckman Kaluza software. 
Antigens expressed on 20% or more of the cells were taken forward for further 
analysis. Figure 4.4 summarises the antigens expressed on the five glioma stem cell 
lines. The percentage expression for each antigen on the five cell lines is listed in 
Appendix 1. All five lines expressed 44 antigens in common including HLA molecules 
and CD56 (neural cell adhesion molecule, NCAM), which is a neural marker (Sundberg 
et al. 2009) as well as being expressed by NK cells. 
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Figure 4.3. Multiplex surface screen. a) Cells were stained with different cell tracker 
dyes, mixed and aliquoted into 96-well plates. Each plate was subsequently stained for 
a panel of 242 different surface antigens (one antigen/well). b) Cells were analysed by 
flow cytometry. Live cells were identified by their morphology (FSC/SSC) and using a 
fluorescent dead cell discriminator. The cell tracker dyes enabled resolution of the 
different populations. The dot plot of the violet and orange channels shows separation 
of GBM11 (orange) and GBM4 (purple) cells. c) Viable cells were assessed for the 
presence of antigen. An Alexa Fluor 647 conjugated secondary antibody was used to 
detect the primary antibody bound to the surface protein and the signal acquired in 
the APC channel (640-680 nm). The histograms show an example of staining (CD15) for 
each of the four GBM lines used in the second screen. 
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Figure 4.4. Multiplex surface screen. A large scale surface screen was 
performed using five GBM stem cell lines (GBM1, GBM4, GBM11, GBM13 
and GBM20). a) The Venn diagram (generated with 
http://bioinformatics.psb.ugent.be/webtools/Venn/) details the number of 
antigens expressed on at least 20% of the cells. b) The table lists the 
antigens present within each section of the Venn diagram. 
GBM stem cells Total Antigens (CD no. if applicable) 
GBM1 GBM11 GBM13 
GBM20 GBM4 
44 9 26 29 34 44 46 47 49b 49c 49d 49e 49f 54 56 
57 59 63 71 73 81 90 91 94 95 97 98 99 99R 
107A 119 142 146 147 151 164 165 166 227 
271 340 b2m GD2 HLA ABC HLA DQ 
GBM1 GBM11 GBM20 
GBM4 
2 58 140A 
GBM1 GBM13 GBM20 
GBM4 
1 200 
GBM1 GBM11 GBM13 
GBM20 
1 321 
GBM11 GBM13 GBM20 
GBM4 
16 49f 55 51/61 61 105 107B 112 120A 130 141 
172B 184 221 268 274 338  
GBM1 GBM20 GBM4 2 15 SSEA1 
GBM1 GBM11 GBM20 1 106 
GBM13 GBM20 GBM4 9 24 118 140B 152 209 220 egfr HLAA2 MICA/B 
GBM11 GBM13 GBM20 2 77 80 
GBM1 GBM13 1 49a 
GBM11 GBM4 1 109 
GBM11 GBM13 1 104 
GBM11 GBM20 5 74 205 273 HLA DR HLA DRPQ 
GBM13 GBM20 2 50 108 
GBM11 6 10 38 40 62P 121B 201 
GBM13 4 144 326 329 SSEA4 
GBM20 7 75 88 120B 138 171 231 
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4.4.1   Bimodal populations 
Flow cytometry allows the expression of antigens to be analysed across a population of 
cells. This allows heterogeneity of the cell population to be analysed and the 
expression of antigens within subpopulations to be determined. Bimodal peaks are 
indicative of two separate populations of cells in relation to a particular antigen. The 
multiplex screen revealed bimodal peaks as well as single peaks with a smaller 
shoulder population. For example, expression of human embryonic stem cell marker 
CD24 (Assou et al. 2007), the neural stem cell markers CD90 and CD184 (Sundberg et 
al. 2009) and other antigens such as CD15, CD138 and CD172b showed evidence of 
distinct populations of cells (Figure 4.5). The expression of the stem cell markers on 
GBM stem cells is not surprising, but their bimodal distribution suggests that the 
isolated cells exist as heterogeneous populations containing subsets of cells that are 
enriched with stem cell characteristics. 
Interestingly, gene expression data for some of the antigens, including a few of those 
with a bimodal expression pattern, are associated with differential prognosis. The 
Repository of Molecular Brain Neoplasia Data (REMBRANDT) database (now housed in 
Georgetown University's G-DOC System) was used to produce Kaplan-Meier survival 
curves that assess the association between the mRNA expression level for each antigen 
and patient survival (Figure 4.6). In the REMBRANDT study, RNA was extracted from 
whole tumour tissue and information about which cells express the particular mRNA 
cannot be determined. 
The results show that patients with down regulation of signal-regulatory protein beta-
1 (SIRPβ1, CD172b) have a poorer survival outcome than patients with an intermediate 
or high level of expression of this molecule. Signal-regulatory proteins are 
immunoglobulin-like transmembrane glycoproteins involved in the regulation of 
leukocyte function (van Beek et al. 2005). SIRPβ1 generates a positive signal via the 
ITAM of DAP12 (Takizawa & Manz 2007). It is possible that the poor prognosis seen 
with a lower amount of SIRPβ1 is indicative of inactive immune cells. However, the 
screen showed expression of SIRPβ1/CD172b on the GBM stem cells themselves so 
maybe positive regulation of tyrosine signalling promotes cancer cell activities. 
Likewise, patients with low expression of CD80 had a worse prognosis; CD80 is 
involved in co-stimulation of T cells (Harris & Ronchese 1999) and a lack of CD80 in the 
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tumour microenvironment might prevent the activation of T cells, thereby enabling the 
tumour cells to evade T cell lysis. Although three of the cell lines, GBM4, GBM13 and 
GBM20, were positive for CD80, only 28%, 25% and 50% of the cells respectively were 
positive for the antigen. Cells expressing higher levels of CD80 (or other co-stimulatory 
molecules) are predicted to act as better stimulators of T cell responses, for example 
triggering CD8 cytotoxic cells. Thus, patients with tumours expressing lower levels of 
CD80 mRNA might exhibit poorer survival due to weaker T cell responses. 
For both lymphocyte antigen 75 (Ly75, CD205) and intracellular adhesion molecule 3 
(ICAM3, CD50), high expression within the tumour correlates with a worse prognosis. 
Ly75 is found on dendritic cells that are able to present antigens on both class I and II 
MHCs (Palucka & Banchereau 2012), enabling stimulation of other immune cells. 
Therefore, one might expect a high expression level to reflect more dendritic cells 
within the tumour that can process antigen, prime T cell responses in the lymph node 
and generate an anti tumour immune response, in turn improving prognosis. However, 
high expression of Ly75 has also been found in epithelial ovarian cancer and promotes 
a metastatic phenotype (Faddaoui et al. 2016). CD50 has been shown to be important 
for the recruitment of phagocytes to apoptotic lymphocytes and their subsequent 
clearance (Torr et al. 2012). Perhaps expression of CD50 could lead to recruitment of 
phagocytes to the tumour and lead to the elimination of anti tumour immune cells. 
Another pro-tumour role has also been proposed for CD50. An in vitro study using a 
NSCLC cell line overexpressing CD50 suggest it stimulates cancer cell migration and 
invasion pathways (Park et al. 2010). Clearly, the actual role of any of these molecules 
requires further study and elucidation of their function in regulating survival requires 
linking of survival data to expression of mRNA or protein in particular tumour or 
stromal cell types. 
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Figure 4.5. Bimodal 
populations. Histograms 
for the four GBM lines 
analysed simultaneously 
showing the expression 
of markers that exhibit 
bimodal or shoulder 
populations. These 
include stem cell 
markers CD15, CD24, 
CD90 and CD184 and 
other markers such as 
CD172b and CD138.
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Figure 4.6. Kaplan-Meier 
survival plots for samples 
with differential mRNA 
expression for the genes 
(and antigens) listed. The 
REMBRANDT database 
was used to generate 
Kaplan-Meier plots that 
test for association of 
expression level (up 
regulated red, 
intermediate yellow, down 
regulated green) of each 
gene based on levels of 
mRNA extracted from 
tumour tissue and patient 
survival. Survival data for 
GBM patients is shown in 
blue. The number of 
samples analysed in each 
group is listed. The log-
rank p-value (for 
significance of difference 
of survival between group 
of samples) is also listed 
(Institute National Cancer 
2005).
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4.4.2   Antigens of interest 
Many of the antigens detected in the multiplex surface screen were of particular 
interest because they have previously been implicated in either immune regulation or 
immune evasion. These are summarised in figure 4.7 and include molecules such as 
MIC-A and Nectin-2 (CD112) which are ligands for the NK cell activation receptors 
NKG2D and DNAM-1 respectively. Supporting the detection of GBM and activation of 
NK cells via these receptor-ligand interactions are in vitro cytotoxic assays that use 
blocking antibodies to prevent receptor-ligand interaction and disrupt killing (Codo et 
al. 2014). 
Antigens of interest for their immune evasion properties include CD73, programmed 
cell death ligands PD-L1 and PD-L2 and CD200. CD73 (an ectonucleotidase) is found on 
the membranes of anti-inflammatory immune cells (such as Tregs) and helps to limit 
the immune response by dephosphorylating AMP to generate adenosine (Antonioli et 
al. 2013). Adenosine mediates immune-suppressive and anti-inflammatory activities of 
Tregs by engaging with A2A receptors on T cells (Deaglio et al. 2007), causing inhibition 
of effector functions of activated cells (Huang et al. 1997). Increased CD73 mRNA has 
previously been reported in glioma cells compared to normal astrocytes (Wink et al. 
2003). However, analysis of the REMBRANDT database reveals that CD73 mRNA levels 
are not associated with survival (data not shown). 
Another protein that keeps the immune response in check and is exploited by cancer 
cells to avoid immune destruction is PD-1/CD279 (Jadus et al. 2012; Zou & Chen 2008). 
This molecule is expressed on B cells, NK cells, dendritic cells, monocytes and T cells 
(Keir et al. 2008). Its ligands, which include PD-L1/CD274 and PD-L2/CD273, were 
detected on the tumour cells in the screen (Figure 4.4 and appendix 1); these ligands 
suppress TCR activation and reduce T cell survival, cytokine production and 
proliferation (Rozali et al. 2012). The use of antibodies targeting the receptor for PD-L1 
(PD-1) have shown promising results in clinical trials to treat metastatic melanoma 
(NCT01927419) and similar trials are underway for patients with GBM (NCT02617589, 
NCT02017717, NCT02529072). Importantly, results in chapter 3 demonstrated that 
GBM infiltrating T cells expressed high levels of PD-1 compared to their counterparts in 
patient blood (Figure 3.5). Detection of the PD-1 ligands, PD-L1 and PD-L2 on the GBM 
cells themselves indicates that tumour infiltrating T cells will likely be inhibited via the 
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PD-1:PD-L1/PD-L2 interactions. Indeed, patients expressing high levels of PD-L1 have a 
worse prognosis (Nduom et al. 2016). This provides a rationale for the use of anti-PD-1 
antibodies (e.g. Nivolumab and Pembrolizumab) in this disease. Optimal T cell 
activation requires engagement via the TCR and via co-stimulatory molecules. Whilst 
GBM cells express high levels of MHC class I (for antigen presentation to the TCR; 
Figure 4.4 and appendix 1), I did not detect expression of CD86 and four out of the five 
lines tested had low or no expression of CD80 (Figure 4.4). Both proteins are known 
ligands for the costimulatory T cell antigen CD28. This surface antigen screen suggests 
that GBM cells have a cell surface phenotype that is consistent with inhibiting T cell 
activity rather than stimulating anti-tumour immunity. 
CD200 is a membrane glycoprotein that plays an important role in immunosuppression 
and regulation of anti-tumor activity (Kretz-Rommel et al. 2007). Overexpression of 
CD200 correlates with poor prognosis in many human blood cancers (McWhirter et al. 
2006; Moreaux et al. 2006; Tonks et al. 2007) and has been directly linked with the 
suppression of NK cells (Coles et al. 2011). CD200 was expressed on GBM1, GBM4, 
GBM13 and GBM20 and possibly contributes to NK cell evasion. 
Some of the antigens detected in the screen are the targets of current antibody 
therapies, or receptors for oncolytic viruses (Figure 4.7). For example, CD340/HER2 is 
targeted with Trastuzumab (best known for its role in the treatment of breast cancer; 
(Romond et al. 2005; Piccart-Gebhart et al. 2005). The CD33 antigen is targeted by the 
antibody Gemtuzumab and an antibody-drug conjugate known as Gemtuzumab 
ozogamicin (Mylotarg) has been used to treat acute myelogenous leukaemia (Cohen et 
al. 2002). EGFR is targeted by Cetuximab as part of existing therapies for several 
tumours, including colorectal cancer (Scott et al. 2012). Although EGFR was expressed 
on GBM4, GBM13 and GBM20, it was not detected in the screen for GBM1 and 
GBM11. However, EGFR is frequently mutated in human gliomas, and 20-25% of GBM 
express the EGFRvIII variant (Kogiku et al. 2008; Saikali et al. 2007; Xu et al. 2009). This 
is a glioma stem cell associated antigen and is being developed as an antigen for use in 
dendritic cell based immunotherapy for GBM treatment (Sampson et al. 2009). The 
antibody used in the screen does not detect the mutated variant. The expression of 
therapeutic antibody targets on the GBM cells may be of relevance to future 
therapeutic strategies. However, whilst immune cells can cross the blood brain barrier 
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via the dynamic process of transendothelial migration, molecules greater than 500 
Daltons in size (equivalent to a four or five amino acid peptide) are prevented from 
entering the brain under normal conditions (an IgG antibody has a molecular weight of 
approximately 150 kDa). However, the blood brain barrier is much less selective in the 
presence of GBM, evidenced by a higher accumulation of temozolomide (Rosso et al. 
2009) and contrasting agents (Zhou & Lu 2013) in glioma tissue compared to normal 
brain. In addition, strategies are being developed to enhance the permeability of the 
blood brain barrier for therapeutic delivery (e.g. the localised delivery of TNF to 
enhance endothelial permeability; (Connell et al. 2013) and focused ultrasound 
(Rodriguez et al. 2015). The use of bevacizumab (anti-VEGF) in patients changed the 
vessel morphology within the tumour (Lampson 2011), suggesting that antibodies are 
able to gain access to the tumour. 
The reovirus receptor, CD321 (also known as JAM-A, JAM1 and F11R) was expressed 
on GBM1 (22%), GBM11 (20%), GBM13 (84%) and GBM20 (42%) but was not detected 
for GBM4. The presence of the receptor indicates the possibility that reovirus could be 
used in the treatment of GBM as in many other cancer types where it has reached 
stage III clinical trials (Adair et al. 2012). Importantly, reovirus (and other oncolytic 
viruses) exert anti-tumour activity via (at least) two distinct mechanisms; direct killing 
of the tumour cell upon infection and replication and the promotion of anti-tumour 
immunity (Turnbull et al. 2015). Reovirus stimulates human NK cell activation in vivo 
(El-Sherbiny et al. 2015) and Reovirus reaches GBM tumours after intravenous delivery 
(Alan Melcher, personal communication). This suggests that Reovirus might prove a 
useful therapeutic agent to treat GBM. High expression (above 89%) of CD46 was 
observed on all of the GBM cell lines screened. The CD46 molecule is a receptor for 
group B adenoviruses (Gaggar et al. 2003) which are being developed as vectors for 
cancer gene therapy (Wold & Toth 2013). This too might lend itself for the 
development of new GBM therapies. 
Cancer stem cell markers for solid tumours were observed in the screen. These 
included those identified in glioma, such as CD98 and CD90, and those that are 
presented by other tumours; CD44 (breast, colon, liver, ovarian, pancreatic and 
prostate), CD26 (colon) and CD24 (breast, colon, liver, ovarian and pancreatic) 
(Medema 2013). Expression of CD98 predicts poor prognosis in many cancers as it 
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promotes survival, growth and metastasis (Cantor & Ginsberg 2012). Interestingly, 
ovarian cancer cells bearing CD24 were found to be resistant to chemotherapy yet 
preferentially lysed by NK cells (Koh et al. 2012). If the same is true of GBM, then 
assessing CD24 expression at the time of resection might predict the response to 
subsequent chemo- or immunotherapies. 
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Figure 4.7. Antigen expression 
on GBM stem cells grouped into 
functional categories. A 
selection of screen hits classified 
into functional categories; 
immune evasion, T cell and NK 
cell ligands, stem cell markers, 
small molecule targets, antibody 
targets (antibodies are listed) 
and oncolytic virus receptors. 
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4.5   Characterising neural progenitor cells 
Successful cancer therapies must target the tumour cells, but spare non-transformed 
healthy cells. This is especially important in the brain where damage to healthy cells 
could result in severe morbidity. Highly sophisticated mechanisms employed by the 
immune system ensure that responses are specific to infected or malignant cells. 
Hence, exploitation of the immune system is of great interest for the development of 
cancer therapies. However, the immune system is not fool proof, and it can damage 
healthy tissues, as shown by the prevalence and severity of autoimmune and 
autoinflammatory diseases, including those occurring in the brain, such as multiple 
sclerosis (Goldenberg 2012). The immune response to cancer cells is, by definition, an 
autoimmune reaction (or at least, a response to altered self) and effective tumour 
elimination with minimal collateral damage is a challenge. 
To address the specificity of NK cells towards tumour cells compared to healthy brain 
tissue, I made use of non-malignant, neural progenitor cells. Characterising non-
malignant, neural progenitor cells was undertaken to identify potential immune cell 
interactions that help protect these stem cells from an immune response. The cells 
studied (NP1) were derived from an epilepsy patient (without cancer). The NP1 cells 
were established by the Wurdak group using the same method to isolate the GBM 
stem cells. The GBM cell lines express the stem cell markers CD24 (GBM4 99%, GBM13 
78% and GBM20 89%), CD90 (GBM1 81%, GBM4 64%, GBM11 30%, GBM13 99%, 
GBM20 99%) and CD184 (GBM4 61%, GBM11 44%, GBM13 57% and GBM20 48%) 
(Figure 4.5 and appendix 1) and flow cytometry showed that these molecules were 
also expressed to a similar level by the NP1 cells (CD24 72%, CD90 99% and CD184 
44%) (Figure 4.8), indicating a degree of similarity between the malignant GBM cells 
and the normal NP1 cells. 
The expression of ligands for the NK cell activation receptors DNAM-1, NKG2D and 
NKp30 was also assessed. Surprisingly, NP1 cells expressed high levels of Nectin-2 
(CD112) and ULBP1 (Figure 4.8), which are ligands for DNAM-1 and NKG2D 
respectively. Lower levels of a second NKG2D ligand, MIC-A/B (Figure 4.8), and the 
NKp30 ligand, B7H6 were also detected. The expression of these molecules suggests 
that the NP1 cells would be susceptible to NK cell cytotoxicity. However, the NP1 cells 
also express high levels of HLA class I proteins; these interact with KIRs and other 
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inhibitory receptors to downregulate NK cell activity. Interestingly, the PD-1 ligands, 
CD274 (PD-L1) and CD273 (PD-L2) were also expressed by the NP1 cells (99% and 58% 
respectively) (Figure 4.8); this suggests that NP1 cells might inhibit the activity of T 
cells. 
Having established that NP1 cells display ligands for both activating and inhibitory NK 
cell receptors, functional assays were performed to assess if these non-malignant 
neural progenitor cells were susceptible to NK cell cytotoxicity. 
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Figure 4.8. Neural progenitor (NP1) phenotype. NP1 cells were tested for stem cell markers and NK and T cell ligands using flow cytometry. The 
gates were set at 2% of the isotype control stain. Data is representative of three separate analyses.
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4.6   Selective killing of GBM stem cells 
In section 4.2 above, I demonstrated that activated NK cells can kill GBM stem cells ex 
vivo (Figure 4.2), supporting the hypothesis that immunotherapies which restore NK 
cell function might benefit GBM patients. However, the expression of NK cell activation 
ligands by NP1 neural progenitor cells (Section 4.5; Figure 4.8) suggests that non-
malignant cells in the brain might also be susceptible to NK cell mediated death. This 
could cause severe side effects during immunotherapy. It was therefore paramount to 
compare the capacity of NK cells to selectively target the GBM stem cells. 
To directly compare the susceptibility of the GBM and NP1 cells in a mixed population 
(as would be found in a brain tumour), I modified the standard cytotoxicity assay. GBM 
stem cells (GBM) and neural progenitors (NP) were stained with different cell tracker 
dyes and then mixed in a 1:1 ratio to provide the target cells (denoted GBM+NP1). 
Green and violet cell tracker dyes were used to identify the GBM+NP1 targets. These 
dyes did not affect cell death; neither directly, nor by making them more susceptible to 
NK cell mediated cytotoxicity (data not shown). Donor derived NK cells (effectors) 
were activated with IL-15 and incubated with the GBM+NP1 targets for 5 hours at an 
E:T ratio of 5:1. After the 5 hour incubation period, the cells were stained with a dead 
cell discriminator and assessed by flow cytometry. Death of the GBM and NP cells due 
to NK cell activity was calculated as the difference between the 5 hour and 0 hour 
samples. 
Competitive assays were performed with three GBM stem cell lines (GBM1, GBM4 and 
GBM20) paired with the neural progenitor cells (NP1). The experiments were repeated 
using NK cells from a minimum of three donors. The same trends are observed for all 
pairings (Figure 4.9); at the zero-hour time point a similar, minimal cell death is 
recorded for both cell types (Figure 4.9a left). However, after 5 hours the proportion of 
GBM cells that have been killed is far greater than the proportion of NP1 cells. This 
difference was statistically significant for GBM4+NP1 cells, but the pattern is also 
evident (but not statistically significant) for the GBM1+NP1 and GBM20+NP1 pairs 
(Figure 4.9b). These results show that, despite expressing ligands for NK cell activation 
receptors, the non-malignant neural progenitors are more resistant to NK mediated 
cytotoxicity than the GBM stem cells. This indicates that NK cell based 
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immunotherapies might be effective at targeting the GBM stem cells but sparing 
others. 
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Figure 4.9. Competitive cytotoxicity. GBM stem cells (GBM) and neural progenitors 
(NP) were stained with different cell tracker dyes and mixed in a 1:1 ratio to 
collectively be the target cells. Effectors (activated primary NK cells) were incubated 
with the targets for 5 hours at an E:T ratio of 5:1. After the 5 hour incubation period 
the cells were stained with a dead cell discriminator and assessed by flow cytometry. 
a) Cell tracker positive targets were identified and the NK cell mediated death was 
calculated by subtracting the 0 hour time point from the 5 hour time point. b) A 
comparison of NK cell mediated cytotoxicity was made between GBM stem cells and 
neural progenitors. The experiment was repeated with NK cells from at least 3 
individual donors. Dots of the same colour represent data for each donor. The bar 
indicates the mean± s.d. Statistical analysis was performed using paired t-tests. 
*P<0.05, **P<0.01. 
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4.7   Discussion and conclusion 
In chapter 3, I showed that the cell surface phenotype of NK cells infiltrating GBM 
tumours was altered compared to NK cells from the patients’ blood. A similar 
phenotype was observed when IL-15 treated cells were co-cultured with GBM cells in 
vitro. The downregulation of NK cell activation receptors observed in the tumour 
microenvironment suggests that NK cells in the tumour are less responsive or 
inhibited. This suggests that therapies that prevent NK cell inhibition in the tumour 
microenvironment might enhance the anti-tumour response for patients with GBM. 
However, for the NK centred immunotherapies to be effective, the NK cells must be 
capable of killing the tumour cells once the immunosuppressive brakes of the tumour 
microenvironment are lifted and show specificity for the tumour. 
In vitro cytotoxic assays using IL-15 activated NK cells from healthy donors revealed 
that NK cells successfully kill primary GBM stem cells (Figure 4.2). This finding supports 
an existing publication that used both IL-2 and IL-15 activated NK cells to target glioma 
stem cells (Castriconi et al. 2009). Without the use of activating cytokines, patient-
derived GBM cells are largely resistant to NK cell lysis (Friese et al. 2003; Wischhusen 
et al. 2005). In these published studies, NK cell cytotoxicity was enhanced by the 
plasmid-mediated or adenovirus-mediated overexpression of the NKG2D ligand, MIC-
A, on the target cell (Friese et al. 2003) or by downregulating HLA-E, which interacts 
with the inhibitory NKG2A/CD94 heterodimer (Wischhusen et al. 2005). Although 
previous studies have shown that GBM cells are susceptible to NK cell mediated killing, 
to the best of my knowledge there are no published studies comparing the ability of 
NK cells to recognise and respond to GBM stem cells in comparison to their non-
malignant counterparts. This is very important because immunotherapies must be able 
to specifically target the cancer cells to minimise collateral damage to healthy brain 
cells. 
To assess the specificity of activated NK cell cytotoxicity towards transformed cells, 
competitive killing assays were carried out. A non-malignant neural stem cell line (NP1) 
was used in conjunction with three different primary GBM stem cell lines. In all cases 
selective killing of the GBM stem cells over the non-malignant cells was seen (Figure 
4.9). Even when artificially skewed to an activated status (with IL-15), NK cells still kill 
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target cells in a very specific manner. Interestingly, a recent report using a multiple 
sclerosis mouse model showed that neural stem cells produce IL-15 and can sustain 
functionally competent NK cells (Liu et al. 2016). The NK cells used in the cytotoxic 
assays described here had already been activated with IL-15, but it would be 
interesting to see if co-culture with NP1 cells could enhance GBM cell lysis via 
endogenous IL-15 production. 
Previous studies that have investigated the susceptibility of neural stem cells to NK cell 
lysis, with a view to develop neural stem cell therapy for untreatable neurological or 
psychiatric diseases, have shown conflicting results. One study concluded that neural 
stem cells do not express MHC antigens and are susceptible to NK cell lysis by 
recognition of lack of self MHC and also expression of NKG2D ligands, Rae-1, H60 and 
MULT-1 (Phillips et al. 2013). In contrast, a second study found that despite marginal 
expression of MHC class I and II on neural stem cells they are not susceptible to NK cell 
lysis, even when activated with IL-2 (Mammolenti et al. 2004). The agreement 
between these studies is that neural stem cells lack MHC antigens. This contradicts my 
results; whereby high levels of HLA class I were observed on the NP1 cells (Figure 4.8). 
However, these previous studies were both performed in mice and a recent study 
using human neural stem cells showed similar expression of HLA class I that I report 
(Schmitt et al. 2015). This study also concluded that HLA-G expression was important 
for inferring NK cell resistance. 
Further characterisation of the NP1 cells revealed high expression of Nectin-2 (CD112) 
and ULBP-1 which are ligands for NK cell activation receptors DNAM-1 and NKG2D 
respectively (Figure 4.8). An antibody that detects both MIC-A and MIC-B also showed 
moderate staining (23%) on NP1 cells. Despite the high expression of these activating 
ligands, NP1 cells were largely resistant to NK cell lysis. NK cell activation occurs when 
signals from activating receptors outweighs those from inhibitory ones. The high 
expression of MHC class I molecules by NP1 is predicted to block the activation signals 
delivered by DNAM-1 and NKG2D ligands. However, all GBM stem cells also express 
high levels of MHC class I and the difference in the susceptibility of GBM cells and NP1 
cells to NK cells presumably lies with differences in the expression of ligands that 
activate NK cells. The expression of NKG2D ligands is coupled to the malignant 
phenotype; DNA damage induces ATM/ATR dependent expression of NKG2D ligands 
(Gasser et al. 2005), allowing NK cells to detect damaged cells. However, NKG2D 
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ligands are also upregulated during the cell cycle via E2F (Jung et al. 2012). Hence, any 
cells maintained in culture are likely to induce expression of NKG2D ligands and this 
mechanism might be responsible for the expression of ULBP1 and MIC-A/B on the NP1 
cells. 
The cytotoxicity data demonstrate that GBM cells are selectively targeted in 
preference to normal neural progenitor cells. A limitation of these experiments is that 
the NK cells, NP1 cells and GBM cells used in the assays are all derived from different 
donors. The polymorphism of MHC class I molecules and KIRs means that it is 
theoretically possible that MHC class I molecules from one donor do not inhibit NK 
cells from a different donor. Hence, it is possible that the resistance of the NP1 cells 
results from the expression of MHC class I molecules that inhibit all three donors, 
whereas the GBM cells express MHC class I molecules that do not inhibit the donor NK 
cells. In reality, such a scenario is highly unlikely as most donors possess between 6 
and 16 different KIRs with several KIRs common to many donors (Uhrberg et al. 2002). 
To investigate other potential immune modulating proteins and to better characterise 
the GBM stem cells a large scale surface screen was carried out. Five patient derived 
GBM stem cell lines established by the Wurdak group were analysed. The expression of 
CD112 and MICA/B (ligands of DNAM-1 and NKG2D respectively) was initially detected 
during the GBM surface antigen screen on most of the GBM stem cells (CD112 on 
GBM4/11/13/20, MICA/B on GBM4/13/20) (Figure 4.4). This antigen screening assay 
highlighted the expression on GBM cells of several proteins with the potential to 
modulate anti-tumour immunity or act as therapeutic targets (summarised in Figure 
4.7). 
The very existence of GBM tumours shows that they are able to evade the immune 
system. The previous chapter presented evidence of immunosuppressed GBM 
infiltrating NK cells and thus supports the rationale for developing NK cell based 
immunotherapies. Data presented in this section shows that NK cells skewed to an 
activated status are not only capable of killing GBM stem cells, but that they 
preferentially kill GBM cells over non-malignant neural stem cells. The surface screen 
helped characterise the GBM stem cells and revealed proteins that could influence cell 
fate in vivo or that are interesting for other immune based therapies. 
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In the next chapter, I examine the effects that glucocorticoids, which are currently 
used to treat the cerebral oedema experienced by many brain tumour patients, have 
on the phenotype and function of NK cells.
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Chapter 5 Steroid mediated NK cell immunosuppression 
5.1   Introduction 
The data presented in chapters 3 and 4 supports the rationale for developing NK based 
immunotherapies for the treatment of GBM. However, GBM patients often experience 
complications such as cerebral oedema, which if left untreated, can be fatal. Cerebral 
oedema is treated with corticosteroids such as dexamethasone, which are well known 
for their powerful anti-inflammatory properties; using corticosteroids is likely to 
render immunotherapy ineffective (Zitvogel et al. 2008). It is remarkable that, despite 
the fact that corticosteroids have been used in clinic to treat cerebral oedema since 
the early 1950s (Ingraham et al. 1952), their exact mechanism of action remains 
unclear. An understanding of how glucocorticoids affect NK cells is required in order to 
design immunotherapies that are effective in the presence of concomitant lifesaving 
steroids. 
Chapter 3 demonstrated that the phenotype of GBM infiltrating NK cells mirrored that 
of NK cells that had been treated with TGF-β (Wilson et al. 2011). In this chapter I 
compare the action of TGF-β, which is detected within GBM tumours (Joseph et al. 
2013), with that of dexamethasone, the predominant corticosteroid used to alleviate 
cerebral oedema in to brain tumours and methylprednisolone, which is used in the 
treatment of other cancers. 
5.2   TGF-β, dexamethasone and methylprednisolone prevent the 
IL-15 induced activated phenotype 
To assess potential immune regulatory effects of corticosteroids on NK cells, freshly 
isolated NK cells from healthy donors were treated with dexamethasone or 
methylprednisolone, either alone or in conjunction with IL-15. TGF-β prevents the IL-
15 induced upregulation of activation receptors such as NKp30, NKG2D and DNAM-1 
and was used as a positive control for NK cell inhibition. The NK cells were treated for 
48 hours and assessed for the expression of 7 activation receptors using flow 
cytometry (Figure 5.1). An isotype control antibody was used to assess non-specific 
antibody binding. Unstimulated NK cells (resting) were included as a control to 
measure the basal level of antigen expression. A physiological concentration of TGF-β 
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(5 ng/mL) was used (Porreca et al. 2002; Fogel-Petrovic et al. 2007) and 
dexamethasone (2 x 10-7 M) and methylprednisolone (2 x 10-6 M) were used at a 
concentration achievable in patients receiving these agents (Kostaras et al. 2014; Baylis 
et al. 1982). Within the reported range, the minimum concentration that could 
effectively prevent IL-15 induced CD69 upregulation was used. A time course 
experiment was also carried out; this revealed that the greatest change in receptor 
expression occurred at 48 hours. The experiment was repeated with a minimum of NK 
cells from 3 donors. Results are summarised in figure 5.2. 
One of the most striking differences between IL-15 treated cells and those dual treated 
with IL-15 and dexamethasone or TGF-β, is the change in morphology assessed by flow 
cytometry (Figure 5.3). When NK cells are treated with IL-15 their size and granularity 
increase (Figure 5.3). This is known to correlate with an increase in their metabolic 
activity (Marçais et al. 2014). Both TGF-β and dexamethasone curtail the IL-15 induced 
morphological changes, suggesting that they prevent the IL-15 mediated increases in 
metabolic activity. 
Figure 5.2 shows that TGF-β, dexamethasone and methylprednisolone all prevent the 
upregulation of CD69 that is seen with IL-15 treatment. CD69 is one of the first surface 
expressed proteins displayed subsequent to activation (Ziegler et al. 1993); this result 
suggested that TGF-β, dexamethasone and methylprednisolone all inhibit NK cell 
activation. 
In addition to inhibiting CD69, steroids and TGF-β also inhibited the IL-15 mediated 
induction of NKp30 and NKG2D. The same pattern was observed for DNAM-1, NKp46 
and CD132 (IL-2 receptor subunit gamma), even though the levels of IL-15 induction 
were much lower (Figure 5.2). These results demonstrate that TGF-β and the 
glucocorticoids dexamethasone and methylprednisolone were able to inhibit the IL-15 
mediated NK cell activation phenotype to a similar extent. 
Interestingly, both dexamethasone and methylprednisolone inhibited the IL-15 
induced upregulation of NKp44. However, the same was not true of TGF-β (Figure 5.1 
and 5.2). This suggests that the expression of NKp44 is regulated by different pathways 
than those that control regulation of other activating receptors and that 
glucocorticoids are able to inhibit the NKp44 pathway, whereas TGF-β cannot.
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Figure 5.1. Characterisation of NK cells treated with corticosteroids. NK cells isolated 
from healthy donors were treated at the same time with 100IU/mL IL-15 (orange), IL-
15 + 5 ng/mL TGF-β (pink), IL-15 + 2x10-7 M dexamethasone (green) or IL-15 + 
methylprednisolone (beige) for 48 hours. An isotype control antibody (black shaded) 
was used to establish nonspecific binding and untreated cells (blue) were used to 
establish the resting phenotype. Characterisation was performed using the antibodies 
listed and flow cytometry. The percentage of NK cells that were positively stained for 
each antigen was established by analysing the live cells The gates were set at 2% of the 
isotype control stain. The experiment was repeated 5-7 times. Representative 
histograms are shown.
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Figure 5.2. Summary of all 
donors used for the 
characterisation of 
corticosteroid treated NK 
cells. NK cells derived from 
healthy donors were either left 
untreated (resting) or treated 
with 5 ng/mL TGF-β, 2x10-7 M 
dexamethasone (dex), 2x10-6 M 
methylprednisolone (MP) or a 
combination of these with 100 
IU/mL IL-15. Cells were treated 
for 48 hours then characterised 
for the antigens listed using flow 
cytometry. The median 
fluorescent intensity was used 
to calculate the fold change 
compared to the resting 
expression level. The 
experiment was repeated with 
NK cells from a minimum of 3 
individual donors. Dots of the 
same colour represent data for 
each donor. The bar indicates 
the mean± s.d. Statistical 
analysis was performed using 
ratio paired t-tests. *P<0.05, 
**P<0.01, ***P<0.001, ns= not 
significant.
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Figure 5.3. Morphological changes observed with TGF-β and dexamethasone 
treatments. NK cells derived from healthy donors were either left untreated (resting) 
or treated with 5 ng/mL TGF-β, 2x10-7 M dexamethasone (dex), or a combination of 
these with 100 IU/mL IL-15. Cells were treated for 48 hours then characterised using 
flow cytometry. The forward (FSC) and side (SSC) scatter that are a measure of size and 
granularity respectively were used to study morphological changes with the different 
treatments.
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5.3   Dexamethasone prevents NK cell degranulation and target 
cell killing 
Finding that dexamethasone inhibits IL-15 induced expression of activation receptors 
suggested that NK cell effector functions might also be inhibited. Cytotoxicity assays 
were carried out to assess the ability of dexamethasone treated NK cells to kill the 
prototypic NK cell target cell line, K562. Prior to the cytotoxic assays, NK cells were 
treated with either IL-15 or a combination of IL-15 and dexamethasone for 48 hours. 
Cells were incubated together for 5 hours at different E:T ratios (1:1, 2:1 and 5:1), 
stained with a dead cell discriminator and assessed by flow cytometry. A zero hour 
time point was used to establish the background level K562 death. The experiment 
was repeated 4 times with NK cells from different donors. 
The results show that IL-15 treated NK cells are able to kill K562 in a dose dependent 
manner (Figure 5.4a). However, when NK cells were pre-treated with IL-15 and 
dexamethasone their ability to kill the target cells was greatly reduced (Figure 5.4a 
bottom); NK cells from all donors followed this pattern (Figure 5.4b). 
The cytotoxic function of NK cells depends on them being able to recognise targets and 
respond by releasing the contents of their cytotoxic, secretory lysosomes. Therefore, 
the observed inability of dexamethasone treated NK cells to kill target cells could 
either be due to an inability to respond appropriately or because the lysosomes do not 
contain sufficient lytic proteins. 
To assess the NK cell response to target cells, degranulation assays were performed. 
When an NK cell degranulates, the lysosomal membrane fuses with the plasma 
membrane such that the luminal side of the lysosome is displayed on the cell surface; 
CD107a, also known as lysosomal-associated membrane protein 1 (LAMP-1), is 
expressed on the luminal side of the secretory lysosomes, thus it is exposed to the cell 
surface when the cell degranulates. During degranulation assays (first described using 
T cells by (Betts et al. 2003)), the surface expression of CD107a is used to quantify the 
response of NK cells to target cells. 
Prior to the degranulation assay, NK cells derived from healthy donors were either 
treated with IL-15 or IL-15 and dexamethasone for 48 hours. NK and K562 target cells 
were incubated at a 1:1 ratio for 5 hours. NK cells were identified using a cell tracker 
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dye and an antibody for the NK cell marker, CD56. The expression of CD107a was 
established using antibodies and flow cytometry. The surface expression of CD107a 
was determined both with and without the presence of K562 target cells. The 
expression of CD107a without the presence of K562 was used to establish the basal 
level of cell surface expression. 
In the absence of target cells, neither treatment caused degranulation (Figure 5.5a). 
However, in the presence of K562, IL-15 treated NK cells were able to degranulate and 
this was significantly reduced when NK cells had been pre-treated with a combination 
of IL-15 and dexamethasone. The experiments were performed using NK cells from 4 
donors and the same pattern was observed (Figure 5.5b). 
Secretory lysosomes contain perforin and granzyme family members that function to 
pierce the target cell and initiate the apoptotic cascade. The absence of such proteins 
greatly decreases the lytic function of NK cells (Trapani & Smyth 2002). For example, 
absence of active granzymes greatly compromises NK cell activity (Heusel et al. 1994; 
Simon et al. 1997; Pardo et al. 2002). NK cells derived from healthy donors were 
treated with either TGF-β, dexamethasone, methylprednisolone, or these agents 
combined with IL-15, for 48 hours. Cells were lysed and the level of granzyme B was 
assessed using a Western blot. The results show (Figure 5.5c) that IL-15 induces 
granzyme B levels and that both steroids and TGF-β prevent IL-15 induced granzyme B 
accumulation. 
These results show that dexamethasone is able to impair the cytotoxic activity of IL-15 
activated NK cells. This is achieved by both reducing the ability of the NK cell to 
respond to its target (via reduced expression of target-sensing activation receptors) 
and release the contents of its lytic granules and by the reduction in the amount of the 
key cytotoxic protein, granzyme B. 
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Figure 5.4. Glucocorticoid effect on NK cell cytotoxicity. a) Cytotoxic assays 
were performed using donor derived NK cells treated for 48 hours with 100 
IU/mL IL-15 (top) or IL-15 + 2x10-7 M dexamethasone (bottom). The prototypic 
NK cell target line, K562, was used as a target. Cells were incubated together 
for 5 hours with different NK:K562 ratios, stained with a dead cell 
discriminator and assessed by flow cytometry. The 0 hour time point (left) was 
used to establish the background level K562 death. b) The experiment was 
repeated with NK cells from 4 individual donors. Dots of the same colour 
represent data for each donor. The bar indicates the mean± s.d.  
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Figure 5.5. Glucocorticoid effect on degranulation and granzyme B. a) Degranulation 
assays were performed using donor derived NK cells treated for 48 hours with IL-15 
(top) or IL-15 + dexamethasone (bottom). The prototypic NK cell target line, K562, was 
used as a target. Cells were incubated together for 5 hours at a 1:1 ratio of NK to K562 
cells. Degranulation was quantified using they luminal lysosomal marker CD107a and 
flow cytometry. The basal level of expression of CD107a was assessed (left) without 
the presence of K562. b) The experiment was repeated with NK cells from 4 individual 
donors. Dots of the same colour represent data for each donor. The bar indicates the 
mean± s.d. Statistical analysis was performed using paired t-tests. *P<0.05. c) 
Expression of granzyme B assessed using a Western blot. β actin staining was used as a 
loading control. 
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5.4   How do TGF-β and steroids inhibit NK cell activation? 
The results presented above indicated that dexamethasone and TGF-β have a similar 
effect on the NK cells; both acting to prevent IL-15 activation. To investigate the 
inhibitory mechanisms of dexamethasone and TGF-β on IL-15 activation, gene 
expression profiling using a microarray was performed. This global view of the effects 
of these agents on NK cells should reveal whether dexamethasone and TGF-β act in a 
similar manner to generate the same overall phenotype. 
NK cells from healthy donors were isolated and treated under six different conditions 
for 48 hours; untreated (resting) or addition of dexamethasone, TGF-β, IL-15, IL-
15+dexamethasone and IL-15+TGF-β. Both the morphology of the cells and the cell 
surface expression of CD69 and NKp30 were used to assess the donor response (Figure 
5.6). IL-15 activation causes NK cells to clump together and this is prevented by the 
addition of dexamethasone and TGF-β (Figure 5.6b), consistent with the ability of 
these agents to block the activation signal. Likewise, IL-15 causes the upregulation of 
both CD69 and NKp30, but both dexamethasone and TGF-β counteract this response 
(Figure 5.7). Seven donors were treated in total, with two of the seven showing a weak 
response. The remaining five donors showed strong induction of the activated 
phenotype with IL-15 and antagonism of this effect by dexamethasone and TGF-β. 
Cells from these five donors were used to prepare mRNA for the microarray. The 
surface phenotype of CD69 and NKp30 for these five donors are presented in figure 
5.7. 
Following collection, the samples were sent to an external service provider (see 
materials and methods) who performed the microarray. Standard techniques were 
used to isolate mRNA, synthesize complementary DNA (cDNA), fluorescently label the 
cDNA, hybridise it to the array and acquire the data. The raw intensity files were 
received and analysed using the Affymetrix expression and transcript analysis consoles. 
A bioinformatician (Dr Alastair Droop) facilitated the initial stages of the analysis using 
the computer programming language R. In addition to the quality controls 
incorporated in the Affymetrix expression console, a principal component analysis 
(PCA) was carried out to assess the similarity of the six treatments for each of the five 
donors. The microarray provided expression data across over 60,000 probes 
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(encompassing protein coding and non-coding genes) for the thirty individual samples 
(five donors and six treatments), generating a total of over 1.5 million data points. 
Principal component analysis is a mathematical algorithm that allows the simplification 
of such a large data set while retaining information on the variance. This is achieved by 
establishing directions in the data (known as the principal components) along which 
the variation in the data set is at its greatest (Ringnér 2008). For my data set, 39.6% of 
the variation is described by the first principal component (Figure 5.8). 
Importantly, the principal component analysis (Figure 5.8) shows that the same 
treatments cluster together, confirming that the different donors respond to the 
treatments in a similar way. Cells left untreated (resting) or treated with 
dexamethasone or TGF-β cluster together, as do those treated with IL-15+TGF-β or IL-
15+dexamethasone. The cluster of IL-15 treated cells is far away from the other 
samples; this reflects the dramatic change in phenotype observed with IL-15, with 
dexamethasone and TGF-β blunting these effects and dragging the data closer to the 
phenotype observed for untreated cells. This is also illustrated by the cell surface 
phenotype data. For example, for CD69 (Figure 5.7b) whereby expression levels remain 
low (close to 0% of cells expressing CD69) in the resting, dexamethasone or TGF-β 
treated cells, but greatly upregulated with IL-15 (approximately 60% of cells express 
CD69). The combination treatments significantly inhibit the IL-15 induced CD69 
expression, with approximately 10-20% of cells expressing the antigen. These samples 
are phenotypically more similar to the resting, dexamethasone and TGF-β treated 
samples. The PCA indicated that the global transcription within the cells supports the 
biological changes observed in vitro. 
The expression of several genes were analysed further using quantitative RT-PCR. This 
analysis (performed by Dr Erica Wilson) validated the results observed within the 
microarray, with the same trends in expression observed for the different treatments. 
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Figure 5.6. Protocol for sample treatment and collection for the microarray. a) Approximately 6 x 107 NK cells were isolated (1 x 107/ treatment) 
and either left untreated or treated with 5 ng/Ml TGF-β, 2X10-7 M dexamethasone or these in combination with IL-15. Cells were incubated for 48 
hours before being harvested by centrifugation and resuspended in RNAprotect. Cells were stored at -20°C until all samples had been obtained. Prior 
to collection cells were analysed for their response to the treatments both morphologically (b) and by characterisation of NKp30 and CD69 using flow 
cytometry (figure 5.7). 
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Figure 5.7. Confirming the response of donors used for the 
microarray. a) Quantitative flow cytometric determination 
of CD69 and NKp30 expression on NK cells was used to 
confirm the response of the five donors used for microarray 
analysis to IL15, TGF-β and dexamethasone. An increase in 
CD69 expression confirms NK cell activation upon IL15 
treatment. Activation is significantly attenuated with 
addition of TGF-β and dexamethasone. b) The graphical 
presentation shows the consistency of donor responses. 
Dots of the same colour represent data for each donor. The 
bar indicates the mean± s.d. Statistical analysis was 
performed using paired t-tests. **P<0.01, ***P<0.001, 
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****P<0.0001. 
 
Figure 5.8. Principal component analysis. Principal 
component analysis (PCA) plot of principal components 
1 and 2 for the gene expression profile of NK cells from 5 
donors, with 6 treatments. Each sample is represented 
by one dot. Each colour corresponds to a separate 
treatment. The graph was generated by Alastair Droop 
using R. 
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The Affymetrix transcriptome analysis software enabled the comparison of two 
treatments for the five donors. A paired analysis was carried out to generate the 
average fold change for the five donors for each gene between two treatments. An 
average fold change of 1.5 or more and a p value of 0.05 or less was used as a 
threshold. To assess the suppressive effects of TGF-β and dexamethasone on IL-15 
activation, three paired analyses were carried out; resting vs IL-15, IL-15 vs IL-15 + TGF-
β and IL-15 vs IL-15 + dexamethasone. A comparison of the results is summarised in 
the Venn diagram in figure 5.9. Three regions of the Venn diagram are of particular 
interest. The central overlap containing 564 genes identifies those that are 
upregulated by IL-15 and downregulated in the presence of IL-15+TGF-β and IL-
15+dexamethasone, i.e inhibition is common to both agents. These genes were further 
analysed to identify any potential inhibitory mechanisms that are common to both 
TGF-β or dexamethasone. Two other regions were also analysed in greater detail to 
identify genes that are unique to suppression either by TGF-β or dexamethasone; Venn 
diagram overlaps between ‘Up in IL-15’ and either ‘Down in IL-15+TGF-β’ (132 genes) 
or ‘Down in IL-15+dex’ (409 genes) respectively. 
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Figure 5.9. Venn diagram to compare the suppressive effects of TGF-β and 
dexamethasone on IL-15 activated NK cells. Three paired analyses were carried out; 
resting vs IL-15, IL-15 vs IL-15 + TGF-β and IL-15 vs IL-15 + dexamethasone. A fold 
change of 1.5 and a p value of 0.05 or less was used as thresholds. To analyse 
suppression, the genes up regulated in IL-15 treated NK cells vs resting (Up in IL-15) 
were compared with those down regulated in combination treatments of 
dexamethasone (Down in IL-15 + dex) or TGF-β vs IL-15 (Down in IL-15 + TGF-β) treated 
cells.  
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5.4.1   Strategies to reveal common mechanisms of regulation 
The 564 mRNA transcripts within the central overlap of the Venn diagram are those 
that are upregulated in IL-15 treated cells compared to resting cells and 
downregulated in the presence of IL-15+dexamethasone or IL-15+TGF-β. Analysing this 
region will help to elucidate the suppressive mechanisms common to both 
dexamethasone and TGF-β. 
Presented with a list of RNA transcripts, there are a number of ways to approach the 
analysis (Figure 5.10a). Although each transcript is potentially interesting in its own 
right, analysing the transcripts as a whole allows the identification of enriched 
pathways and the potential cellular functions that they regulate (Figure 5.10a right). 
Once the pathways are established, it is also possible to predict the downstream 
transcription factors that regulate the expression of effector genes (Figure 5.10a left). 
Another approach is to ask which transcription factors are known to regulate the 
expression of the genes for which the transcripts are present (Figure 5.10a bottom). 
These are the ways in which the data was analysed. 
Metacore software was used to analyse the data. Metacore software encompasses an 
integrated knowledge database. The manually curated software allows the 
incorporation of established biological functions into the analysis of whole cell 
transcriptional changes. This enables identification of pathways enriched within 
different data sets and can suggest key transcription factors and pathways regulated 
by the treatments in the data set. 
The transcription factors that regulate the transcription of the RNA within the central 
Venn overlap are listed in figure 5.10b. Metacore contains data about established links 
(published in the literature) between transcription factors and their target genes. The 
software then searches the dataset for these targets and reports functions controlled 
by the target proteins (Figure 5.10c). 
The results strongly suggested that dexamethasone and TGF-β act to prevent IL-15 
induced cell division and that this is potentially mediated by transcription factors such 
as CREB1, c-MYC, E2F1 and/or any of the other transcription factors listed in figure 
5.10b.
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Figure 5.10. Analysis of common gene targets and pathways inhibited by TGF-β and 
dexamethasone. a) Possible approaches to analyse the RNA transcripts collectively. 
The cellular functions of the proteins encoded by the RNA can be identified. The 
presence of multiple RNA transcripts within one pathway indicate pathways activated 
by the treatment. Downstream transcription factors of these pathways can also be 
established. A second approach is to consider transcription factors that are known to 
regulate the expression of RNA within the dataset. b) Transcription factors that 
regulate the expression of the transcripts within the central region of the Venn 
diagram were identified. c) The functions regulated by these transcription factors. 
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Metacore was also instrumental in the second type of analysis performed; 
identification of pathways enriched within the transcripts listed in the central overlap 
of the Venn diagram (Figure 5.9). The cellular functions of these pathways are 
summarised in figure 5.11a. As observed during the transcription factor analysis, 
functions include cell cycle progression. In addition to cell cycle processes, pathways 
involved in the innate immune response and metabolism are also upregulated with 
treatment of IL-15 and inhibited in the presence of dexamethasone and TGF-β. The 
morphological changes observed with the different treatments (Figures 5.1 and 5.6b) 
support the finding that metabolic pathways are enriched in the overlap. 
The key transcription factors that are predicted to regulate the observed gene 
expression changes are shown in figure 5.11b. This implicates NF-κB, E2F1/DP1 and c-
Myc as important transcription factors regulating IL-15 induced cell cycle, metabolic 
upregulation and activation of the innate immune response in NK cells. 
The identification of genes reciprocally regulated by IL-15 and these agents implicated 
c-Myc as a key regulator of NK cell activation. This suggests c-Myc is a common point 
at which TGF-β and dexamethasone block pathways induced by IL-15. This finding led 
to further investigation of Myc reported in section 5.5 and 5.6. 
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Figure 5.11 Cellular functions and key 
transcription factors. a) A list of cell 
cycle processes that are associated with 
pathways enriched within the central 
Venn diagram overlap. b) Key 
transcription factors are identified that 
are downstream of proteins within 
enriched pathways (generated using 
Metacore). 
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5.4.2   Mechanisms specific to dexamethasone or TGF-β suppression of 
IL15 induction 
Analysis of the transcripts that are differentially expressed between the two 
treatments (Figure 5.12) indicated several transcription factors are common to both 
sets of genes, suggesting that these transcription factors are downstream of different 
signals and regulate multiple pathways independently. The listed functions (Figure 5.12 
b and d) indicate that, whilst TGF-β and dexamethasone both exhibit inhibitory 
functions, TGF-β seems to alter expression of genes that regulate glucose uptake 
whilst dexamethasone has other inhibitory effects. 
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Figure 5.12. Cellular functions and key transcription factors that are upregulated by IL-15 and down regulated by either dexamethasone or TGF-β. 
Key transcription factors (a and c) and functions (b and d) regulated by the addition of TGF-β or dexamethasone respectively. 
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5.5   Cell cycle analysis 
Changes in gene expression observed using the microarray suggested that IL-15 
mediated cell cycle control was disrupted by both dexamethasone and TGF-β. The 
transcription factor, c-Myc, was also identified in the microarray; first as a hub for 
regulating the expression of genes that are both upregulated with IL-15 and 
downregulated with the addition of either dexamethasone or TGF-β and secondly, as a 
transcription factor that regulates the cell cycle (Figure 5.10b). I therefore analysed the 
effect of IL-15, TGF-β and dexamethasone on the NK cell cycle. Cell cycle analysis was 
performed using BrdU, a thymidine analogue, and a DNA stain (Hoechst), to detect 
newly synthesised DNA and total DNA respectively. Isolated NK cells were either left 
untreated (resting) or treated with TGF-β, dexamethasone or in combination with IL-
15. A c-Myc inhibitor (Zhao et al. 2015) was also used to confirm the role of c-Myc in 
cell cycle control. 
Cells were treated for 24, 48 and 72 hours and the amount of BrdU incorporation into 
newly synthesised DNA was quantified. The assay was initially performed by incubating 
the cells with BrdU throughout the experiment, but this method was adapted by 
adding BrdU one hour prior to collecting the cells to reduce any effects of BrdU 
associated toxicity. However, the trends observed were the same for both variations 
on the method (Figure 5.13b). The cells were collected and washed in ice cold PBS then 
fixed by gradually increasing the concentration of ethanol to 80%. The samples were 
stored at -20°C until all time points had been collected. Nuclei were prepared by 
treating the cells with pepsin and hydrochloric acid to break down cellular proteins and 
expose the DNA including the incorporated BrdU. The BrdU was detected using an 
antibody and a fluorescent (AF594) conjugated secondary antibody. In addition, the 
fluorescent DNA stain, Hoechst 33342, allowed the cell cycle to be analysed using flow 
cytometry. This method was optimised for the analysis of primary NK cells by Dr Laura 
Wetherill (for use in an unrelated study). 
Cell cycle analysis is based on the knowledge that cells in the G0 or G1 phase of the cell 
cycle will have the normal diploid contents of DNA, G2 cells will have twice that 
amount and cells in S phase will have an intermediate quantity. It is important that 
only single nuclei (singlets) are included in the analysis, as two conjoined G0 nuclei will 
have the same total amount of DNA as one G2 nucleus. Singlets were identified based 
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on the pulse width and area on the channel used to detect total DNA (i.e the Hoechst 
stain was detected using the pacific blue channel). When a particle passes through the 
laser beam, a pulse is generated (Figure 5.13a). The width is the time taken for an 
object to pass through the laser beam and it is proportional to the object size and the 
duration of signal. The height of the pulse is the intensity of the signal. Both a cell in 
the G2 phase of the cell cycle and two G0 cells stuck together will have the same 
intensity. However, they can be distinguished based on the width of the pulse; a G2 
nucleus will take less time to pass the laser beam than two nuclei together. 
Unfortunately, the separation of the pacific blue signal based width was not 
pronounced (Figure 5.13b(i)) and the cell cycle profile subsequently generated based 
on the ‘singlets’ gate (Figure 5.13b(ii)) contained a pattern associated with conjoined 
nuclei. To overcome this problem, the ‘singlets’ gate was modified (Figure 5.13b(iii)) to 
exclude the conjoined nucleus stain pattern (Figure 5.13b(iv)). 
The gating strategy identified in figure 5.13b was used to generate cell cycle profile 
plots for the different treatments (Figure 5.14a). The experiment was carried out using 
NK cells from 3 donors (only 2 donors with the c-Myc inhibitor). During the initial 
experiment, the 24-hour time point revealed that less than 5% of cells had entered S 
phase (data not shown). Therefore, future experiments were set up with just the 48 
and 72 hour time points. The amount of cells in S phase and cell death was analysed. 
Data for all donors is presented in figure 5.14b. The results show that the mitogenic 
activity of IL-15 on NK cells is antagonised by both TGF-B and dexamethasone, as 
suggested by the microarray data. By 48 hours, approximately 10% of the IL-15 treated 
cells have entered S phase, whereas this is inhibited (approximately 2 fold) in the cells 
treated with IL-15 in combination with dexamethasone or TGF-β. This effect is more 
pronounced by 72 hours. Importantly, the same trend was also observed with the 
addition of the c-Myc inhibitor, suggesting that c-Myc regulates the transcription of 
genes required for cell cycle entry, as indicated by the transcription factor analysis of 
the microarray data (Figure 5.10b). 
Interestingly, when analysing the differences in cell death it became apparent that IL-
15 is capable of preventing the cell death that is seen with the treatment of 
dexamethasone alone. However, this rescue effect of IL-15 is not observed when the 
cells are treated with IL-15 together with the c-Myc inhibitor. This suggests that c-Myc 
is required for the pro-survival functions of IL-15. 
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Figure 5.13. Analysis of the 
cell cycle by flow 
cytometry. a) The width and 
height of the pulse 
generated when a particle 
passes through the laser 
beam can be used to infer 
the amount of taken for the 
object to pass and the 
intensity of the signal 
respectively. The width is 
therefore proportion to the 
size of the object. b) The 
original ‘singlets’ gate (i) 
had to be modified (iii) to 
exclude patterns associated 
with conjoined nuclei (ii). 
Subsequent gates were 
established to identify 
nuclei of dead cells (blue), 
G0 (green), S phase (purple) 
and G2 cells (orange) (iv). 
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Figure 5.14. Cell cycle analysis. a) Example cell cycle plots are shown for the treatments with 5 ng/Ml TGF-β, 2X10-7 M dexamethasone (dex) in the 
presence (right) or absence of 100 IU/mL IL-15 at 48 and 72hours. The colours identify nuclei from dead cells (blue), G0 (green), S phase (purple) and 
G2 cells (orange), along with the proportion of cells within each phase. b) The experiment was carried out using NK cells from 3 donors (only 2 
donors with the c-Myc inhibitor). Dots of the same colour represent data for each donor. The bar indicates the mean± s.d. 
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5.6   Intracellular signalling 
Both the microarray and the c-Myc inhibitor used in the cell cycle assays indicate that 
c-Myc plays a central role in IL-15 induced NK cell proliferation and survival. 
Collectively, the data suggests that c-Myc is a regulatory hub for pro- and anti-
activation pathways, the latter coordinating the inhibitory functions of TGF-β and the 
corticosteroids. I therefore analysed the effect of IL-15, TGF-β and dexamethasone on 
c-Myc protein by Western blotting. The results showed that IL-15 upregulates c-Myc 
expression compared to resting cells and that this response is suppressed by TGF-β, 
dexamethasone and methylprednisolone (Figure 5.15). The same effect was observed 
at both 48 and 72 hours post treatment. 
 
 
 
Figure 5.15. Western blot analysis of c-Myc. NK cells derived from a healthy donor 
were treated with either 5 ng/mLl TGF-β, 2x10-7 M dexamethasone, 2x10-6 M 
methylprednisolone or these treatments in conjunction with 100 IU/mL IL-15. Cells 
were collected after the specified time, lysed and prepared for analysis by Western 
blot. An equal number of cells were analysed for each sample. βactin has been used as 
a loading control. 
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To investigate potential differences in the suppressive mechanisms of dexamethasone 
and TGF-β on IL-15 signalling, proteins acting downstream of the IL-15 and TGF-β 
receptors were investigated. 
The IL-15 receptor consists of three subunits; α, β and γ (Ma et al. 2006). When bound 
by IL-15, Janus kinases 1 and 3 (JAK1 and JAK3) are auto-phosphorylated and initiate at 
least three signalling cascades; Ras-Raf-MEK, PI3K-AKT-mTOR and signal transduction 
and activation of transcription (STAT) 5 pathways (Nandagopal et al. 2014). As 
expected, treatment of NK cells with IL-15 was shown to induce the phosphorylation of 
STAT5 (Figure 5.16). NK cells treated with both IL-15 and TGF-β did not alter the 
phosphorylation of STAT5, a result consistent with previous data from our laboratory 
using human NK cells (Wilson et al. 2011) and a recent publication using mouse NK 
cells (Viel et al. 2016). Conversely, dexamethasone and methylprednisolone were both 
able to prevent IL-15 induced STAT5 phosphorylation. This supports the finding that 
dexamethasone prevents IL-2 induced STAT5 phosphorylation in NK cells (Michelo et 
al. 2016). 
The TGF-β receptor is a tetrameric complex made up of two TGF-βRI chains and two 
TGF-βRII chains. When bound by TGF-β, the type I chains phosphorylate the type II 
chains which enables the phosphorylation of transcription factors Smad2 and Smad3 
(Smad2/3). The SMAD2/3 complex is then able to translocate to the nucleus where it 
interacts with Smad4 and other proteins to regulate transcription (Derynck & Zhang 
2003). In keeping with this mechanism, TGF-β induced the phosphorylation of 
Smad2/3 (Figure 5.16). This was not observed for dexamethasone or 
methylprednisolone treated cells where no difference in SMAD2/3 phosphorylation 
was observed compared to the IL-15 treated cells. Differential activation of the SMAD 
and STAT signalling pathways identifies differences between the actions of TGF-β and 
dexamethasone. 
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Figure 5.16. Flow cytometry to assess phosphorylated STAT5 and phosphorylated 
SMAD2/3. NK cells derived from healthy donors were either left untreated (resting) or 
treated with 5 ng/Ml TGF-β, 2x10-7 M dexamethasone (dex), 2x10-6 M 
methylprednisolone (MP) or a combination of these with 100 IU/mL IL-15. Cells were 
treated for 48 hours then characterised for phosphorylated STAT5 or phosphorylated 
SMAD2/3 using flow cytometry. The surface phenotype and cell death were analysed 
by flow cytometry. Only live cells were included in the analysis. The median fluorescent 
intensity was used to calculate the fold change compared to the resting expression 
level. The experiment was repeated with NK cells from a minimum of 4 individual 
donors. Dots of the same colour represent data for each donor. The bar indicates the 
mean± s.d. Statistical analysis was performed using ratio paired t-tests. *P<0.05, 
**P<0.01, ns= not significant. 
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The treatment of NK cells with IL-15 causes an increase in the size and granularity of 
cells (Figure 5.1) and initiates the cell cycle (Figure 5.14), with TGF-β and 
dexamethasone attenuating these responses. The serine/threonine protein kinase 
mammalian target of rapamycin (mTOR) was discovered due to its role in inhibiting cell 
proliferation (Thomson et al. 2009) and is now known to be downstream of the IL-15 
signalling pathway (Marçais & Walzer 2014). Therefore, I analysed the effect of TGF-β 
and dexamethasone on the mTOR signalling pathway. 
Two of the most well-studied downstream targets of mTOR are the p70 S6 kinase 
pathway and the 4EBP1/eIF4E pathway (Figure 5.17a) which act in parallel to control 
translation (Fingar et al. 2004). The eukaryotic translation initiation factor 4E (eIF4E) 
forms part of a translational complex. When bound by 4E-binding protein 1 (4E-BP1), it 
is inhibited from forming this complex and translation is reduced. Phosphorylation of 
4E-BP1 by mTOR causes the release of eIF4E and the brake on translation is lifted 
(Fingar et al. 2004). Additionally, mTOR is able to phosphorylate p70 S6 kinase, which 
in turn phosphorylates the 40S ribosomal S6 protein, which is also thought to increase 
translation (Fingar et al. 2004).  
NK cells treated with TGF-β, dexamethasone, methylprednisolone alone or in 
combination with IL-15 were incubated for 48 hours and analysed for sustained 
changes in signalling pathways using flow cytometry or Western blotting. The results 
show that IL-15 treatment of NK cells causes an increase in the amounts of 
phosphorylated mTOR (Figure 5.17b), phosphorylated p70 S6 kinase (Figure 17c) and 
phosphorylated S6 (Figures 5.17b/c). These phosphorylation events were reduced 
when NK cells were treated with IL-15 in combination with TGF-β, dexamethasone or 
methylprednisolone (Figure 5.17b and c), identifying similarities in the actions of these 
immunosuppressive molecules. 
Analysis of the 4EBP1/eIF4E pathway reveals that IL-15 treatment induced the overall 
expression of 4E-BP1 and this is reduced with the addition of methylprednisolone or 
dexamethasone (Figure 5.17d). However, the same is not true of the IL-15/TGF-β 
treatment. The blot reveals different isoforms of 4E-BP1, as previously reported 
(Gingras et al. 1999; Wang et al. 2006; Takabatake et al. n.d.). Results show that TGF-β, 
dexamethasone and methylprednisolone all induce the α form (compared to resting 
NK cells). Interestingly, a previous paper investigating the mTOR pathway in an 
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osteosarcoma cell line showed that inhibition of S6 kinase or treatment with 
Rapamycin (an inhibitor of mTOR) restricted 4E-BP1expression to just the α form 
(Fingar et al. 2004). It is possible that the α form has a greater affinity for eIF4E and is 
preferentially expressed with these treatments. The IL-15 induced phosphorylation of 
4E-BP1 at threonine 37/40 is reduced with the addition of the steroid treatments but 
not with TGF-β. However, it has been suggested that the phosphorylation at Thr37/40 
is essential for the phosphorylation of other sites on 4E-BP1 that are in the binding site 
for eIF4E, but they themselves do not alter the pairing (Gingras et al. 1999). The 
amount of the non-phosphorylated form of 4E-BP1 is also reduced, but not 
undetectable, with the addition of IL-15 in all treatments. The antibody used 
recognises threonine 46 without a phosphate; hypophosphorylated 4E-BP1 interacts 
strongly with eIF4E (Gingras et al. 1999) and prevents its association with mRNA. The 
Western blots for the phosphorylated and non-phosphorylated forms of 4E-BP1 are 
consistent with patterns seen for the surface phenotype, the microarray and cell cycle 
analysis; dexamethasone and TGF-β dampen the IL-15 response but do not completely 
inhibit it. 
 
 
132 
Figure 5.17. mTOR pathway 
analysis. a) Schematic of the 
mTOR pathway. The 
phosphorylation of 4E-BP1by 
mTOR causes the release of eIF4E 
that forms part of a translation 
complex. mTOR also 
phosphorylates p70 S6 kinase (p70 
S6K), that phosphorylates S6, 
which in turn phosphorylates 40S 
ribosomal protein which also 
forms part of the translation 
complex (Based on information in 
(Fingar et al. 2004). b) Flow 
cytometry data for 
phosphorylated mTOR and S6. A 
separate colour has been used for 
each donor. pS6 tested for in one 
donor. The bar indicates the 
mean± s.d. Statistical analysis was 
performed using ratio paired t-
tests. *P<0.05, **P<0.01. c) 
Western blots for phosphorylated 
p70 S6 kinase, total and 
phosphorylated S6. d) Western 
blots for 4E-BP1analysis; total 
protein as well as phosphorylated 
and non-phosphorylated protein. 
β actin was used as a loading 
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5.7   Reactivation of NK cells after glucocorticoid treatment. 
These data demonstrate that dexamethasone is able to antagonise the effects of IL-15; 
downregulating NK cell activation receptor expression, preventing NK cell cytotoxicity, 
inducing cell death and preventing NK cells from entering the cell cycle in vitro. If the 
same is true in vivo, then the administration of dexamethasone to treat tumour 
induced cerebral oedema is predicted to render NK cell based immunotherapies 
ineffective. Indeed, evidence suggests that the administration of dexamethasone could 
negatively impact GBM patient prognosis (Hohwieler Schloss et al. 1989). The 
lifesaving action of steroids means that avoiding their use is not an option. My results 
show that future therapies must consider the combination of immunotherapy and 
steroids such that the steroids do not inhibit the anti-tumour activity of NK cells or 
other immune cell types. 
I attempted to model the effects of steroid treatment on subsequent NK cell activation 
by IL-15 in vitro. Figure 5.18 shows the experimental design. NK cells were isolated 
from healthy donors, aliquoted into two 24-well plates and treated as follows; resting 
(R), dexamethasone (D), methylprednisolone (MP) or these treatments in combination 
with IL-15. One plate was incubated for 24 hours and the other for 48 hours. After 
initial incubation, cells were characterised by flow cytometry for panel of NK cell 
activation receptors to establish the surface phenotype (p in figure 5.18) and to 
quantify cell death. Cells were subsequently washed with PBS and resuspended in 
media containing IL-15. Cells were characterised again at both 24 and 48 hours after IL-
15 treatment. The experiment was carried out using NK cells isolated from 2 individual 
donors. 
The cell death observed during the cell cycle analysis with dexamethasone treatment 
alone was replicated in this analysis (Figure 5.14 and 5.19). So too was the finding that 
IL-15 in conjunction with dexamethasone acts to prevent death. Methylprednisolone 
also follows this pattern. Unsurprisingly, the amount of death increases as the time of 
dexamethasone or methylprednisolone exposure increases. Interestingly, when NK 
cells were initially treated with dexamethasone or methylprednisolone, washed and 
re-cultured in IL-15, the same survival effect as that seen when cells are 
simultaneously cultured with IL-15 and dexamethasone or methylprednisolone was 
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not observed. This suggests that a proportion of cells are already committed to cell 
death before the IL-15 survival signal is presented. The plateau of the death curves 
may indicate that only cells not already dying respond to the survival cue from IL-15. 
When analysing the cell surface expression of CD69, a similarity between the two 
donors is seen (Figure 5.19). As previously described, NK cells treated with IL-15 
upregulate CD69 expression compared to all other conditions including resting, steroid 
and dual steroid/IL-15 treatments.  
The same trend is clearly seen for NKp30 and NKG2D and to a lesser extent NKp46 and 
DNAM-1. This supports the data presented in section 5.2. Once the cells had been 
washed and treated with IL-15 the general trend showed an increase in the expression 
of all antigens studied (CD69, NKp30, NKp46, NKG2D and DNAM-1). For CD69, NKG2D 
and NKp30 (48 hour treatment) the level of expression had increased by 24 hours and 
again by 48 hours. However, when NK cells were pre-treated with steroids, the 
induction of NK cell receptors by IL-15 was blunted. This is most apparent when 
examining the CD69 data whereby cells initially treated with methylprednisolone, 
dexamethasone or dexamethasone/IL-15 before IL-15 treatment have a much lower 
expression than cells initially left resting or treated with IL-15 (Figure 5.19). Specifically, 
only 42% and 23% of the 48 hour dexamethasone treated cells for donor 1 and 2 
respectively expressed CD69 when subsequently activated with IL-15. Furthermore, 
the longer the initial exposure to dexamethasone, the lower the CD69 expression with 
subsequent IL-15 treatment. 
If this finding mirrors the patient response to treatment with dexamethasone, then a 
suitable window for immunotherapy would likely be 2-3 days following the withdrawal 
of dexamethasone. After extended periods exposed to dexamethasone it would be 
sensible to assess the number of NK cells present within the patient’s blood before 
embarking on NK cell centred immunotherapies. 
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Figure 5.18. Schedule for the characterisation of NK cells reactivated after initial treatment with glucocorticoids. NK cells were isolated, plated into 
two 24 well plates and either left untreated (R) or treated with 2x10-7 M dexamethasone (D), 2x10-6 M methylprednisolone (MP) or these with the 
addition of 100 IU/mL IL-15 (15). One plate was incubated for 24 hours and the other for 48 hours. The surface phenotype (p) was characterised 
before the cells were washed with PBS and resuspended in media containing IL-15. The cells were then incubated for a further 24 or 48 hours before 
being re-characterised. 
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Figure 5.19. Characterisation of NK cells reactivated after initial treatment with 
glucocorticoids. NK cells were isolated, plated into two 24 well plates and either left 
untreated (light blue) or treated with 2x10-7 M dexamethasone (orange), 2X10-6 M 
methylprednisolone (grey) or these with the addition of 100 IU/Ml IL-15 (yellow, dark 
blue and green respectively). One plate was initially incubated for 24 hours (initial 
treatment 24 hours) and the other for 48 hours (initial treatment 48 hours). The 
amount of cell death (top) and the surface phenotype (antigens listed) were 
characterised before the cells were washed with PBS (Before reactivation) and 
resuspended in media containing IL-15 (+IL-15). The cells were then incubated for a 
further 24 or 48 hours before being re-characterised. Data is shown for two donors. 
The surface phenotype and cell death were analysed by flow cytometry. The 
percentage of NK cells that were positively stained for each antigen was established by 
analysing the live cells The gates were set at 2% of the isotype control stain. 
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5.8   Discussion and conclusion 
The data presented in this chapter shows that NK cells are suppressed by both TGF-β 
and the glucocorticoids, dexamethasone and methylprednisolone. All three agents 
inhibit the IL-15 induced upregulation of activation receptors NKp30, NKG2D, DNAM-1, 
CD132, with IL-15 induced NKp44 expression blocked by the steroids but not TGF-β. 
The different patterns of expression observed between IL-15 and IL-15/TGF-β treated 
blood NK cells (Figure 5.2 and 5.3) mirrored those seen between the patient blood and 
tumour samples (Figure 3.4). This supports the hypothesis that TGF-β is an important 
suppressor molecule in GBM patients (Crane et al. 2010; Joseph et al. 2013). My data 
also supports previous publications that implicate TGF-β in preventing the 
upregulation of NK cell activating receptors (Wilson et al. 2011; Ikushima & Miyazono 
2010; Friese et al. 2004; Lee et al. 2004). Dexamethasone has also previously been 
shown to prevent both the surface expression of NK cell activation receptors and 
effector functions. For example, the lenalidomide-induced upregulation of NKG2D and 
NKp46 was thwarted with the addition of dexamethasone. So too was the NK cell 
cytotoxic activity towards the K562 target cell line (Hsu et al. 2011). This is in 
agreement with the functional data presented here, whereby dexamethasone inhibits 
NK cell cytotoxicity (Figure 5.4), by both decreasing the amount of degranulation 
against target cells (which might be related to reduced expression of activation 
receptors) and reducing the amount of the pro-apoptotic serine protease granzyme B 
(Figure 5.5). Other reports show that methylprednisolone inhibits surface expression 
of NKp30 and NKp44 (Chiossone et al. 2007). 
Gene expression profiling revealed that pathway components regulated by the 
transcription factor c-Myc were differentially expressed between the IL-15 treated NK 
cells and those treated with IL-15/TGF-β and IL-15/dexamethasone (Figure 5.10). 
Western blot analysis supported this hypothesis, as levels of c-Myc were higher in IL-15 
treated cells compared to resting cells and cells treated with IL-15/TGF-β and IL-
15/dexamethasone (Figure 5.15). The suppression of c-Myc by TGF-β was observed in 
keratinocytes in the late 1980s and was shown to be due to transcriptional inhibition 
(Pietenpol et al. 1990). Similarly, dexamethasone has previously been reported to 
prevent c-Myc transcription in PBMCs that have been treated with the lectin mitogen 
phytohemagglutinin (PHA) and recombinant IL-2 (Reed et al. 1985). Although it is 
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known that IL-15 activation of NK cells induces c-Myc, the inhibition of such signals 
have not previously been reported for dexamethasone or methylprednisolone in NK 
cells. 
The results of the microarray suggested that IL-15 induces NK cell proliferation and 
that this is inhibited by TGF-β and dexamethasone. Cell cycle analysis confirmed this 
finding in vitro (Figure 5.14), which is supported by a recent publication demonstrating 
that TGF-β is able to prevent IL-15 induced activation, including proliferation, and that 
this is achieved by inhibition of the mTOR pathway (Viel et al. 2016). For many cell 
types it has also been reported that corticosteroids such as dexamethasone and 
methylprednisolone inhibit proliferation. For example, dexamethasone inhibits the 
proliferation of smooth muscle cells (SMC) (Reil et al. 1999), basic fibroblast growth 
factor-(bFGF) stimulated rat gastric epithelial cell proliferation (Luo et al. 2008) and T 
cells (Gutsol et al. 2013). However, a paper that presents data based on a very similar 
set of experiments to those described in this chapter, including expression of 
activation receptors, degranulation assays, and cell cycle analysis using glucocorticoids 
in conjunction with IL-15 on NK cells, reveals contradictory results. The paper reports 
that glucocorticoids (hydrocortisone, methylprednisolone and dexamethasone 
enhance IL-15 mediated NK cell division and that there is no change in NK cell 
degranulation against K562 target cells (Moustaki et al. 2011). The difference in results 
cannot be explained by differential amounts of IL-15 or glucocorticoids used, as a 
similar concentration of IL-15 was used, an identical concentration of 
methylprednisolone and double the concentration of dexamethasone was used in this 
report compared to mine. However, a different method was used to analyse cell 
proliferation; a CFSE assay, at different time points. The authors investigated the 
effects of the glucocorticoids on NK cells after 6 and 8 days in culture. Interestingly, 
their results at day 6 show that the IL-15 cells are proliferating more than the cells 
treated with dexamethasone and most have only gone through one cell division. 
However, according to the authors, by day 8, 50% or more of the cells have undergone 
5 cell divisions or more; this seems very unlikely given that the first division took five 
days. The authors also state that the analysis was ‘gated on live NK cells’ but there is 
no indication of how this was performed. In my study, when optimising the loading of 
both NK cells and GBM cells with different cell tracker dyes, it became apparent that as 
cells begin to die they start to leak the dye and this can precede morphological 
 
140 
changes (data not shown). Dead cells incorporated in CFSE analysis would mimic 
dilution of dye due to cell division. My data shows that by 72 hours (with half the 
concentration of dexamethasone used in this study) approximately 60-80% of cells are 
dead, close to the proportion of NK cells reported that have divided in the contrary 
study. 
A separate study investigating the effects of methylprednisolone on IL-2 or IL-15 
treated NK cells supports the results within this chapter (Chiossone et al. 2007); 
methylprednisolone was found to inhibit the upregulation of IL-15 induced NKp30 and 
NKp44, prevent NK cell cytotoxic activity and reduce granule exocytosis. The paper also 
reports that IL-15 prevented glucocorticoid induced apoptosis, validating the IL-15 
rescue effect that is evident in the cell cycle assay (Figure 5.14). IL-15 signalling has 
been implicated in the maintenance of anti-apoptotic factor Bcl-2 (Ranson et al. 2003; 
Huntington et al. 2007) which could counteract glucocorticoid induced apoptosis. In 
one study (Chiossone et al. 2007) the down regulation of IL-15 induced phosphorylated 
STAT5 by methylprednisolone shows the agent is able to inhibit the JAK/STAT pathway. 
This result was mirrored in my results for both methylprednisolone and 
dexamethasone, but was not seen with TGF-β (Figure 5.16). The finding that STAT5 
phosphorylation was unchanged by IL-15/TGF-β also supports published findings (Viel 
et al. 2016). 
The inhibitory effects of TGF-β, dexamethasone and methylprednisolone on IL-15 
activated NK cells seems to be mediated by the mTOR pathway, with c-Myc implicated 
as an important transcriptional regulator. When considering NK cell based 
immunotherapies for patients with GBM, it is worrying that the clinically administered 
glucocorticoid dexamethasone employs the same immunosuppressive pathways as 
TGF-β. If the use of dexamethasone is unavoidable, then a suitable time to issue 
immunotherapy needs to be established. Experiments that aimed to investigate if NK 
cells could be activated after treatment with dexamethasone or methylprednisolone 
revealed that it was possible to increase the concentration of activation receptors but 
that extended treatments with the steroids without a survival signal caused large 
amounts of cell death (Figure 5.19). Dexamethasone is also known to cause 
lymphopenia (Anderson et al. 1999) in vivo. The phenotypic data in figure 5.19 
suggests that NK cells can be activated after the withdrawal of glucocorticoids 
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dexamethasone and methylprednisolone. Assessing their cytotoxic activity after 
withdrawal of dexamethasone and activation with IL-15 would confirm this prediction. 
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Summary and discussion 
In this work I have analysed the immune response to human glioblastoma multiforme, 
focussing on the interactions between NK cells and the cancer cells. The impetus for 
this work is the clear need to develop new therapies against this disease. Current 
treatments of surgery combined with chemotherapy (using temozolomide) extend a 
patient’s life by just 9 months (Perry et al. 2016); immunotherapy holds the potential 
to improve this. This is best demonstrated by recent success in melanoma, where use 
of checkpoint inhibitors has extended survival times (Callahan et al. 2014) and trials 
are now underway to test these antibody therapies for use in GBM. 
Natural killer (NK) cells have potent anti-tumour function and hold great potential for 
immunotherapy (Vivier et al. 2011; Pahl & Cerwenka 2015). Indeed, NK cells are 
already harnessed in standard therapies. For example, the efficacy of both rituximab 
(anti-CD20, for haematological malignancies) and Herceptin (trastuzumab, anti-HER2, 
for breast cancer) is, at least in part, due to the ability of NK cells to kill antibody 
coated target cells via ADCC (Dall’Ozzo et al. 2004; Roda et al. 2007; Carson et al. 
2001). Furthermore, NK cell activity is harnessed in graft versus leukemia responses 
(Ruggeri et al. 2002). NK cells are also being exploited in several trial therapies. For 
example, antibodies that block KIR-MHC class I interactions are in clinical trials 
(Romagné et al. 2009). These antibodies inhibit NK cell inactivation by MHC class I+ 
tumour cells and their action is akin to releasing an NK cell checkpoint. Oncolytic 
viruses also exert some of their action via NK cells; the anti-viral activity of NK cells 
allows the oncolytic virus to activate NK cells (via type I interferon responses) and this 
heightened NK cell activation allows greater anti-tumour activity (El-Sherbiny et al. 
2015). These existing and emerging NK cell based therapies suggest that NK cells do 
indeed offer great potential for NK cell based therapies in the future. However, there is 
a lack of information on the interaction between NK cells and GBM. Indeed, the 
difficulty in accessing brain tumour samples and analysing immune infiltration and 
immune responses has greatly limited the study of the immune response to GBM. My 
study aimed to address this.  
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Principal findings 
1. NK cells and T cells infiltrate human GBM tumours but have an altered cell 
surface phenotype compared to their counterparts in patients’ blood and 
healthy donor blood (chapter 3). Importantly, NK cells in the tumour 
microenvironment exhibited reduced cell surface expression of key tumour-cell 
detecting activation receptors such as NKp30, NKG2D and DNAM-1. Analysis of 
bulk tumour infiltrating T cells demonstrated the increased expression of key 
inhibitory checkpoint molecules on the T cells, namely PD-1, LAG-3 and CTLA-4. 
This is the first study to report such phenotypic changes on GBM infiltrating NK 
cells and T cells.  
2. GBM stem cells are more susceptible to NK cell lysis in vitro compared to a non-
cancerous neural progenitor cell line and GBM cells express numerous ligands 
that regulate NK cell activity and other components of the immune system 
(Chapter 4). 
3. A multiplex cell surface antigen screen analysing expression of 242 cell surface 
antigens identified 44 antigens in common between the five GBM cancer stem 
cell-like cell lines. The GBM cells expressed multiple ligands known to activate 
NK cells (including MIC-A/B and Nectin-2) as well as a number of other cell 
surface molecules known to modulate T cell activity and other immune cell 
types, in addition to a number of molecules under investigation in other 
systems as therapeutic targets. 
4. Analysis of the effect of corticosteroids on NK cell activation revealed them to 
have a potent inhibitory effect, consistent with the use of these molecules as 
anti-inflammatory agents (e.g in the treatment of inflammatory and 
autoimmune disease). In brain cancer, corticosteroids are administered to 
prevent oedema. My results show that steroid use is likely to severely limit any 
NK cell-based immunotherapy and these results have implications for the 
timing of immunotherapy relative to steroid treatment. 
5. Gene expression profiling identified c-MYC as a key regulatory hub in NK cell 
activation. Biochemical studies showed that IL-15 potently induces c-MYC and 
this induction is inhibited in the presence of dexamethasone and the 
immunosuppressive cytokine TGF-β. Both steroids and TGF-β inhibit IL-15 
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mediated mTOR signalling. The fact that NK cells utilise mTOR and c-Myc is also 
highly relevant to designing new therapeutic strategies as both molecules are 
identified as important targets for inhibition in cancer cells themselves (Pópulo 
et al. 2012; Huang et al. 2014). Clearly, immunotherapy requiring mTOR 
activation and c-Myc dependent pathways is unlikely to be optimal in patients 
receiving mTOR inhibitors (e.g. rapamycin and derivative rapalogues, such as 
tacrolimus) or c-MYC inhibitors. 
Discussion 
Studies in other cancers have revealed that T lymphocyte infiltration of tumours is 
generally a good prognostic marker. For example, in melanoma, T cell infiltration is 
correlated with improved survival (reviewed in (Lee et al. 2016)). Recent studies have 
used transcriptome data from the bulk tumour to look for evidence of infiltration of 
particular lymphocytes. For example, in colorectal cancer (Bindea et al. 2013) T cell 
infiltrates reduce as the tumours progress. The interpretation of T cell data is difficult 
because of the existence of multiple subsets with different roles. For example, 
whereas CD8+ cytotoxic T cells might provide an anti-tumour activity, FOXP3+ Treg are 
associated with a poorer prognosis as they inhibit anti-tumour immunity (Curiel et al. 
2004; Wolf et al. 2005; Deng et al. 2010). However, the role of Tregs is complex as they 
have also been reported to prevent tumour progression by limiting inflammatory 
activity that promotes tumour development (Whiteside 2015). For GBM patients, 
Tregs seem to have a detrimental role as infiltration of Tregs correlates with grade (El 
Andaloussi & Lesniak 2006). In my work, only bulk T cells were analysed as the samples 
were too small to perform the necessary phenotyping. However, my results show that 
whatever T cells are present, they express high levels of checkpoint molecules 
(especially PD-1) which are indicative of an inhibited T cell response (unlike the blood). 
This indicates that patients could benefit from antibody therapy targeting checkpoints 
and these are being trialled (despite limitations of the BBB and Ab penetration). 
NK cell infiltration is also prognostic in several cancers (Coca et al. 1997; Takanami et 
al. 2001; Ishigami et al. 2000; Villegas et al. 2002). However, NK cells in the tumour 
microenvironment have an altered phenotype. For example, reduced expression of 
activation receptors ((Wilson et al. 2011; Carlsten et al. 2009; Carlsten et al. 2007) or 
 
145 
even a pro-angiogenic phenotype (Bruno et al. 2014). In GBM I found reduced 
expression of NKp30, DNAM-1 and NKG2D, suggestive of an impaired ability to 
respond to the tumour cells, although numbers of cells present prevented me from 
testing effector functions. In the ovarian cancer study (Wilson et al. 2011) TGF-β, an 
immunosuppressive cytokine known to be important in tumour progression and the 
immune response (Flavell et al. 2010) mimics the effects of the tumour 
microenvironment and inhibition of TGF-β activity restores the NK cell phenotype and 
anti-tumour function in vitro (Wilson et al. 2011). The phenotype of GBM resident NK 
cells (chapter 3) resembles that of TGF-β exposed NK cells. TGF-β is elevated in the 
serum of GBM patients with a large tumour burden and alters the phenotype of blood 
NK cells (Crane et al. 2010). Although GBM cells are known to make TGF-β (Constam et 
al. 1992), I could not find a role for TGF-β in the in the downregulation of NK cell 
activation receptors in the NK-GBM in vitro co-cultures. 
An important result of the study is that NK cells and T cells are able to traffic to the 
tumour, either through the BBB, or maybe the BBB is impaired in GBM. NK cells are 
present in low numbers, though the ratio to bulk T cells is similar. This demonstrates 
that NK cells can traffic to the tumour and hence the design of therapies that enhance 
activity in the tumour microenvironment are likely to offer some benefit (as opposed 
to a situation where NK cell infiltration is absent). Whether TGF-β inhibitors or anti-KIR 
antibodies might help to restore NK cell function in the tumour microenvironment is 
unclear and it is premature to make predictions as there are many ways that tumors 
can evade NK cells as well as other immune cell types (Pahl & Cerwenka 2015; Vitale et 
al. 2014; Drake et al. 2006). 
Results from chapter 4 showed that, when activated optimally (with IL-15), NK cells 
were able to recognize and kill GBM. Furthermore, GBM cells were preferentially killed 
over NP1 cells. Whilst this seems like an obvious result, most studies of NK cell-tumour 
cell interactions ignore the specificity of NK cells for the tumour cell compared to 
healthy normal tissue. This is particularly important in the brain where healthy tissue 
damaged by immune response is less likely to be repaired/regenerate compared to 
other tissues and is also likely to have severe morbidity. The mechanism behind the 
recognition and killing of GBM by NK cells was not explored in detail. My cell surface 
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antigen screen (chapter 4) identified expression of several well charactersied NK cell 
receptor ligands (e.g. ligands of NKG2D and DNAM-1) but these were expressed 
alongside high levels of MHC class I. Other studies have used blocking Ab to determine 
the roles of particular receptor-ligand interactions in anti-tumour activity (e.g. results 
from this lab; (Holmes et al. 2011; El-Sherbiny et al. 2007), in Ewings sarcoma and 
myeloma respectively). However, I did not perform these studies in GBM. It is 
noteworthy that the NK cells infiltrating the tumour exhibited a reduced surface 
expression of NKG2D, DNAM and NKp30 and the assumption is made that this will 
affect GBM recognition and killing. However, formally I haven’t shown that these 
receptors are important in GBM recognition. Future experiments could use NK cell 
receptor blocking antibodies and RNA interference methods to investigate these 
interactions.  
In addition to NK cell receptor ligands, the surface antigen screen identified several 
proteins of interest. PDL-1 was expressed on four of the five GBM cell lines tested, 
providing a plausible mechanism by which GBM evades T cell activity as my results 
from chapter 3 clearly demonstrate expression of PD-1 on the infiltrating T cells. In 
addition, several other proteins were identified that are targets of clinically approved 
antibody therapies. However, efficacy of these treatments might be restricted as the 
BBB could prevent the penetration of antibodies into the brain and research is 
underway to optimise BBB permeability for treatment delivery (Connell et al. 2013). 
Interestingly, in this study, TNF enhanced the uptake of trastuzumab targeting Her-2; 
my surface antigen screen revealed the expression of Her2 on all of the GBM cell lines 
analysed. Other targets identified, include proteins contributed to chemotherapy 
resistance such as type I insulin-like growth factor receptor (IGFR1) and ABCG 
transporter (CD338) (Chen & Sharon 2013; Leonard et al. 2003). GBM patients that 
acquire resistance to chemotherapy might benefit from treatments targeting these 
receptors. 
TGF-β is recognised as playing a major role in tumour immune evasion (Flavell et al. 
2010). TGF-β works by antagonising the activation of NK cells by IL-15 (Wilson et al. 
2011; Viel et al. 2016). Interestingly, steroids also inhibit the cytokine activation of NK 
cells (Chiossone et al. 2007) and the resultant cell surface phenotype resembles that 
induced by TGF-β, i.e. reduced activation and induced expression of NKG2D, DNAM 
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and NKp30. Use of steroids in brain cancer is unavoidable, but I hypothesized that 
steroid treatment mimics the effects of TGF-β and is therefore is likely to limit the 
efficacy of immunotherapy when combined. In chapter 5, I analysed the effects of 
steroids on IL-15 induced NK cell activation in more detail. I used gene expression 
profiling in an attempt to identify common pathways of inhibition by steroids and TGF-
β. This approach identified 564 genes that were reciprocally regulated by IL-15 and by 
IL-15+ TGF-β and IL-15+dex. Importantly, this list of genes included proteins crucial for 
NK cell effector functions, such as granzymes and IFN, as well as key receptors (e.g 
DNAM-1), highlighting the inhibitory effect of these agents in NK cell function. 
Bioinformatics analysis implicated the transcription c-Myc as a key molecule in the 
regulation of these 564 genes. Further biochemical studies in chapter showed that IL-
15 induces c-Myc protein and that this induction is blocked by both TGF-β and 
steroids. In T cells, it is established that SMAD2/3 repress the expression of MYC in a 
Foxp1 dependent manner (Stephen et al. 2014). Furthermore, c-Myc orchestrates 
several T cell activation functions, not least the induction of the metabolic pathways 
that provide energy and the building blocks for biosynthesis required for cellular 
activation and proliferation (Buck et al. 2015). My results show that TGF-β and steroids 
inhibit IL-15 induced Myc protein production in NK cells and further experiments from 
my colleagues show that this occurs at the level of c-Myc transcription. It seems likely 
that TGF-β exerts these effects in a similar manner to that described in T cells. 
However, the mechanism by which steroids might regulate Myc is currently unclear. 
The importance of Myc as a regulator of NK cell activation is perhaps not surprising 
given that it is regulates many thousands of genes in many different cell types (Nie et 
al. 2012; Littlewood et al. 2012; Sabò et al. 2014). In one model, Myc acts as an 
amplifier of ongoing gene expression (Nie et al. 2012; Littlewood et al. 2012) and the 
ability of TGF-β to counteract the effects of IL-15 are consistent with this role, whereby 
blocking MYC induction would prevent the amplification of this expression. 
Furthermore, such a model is consistent with the fact that TGF-β does not completely 
block expression of many genes, but abrogates the IL-15 mediated increases in gene 
expression (Wilson et al. 2011). Whatever the mechanism, my results indicate that 
Myc is important to NK cell activation and this is blocked by steroids and by TGF-β. The 
most accepted mechanism of steroid activity is that they bind a cytosolic GR, which 
translocates to the nucleus and regulates gene expression. Steroids have been shown 
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to interfere with the NF-κB pathway and to block Myc induction in many cell types 
(Chang et al. 1997; Crinelli et al. 2000; Aghai et al. 2006). Clearly, further studies are 
required to elucidate the mechanisms by which steroids and TGF- β block Myc 
induction in NK cells. Furthermore, my data with Myc inhibitors are somewhat limited 
because they are toxic to NK cells (Chapter 5). This is probably related to the fact that 
preventing Myc activity blocks the IL-15 induced survival functions of NK cells. The 
induction of mTOR activity and Myc is important in T cell activation. However, it is not 
clear how mTOR and Myc are linked; studies in this lab have shown that Myc induction 
is unaffected by rapamycin (Erica Wilson, personal communication) and there is not a 
simple linear pathway between IL-15, mTOR and Myc. However, the observation that 
NK cells require mTOR and Myc for efficient activation has important consequences for 
future cancer therapy. mTOR inhibitors are in trials for several cancers as a means to 
block the high metabolic activity of tumour cells, reviewed in (Zaytseva et al. 2012). 
However, mTOR inhibitors will block T cell and NK cell activation and hence they will 
be incompatible with immunotherapy (Chaoul et al. 2015). Similarly, c-Myc inhibitors 
would not be compatible with immunotherapy. Together with my results showing that 
steroids block immune activation, it is clear that the effective exploitation of 
immunotherapy will require detailed studies of the best way to apply these different 
drugs, such that the anti-tumour activities of these agents do not prevent immune 
activation. Whilst this appears to be highly complex, it could be resolved by the 
appropriate sequencing and timing of different agents, as my experiments with steroid 
pretreatment in chapter 5 illustrate. 
In summary, NK cells are capable of reaching the tumour site and recognizing and 
killing GBM cells. However, the optimisation of NK cells and indeed other 
immunotherapy approaches will clearly require a more complete understanding of the 
mechanisms used by immune cells to recognize and be activated by GBM cells and 
how different therapies might interact, either positively or negatively.  
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Appendix 
Appendix 1. 
The percentage expression for each antigen on the five cell lines. 
CD number Gene name  % expression on GBM1 cells 
47 CD47 91.6 
147 BSG 90.9 
HLA ABC  90.8 
81 CD81 89.8 
46 CD46 89.3 
49b ITGA2 89.1 
151 151 89 
165 X 87.8 
166 ALCAM 87.3 
99 CD99 87.2 
71 TFRC 87.1 
97 CD97 86 
b2m B2M 83.8 
146 MCAM 83.3 
63 CD63 83.2 
56 NCAM1 82.7 
142 F3 82.6 
90 THY1 81.3 
59 CD59 80.9 
58 CD58 77.2 
164 CD164 76.7 
98 SLC3A2 75.6 
119 IFNGR 75.1 
95 FAS 73.8 
44 CD44 71.6 
57 B3GAT1 71.3 
200 CD200 70.6 
94 KLRD1 70.5 
49e ITGA5 68.6 
49f ITGA5 63.8 
29 ITGB1 62 
SSEA1  58.9 
91 LRP1 57.7 
GD2  53.8 
271 NGFR 53.4 
227 MUC1 50.5 
107A LAMP1 41.4 
HLA DQ  40.3 
73 NT5E 37.9 
15 FUT4 36.8 
 
169 
99R  36.7 
49a ITGA1 34.9 
34 CD34 33.8 
26 DPP4 32 
49d ITGA4 31 
49c ITGA3 29.2 
140A THBD 28.2 
340  Her2 26.8 
9 CD9 26.7 
106 VCAM1 25.6 
54 ICAM1 23.6 
321 F11R 21.5 
 
CD number Gene name  % expression on GBM4 cells 
47 CD47 100 
98 SLC3A2 100 
147 BSG 100 
49b ITGA2 99.99 
97 CD97 99.99 
99 CD99 99.99 
46 CD46 99.98 
59 CD59 99.98 
HLA ABC  99.97 
9 CD9 99.96 
63 CD63 99.92 
165 X 99.92 
151 151 99.86 
b2m B2M 99.81 
81 CD81 99.8 
71 TFRC 99.75 
24 CD24 99.67 
57 B3GAT1 98.98 
119 IFNGR 98.89 
164 CD164 98.76 
49f ITGA5 98.52 
105 ENG 98.24 
166 ALCAM 98.03 
95 FAS 97.53 
44 CD44 97.35 
HLAA2  97.18 
200 CD200 95.55 
340  Her2 94.98 
29 ITGB1 94.81 
146 MCAM 94.54 
271 NGFR 93.53 
 
170 
HLA DQ  93.52 
94 KLRD1 92.85 
99R  92.65 
GD2  92.33 
142 F3 92 
130 IL6ST 91.14 
91 LRP1 90.62 
221 IGF1R 88.91 
49e ITGA5 88.34 
141 PDGFRB 86 
49c ITGA3 83.81 
CD49f  83.26 
112 PVRL2 79.71 
172B SIRPB1 75.75 
107A LAMP1 73.59 
55 CD55 73.42 
54 ICAM1 73.14 
56 NCAM1 69.62 
90 THY1 64.35 
184 CXCR4 61.1 
73 NT5E 60.17 
140B PDGFRA 55.76 
51/61 ITGAV 55.64 
227 MUC1 55.26 
34 CD34 54.75 
49d ITGA4 51.39 
140A THBD 50.48 
220 INSR 50.1 
120A TNFRSF1A 47.52 
268 TNFRSF13C 46.26 
26 DPP4 45.72 
MICA/B MICA 40.37 
107B LAMP2 38.39 
118 LIFR 36.06 
61 ITGB3 31.87 
SSEA1  31.86 
egfr EGFR 31.04 
15 FUT4 28.24 
152 CTLA-4 27.17 
209 CD209 26.39 
338 ABCG2 21.76 
109 CD109 20.36 
274 CD274 20.2 
 
 
171 
CD number Gene name  % expression on GBM11 cells 
9 CD9 100 
44 CD44 100 
46 CD46 100 
49c ITGA3 100 
49e ITGA5 100 
59 CD59 100 
98 SLC3A2 100 
47 CD47 99.99 
71 TFRC 99.99 
147 BSG 99.99 
73 NT5E 99.98 
97 CD97 99.98 
164 CD164 99.98 
HLA DR  99.98 
49b ITGA2 99.97 
HLA ABC  99.97 
63 CD63 99.96 
b2m B2M 99.96 
HLA DRPQ  99.95 
GD2  99.94 
99 CD99 99.86 
81 CD81 99.84 
56 NCAM1 99.75 
166 ALCAM 99.68 
165 X 99.67 
49f ITGA5 99.67 
205 LY75 99.62 
HLA DQ  99.46 
54 ICAM1 99.41 
107A LAMP1 99.4 
91 LRP1 99.32 
34 CD34 99.26 
119 IFNGR 99.06 
104 ITGB4 98.99 
55 CD55 98.61 
106 VCAM1 98.22 
107B LAMP2 98.22 
271 NGFR 98.13 
95 FAS 98.11 
274 CD274 97.28 
51/61 ITGAV 96.93 
49d ITGA4 96.86 
146 MCAM 96.73 
 
172 
CD49f  95.89 
227 MUC1 95.48 
74 CD74 95.29 
120A TNFRSF1A 93.31 
61 ITGB3 91.58 
57 B3GAT1 88.91 
99R  88.77 
151 151 88.73 
340  Her2 86.48 
77 A4GALT 85.22 
273 PDCD1LG2 81.29 
142 F3 78.23 
94 KLRD1 75.71 
26 DPP4 70.04 
141 PDGFRB 61.41 
130 IL6ST 56.11 
10 MME 48.99 
105 ENG 48.77 
184 CXCR4 43.79 
268 TNFRSF13C 41.13 
201 PROCR 40.7 
29 ITGB1 39.52 
338 ABCG2 38.87 
221 IGF1R 37.27 
38 CD38 36.44 
40 CD40 34.05 
172B SIRPB1 34.05 
112 PVRL2 32.23 
90 THY1 30.33 
109 CD109 29.73 
80 CD80 28.97 
140A THBD 23.9 
121B IL1R2 23.32 
62P SELP 20.62 
321 F11R 20.37 
 
CD number Gene name  % expression on GBM13 cells 
9 CD9 100 
44 CD44 100 
46 CD46 100 
49c ITGA3 100 
55 CD55 100 
97 CD97 100 
98 SLC3A2 100 
 
173 
99 CD99 99.99 
147 BSG 99.99 
HLA ABC  99.99 
47 CD47 99.98 
49b ITGA2 99.98 
165 X 99.98 
73 NT5E 99.97 
GD2  99.96 
59 CD59 99.95 
b2m B2M 99.94 
49e ITGA5 99.93 
63 CD63 99.92 
151 151 99.89 
271 NGFR 99.87 
81 CD81 99.83 
49f ITGA5 99.77 
95 FAS 99.76 
HLA DQ  99.72 
56 NCAM1 99.56 
71 TFRC 99.55 
166 ALCAM 99.47 
99R  99.45 
91 LRP1 99.25 
HLAA2  99.22 
142 F3 99.19 
90 THY1 99.06 
141 PDGFRB 98.98 
119 IFNGR 98.85 
146 MCAM 98.83 
200 CD200 98.67 
CD49f  98.28 
94 KLRD1 97.98 
340  Her2 97.36 
57 B3GAT1 96.16 
164 CD164 96.08 
54 ICAM1 94.73 
130 IL6ST 93.38 
51/61 ITGAV 93.03 
29 ITGB1 91.72 
172B SIRPB1 89.85 
105 ENG 88.5 
107A LAMP1 88.26 
61 ITGB3 84.77 
321 F11R 84.49 
 
174 
220 INSR 81.34 
221 IGF1R 78.72 
24 CD24 78.56 
274 CD274 75.63 
120A TNFRSF1A 71.32 
112 PVRL2 71.2 
104 ITGB4 70.65 
26 DPP4 70.49 
108 SEMA7A 65.92 
77 A4GALT 64.76 
CD326  63.61 
227 MUC1 62.9 
209 CD209 61.79 
184 CXCR4 56.94 
34 CD34 55.04 
107B LAMP2 54.28 
egfr EGFR 53.2 
268 TNFRSF13C 50.41 
118 LIFR 44.6 
MICA/B MICA 43.86 
144 CDH5 41.24 
338 ABCG2 38.32 
152 CTLA-4 37.74 
140B PDGFRA 37.51 
49a ITGA1 35.63 
329 SIGLEC8 34.7 
SSEA4  32.18 
80 CD80 25.44 
49d ITGA4 23.75 
50 ICAM3 21.35 
 
CD number Gene name  % expression on GBM20 cells 
47 CD47 100 
81 CD81 100 
98 SLC3A2 100 
147 BSG 100 
b2m B2M 100 
99 CD99 99.99 
46 CD46 99.98 
151 151 99.98 
9 CD9 99.97 
97 CD97 99.97 
165 X 99.97 
49c ITGA3 99.96 
 
175 
63 CD63 99.95 
HLA ABC  99.95 
HLAA2  99.94 
59 CD59 99.92 
73 NT5E 99.87 
44 CD44 99.84 
49e ITGA5 99.83 
GD2  99.82 
56 NCAM1 99.75 
57 B3GAT1 99.75 
71 TFRC 99.64 
49b ITGA2 99.33 
90 THY1 99.04 
200 CD200 98.92 
271 NGFR 98.5 
HLA DQ  98.28 
119 IFNGR 98.14 
130 IL6ST 98.03 
99R  97.86 
142 F3 97.51 
164 CD164 97.38 
146 MCAM 96.92 
95 FAS 96.69 
HLA DR  96.45 
HLA DRPQ  95.51 
141 PDGFRB 94.31 
51/61 ITGAV 94.17 
166 ALCAM 94.15 
91 LRP1 94.09 
49f ITGA5 93.66 
227 MUC1 91.57 
338 ABCG2 90.98 
94 KLRD1 89.63 
24 CD24 89.22 
61 ITGB3 88.07 
49d ITGA4 82.31 
220 INSR 81.45 
340  Her2 79.74 
107A LAMP1 78.66 
MICA/B MICA 77.53 
152 CTLA-4 75.76 
108 SEMA7A 75.15 
105 ENG 74.88 
268 TNFRSF13C 73.6 
 
176 
274 CD274 72.22 
107B LAMP2 71.14 
172B SIRPB1 70.02 
120A TNFRSF1A 69.01 
egfr EGFR 68.68 
15 FUT4 67.12 
140B PDGFRA 66.96 
SSEA1  66.06 
77 A4GALT 65.45 
29 ITGB1 65.05 
CD49f  61.16 
221 IGF1R 58 
80 CD80 57.11 
34 CD34 56.14 
112 PVRL2 55.1 
26 DPP4 55.02 
184 CXCR4 47.56 
209 CD209 47.54 
88 C5AR1 47.35 
138 SDC1 47.21 
106 VCAM1 45.03 
321 F11R 42.19 
120B TNFRSF1B 41.99 
54 ICAM1 38.51 
74 CD74 37.5 
171 L1CAM 36.09 
273 PDCD1LG2 34.4 
55 CD55 34.17 
50 ICAM3 31.08 
140A THBD 26.31 
75 ST6GAL1 22.84 
231 TSPAN7 21.87 
205 LY75 20.88 
118 LIFR 20.41 
 
